Tuesday, 20 October 2015

Other  
08:30 - 17:55  
Room Madrid

**Novel Viral and Cellular Targets Against HIV**  
(extra registration required due to a limited seat availability)

EACS Satellite Symposium Convened by HIVinnov, HIT HIDDEN HIV and Thinpad, 3 European Consortia Supported by the European Union’s Seventh Framework Programme for Research and Technological Development

**Chairs:**  
Richard Benarous, France  
Monsef Benkirane, France  
Maurizio Botta, Italy

**Welcome**  
Manuel Battegay, Switzerland

08:30 - 08:45

**The Current Landscape of EU-Funded Research on HIV/AIDS and Future Prospects within Horizon 2020**  
Alessandra Martini (European Commission)

08:45 - 09:00

**Session 1: Novel Viral Targets and New Classes of Drugs Against HIV**  
Chair: Alessia Zamborlini (France)

**NCIs Are Multimodal Inhibitors Affecting Viral Production**  
Gilles Mirambeau, Spain

09:00 - 09:25

**Structural Basis for Retroviral Integration Into Nucleosomes**  
Peter Cherepanov, United Kingdom

09:25 - 09:50

**Killing Two Birds With One Stone: The Mode of Action of Allosteric Inhibitors of IN**  
Richard Benarous, France

09:50 - 10:15

**Design and Synthesis of Non-Covalent NC Inhibitors Targeting the Hydrophobic Pocket**  
Maurizio Botta, Italy

10:15 - 10:30

**Role of Phenotypic Investigation in the Evaluation of HIV-1 Drug Susceptibility**  
Francesco Saladini, Italy

10:30 - 10:45

**Coffee Break**  

10:45 - 11:05

**Session 2: New Cellular Targets and the Development of Novel Strategies Against HIV**  
Chair: Maurizio Botta (Italy)

**In Vitro and In Vivo Modelling of HIV Latency and Persistence**  
Monsef Benkirane, France

11:05 - 11:30

**Modification of Restriction Factors by SUMO Proteins: Implications for Retroviral Replication**  
Alessia Zamborlini, France

11:30 - 11:45
Scientific Programme

11:45 - 12:00
A Novel LEDGF/p75-Associated Complex Controls HIV-1 Latency
Stéphane Emiliani, France

12:00 - 12:25
Modulation of NF-κB Activity by Humans and Simian Immunodeficiency Viruses
Frank Kirchhoff, Germany

12:25 - 13:00
HIV Cell-to-Cell Transmission, Innate and Adaptive Countermeasures
Olivier Schwartz, France

Lunch Break

13:00 - 14:15
Session 3: New Assays and Screenings to Develop New Drugs Against HIV
Chair: Monsef Benkirane (France)

14:15 - 14:40
A Selective Cell-Based Screening to Identify New Antiretroviral Targets
Ariberto Fassati, United Kingdom

14:40 - 15:05
Molecular and Cellular Assays to Identify and Characterize Molecules Targeting the HIV-1 Nucleocapsid Protein
Yves Mely, France

15:05 - 15:30
Transcriptome Approaches for Single Cell and Latency Population Analyses
Angela Ciuffi, Switzerland

15:30 - 15:55
Humanized Immune System Mice for Testing of New Antiretrovirals
Ben Berkhout, Netherlands

Coffee Break

15:55 - 16:10
Session 4: Development of New Drugs Against HIV
Chair: Angela Ciuffi (Switzerland)

16:10 - 16:35
Discovery of New Peptides Interacting with HIV Infections
Wolf-Georg Forssmann, Germany

16:35 - 17:00
Synergies Between Industry and Academia in the Search for New Therapies for HIV
Steven Harper, Italy
Davide de Forni, Italy

Additional Novel Targets

Conclusion
José M. Gatell, Spain
Alessandra Martini (European Commission)
STEPS – A Community Initiative to Design the Pathway to a Long-Term Remission of HIV Infection
(extra registration required)

Chairs:
Tamás Bereczky, Hungary
Giulio Maria Corbelli, Italy

Welcome and Introduction
Brian West, United Kingdom
09:00 - 09:15

The Research for a Cure in Europe: A Framework
Roberto Speck, Switzerland
09:15 - 09:35

Discussion
09:35 - 10:00

The EpiStem Consortium and the Stem-Cell Transplant Strategy
Javier Martínez-Picado, Spain
10:00 - 10:20

Discussion
10:20 - 10:45

Coffee Break
10:45 - 11:00

The CHERUB Initiative and the Strategy Addressing the Reservoir
John Frater, United Kingdom
11:00 - 11:20

Discussion
11:20 - 11:45

Global and European Efforts Towards an HIV Cure
Anna-Laura Ross, United Kingdom
11:45 - 12:05

Discussion
12:05 - 12:30

Lunch Break
12:30 - 14:00

Cure Research in Denmark and the Latency Reversing Agents
Lars Østergaard, Denmark
14:00 - 14:20

Discussion
14:20 - 14:45

Cure Research in France and the Role of Primary Infection
Christine Rouzioux, France
14:45 - 15:05

Discussion
15:05 - 15:30

Coffee Break
15:30 - 15:45

Transatlantic Collaborations and the Broadly Neutralizing Antibodies Strategy
Gerd Fätkenheuer, Germany
15:45 - 16:05

Discussion
16:05 - 16:30

Activities from the Community: AVAC, pxROAR, CUREiculum and More
Kevin Fisher, United States
16:30 - 17:00
## Scientific Programme

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>How Can We Improve Community Involvement in Cure Research in Europe?</td>
<td>17:00 - 17:30</td>
</tr>
<tr>
<td>Damian Kelly, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Brian West, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Wrap Up and Conclusions</td>
<td>17:30 - 18:00</td>
</tr>
<tr>
<td>Brian West, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
### EACS Pre-Educational Course

**Chairs:**  
Tristan Barber, United Kingdom  
Laura Waters, United Kingdom  
Mike Youle, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45</td>
<td>Introduction</td>
<td>Mike Youle, United Kingdom</td>
<td>Room Belgrade</td>
</tr>
<tr>
<td>09:55</td>
<td>Women Living with HIV</td>
<td>Nilani Uthayakumar, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td>Overview</td>
<td>Mel Rosenvinge, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Questions</td>
<td>Panel</td>
<td></td>
</tr>
<tr>
<td>10:55</td>
<td>CHEMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:10</td>
<td>Hepatitis and HIV</td>
<td>Matthias Zaccarin, Denmark</td>
<td></td>
</tr>
<tr>
<td>12:35</td>
<td>Questions</td>
<td>Panel</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:40</td>
<td>Toxicities in HIV</td>
<td>Joanna Sawicz, Poland</td>
<td></td>
</tr>
</tbody>
</table>
Scientific Programme

14:05 - 14:30
Overview
Andrea Calcagno, Italy

14:30 - 14:40
Questions
Panel

Sexually Transmitted Infections

14:40 - 15:05
Clinical Case
Šime Zekan, Croatia

15:05 - 15:30
Overview
Katie Conway, United Kingdom

15:30 - 15:40
Questions
Panel

15:40 - 16:00
Coffee Break

16:00 - 16:25
Clinical Case
Henry Kibble, United Kingdom

16:25 - 16:50
Overview
Cristina Mussini, Italy

16:50 - 17:00
Questions
Panel

Industry Sponsored Session
13:30 - 15:00
Room Cologne

Industry Sponsored Session
(For more details, please visit the <a href="http://www.eacs-conference2015.com/index.php?article_id=47">EACS Conference website</a>)

Course/Workshop
13:30 - 17:00
Room Madrid

WAVE Workshop - Women Against Viruses in Europe - Promoting the Welfare of HIV-positive Women in Europe

Chairs:
Fiona Mulcahy, Ireland
Anna Maria Geretti, United Kingdom

13:30 - 13:40
Welcome and Introduction
Fiona Mulcahy, Ireland

Session 1 - Chairs: Karoline Aebi-Popp (Switzerland); Jane Anderson (United Kingdom)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40</td>
<td><strong>Plenary 1: Gender, Socio-Economic Factors, and HIV Treatment Outcomes</strong>&lt;br&gt;Determinants of treatment outcomes in HIV-positive women, with a focus on socio-economic factors&lt;br&gt;Fiona Lampe, United Kingdom</td>
</tr>
<tr>
<td>14:00</td>
<td><strong>Plenary 2: Strengthening the PMTCT Programme to Minimise Vertical Transmission of HIV and HBV in Cameroon</strong>&lt;br&gt;Researching HIV outcomes where resources are constrained&lt;br&gt;Judith Ndongo Torimiro, Cameroon</td>
</tr>
<tr>
<td>14:20</td>
<td><strong>Case Study 1: Factors Associated with Mother-to-Child Transmission of HIV-1 in Romania: Is Postnatal HIV Infection Still a Risk?!</strong>&lt;br&gt;Covering issues related to HIV transmission, pregnancy and breastfeeding, and care issues pertinent to Eastern Europe - emphasis on lessons to be learned/how things could have been done better&lt;br&gt;Cristiana Oprea, Romania</td>
</tr>
<tr>
<td>14:35</td>
<td><strong>Q&amp;A: Improving Outcomes</strong>&lt;br&gt;Fiona Lampe, United Kingdom&lt;br&gt;Judith Ndongo Torimiro, Cameroon&lt;br&gt;Cristiana Oprea, Romania</td>
</tr>
<tr>
<td>14:50</td>
<td><strong>Coffee Break &amp; Networking - Art Exhibition by Adrienne Seed (United Kingdom)</strong></td>
</tr>
<tr>
<td>15:20</td>
<td><strong>Plenary 3: How Does Contraceptive Use Increase the Risk of HIV Acquisition?</strong>&lt;br&gt;Emerging issues in contraception (including but not limited to drug interactions and address depo-provera and HIV transmission issues)&lt;br&gt;Giovanni Di Perri, Italy</td>
</tr>
<tr>
<td>15:40</td>
<td><strong>Case Study 2: Tackling Challenges in Long-Term Treatment</strong>&lt;br&gt;Care issues relevant to older women&lt;br&gt;Teresa Branco, Portugal</td>
</tr>
<tr>
<td>15:45</td>
<td><strong>Q&amp;A</strong>&lt;br&gt;Giovanni Di Perri, Italy&lt;br&gt;Teresa Branco, Portugal</td>
</tr>
<tr>
<td>16:10</td>
<td><strong>Session 3 - Chairs: Elisabeth Crafer (United Kingdom); Antonella d'Arminio Monforte (Italy)</strong></td>
</tr>
<tr>
<td>16:30</td>
<td><strong>Plenary 4: HPV-related Cancers and Their Prevention in HIV-positive Women</strong>&lt;br&gt;Focus on new data on cervical cancers, anal cancer and other HIV-related cancers, and vaccination-related issues&lt;br&gt;Déborah Konopnicki, Belgium</td>
</tr>
<tr>
<td>16:35</td>
<td><strong>Case Study 3: Missed Opportunities</strong>&lt;br&gt;Covering the patient’s experience of how “things could have gone better” in terms of care received&lt;br&gt;Ophelia Haanyama, Sweden</td>
</tr>
<tr>
<td>16:50</td>
<td><strong>Q&amp;A</strong>&lt;br&gt;Déborah Konopnicki, Belgium&lt;br&gt;Ophelia Haanyama, Sweden</td>
</tr>
</tbody>
</table>
The Next Steps
Fiona Mulcahy, Ireland

16:55 - 17:00

Other
13:45 - 15:00

17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV

(The workshop is an affiliated event of the 15th European AIDS Conference. EACS attendees are welcomed between 13:45 - 15:00 free of charge - based on seat availability in the room. Entire Workshop attendance from October 20 to October 22 requires extra registration.)

Changes in Bone Turnover Markers with HIV Seroconversion and Antiretroviral Therapy Initiation
Laurence Slama, France
13:45 - 14:00

Assessment of Associations between Markers of Renal Function and Bone Mineral Density in HIV-positive and HIV-negative subjects
Elena Alvarez, Ireland
14:00 - 14:15

Role of Antiretroviral Therapy on Bone Mass and Bone Texture
Esteban Martinez, Spain
14:15 - 14:30

Decreased Bone Mass in Perinatally HIV-infected School-aged South African Children on Antiretrovirals
Michael T Yin, United States
14:30 - 14:45

Bone Changes in Young Men Ages 18-22 Enrolled in a Pre-Exposure Prophylaxis (PrEP) Safety and Demonstration Study Using Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC)
Kathleen Mulligan, United States
14:45 - 15:00

Industry Sponsored Session
15:30 - 17:00

Industry Sponsored Session

(For more details, please visit the <a href="http://www.eacs-conference2015.com/index.php?article_id=47">EACS Conference website</a>)

Ceremony
17:30 - 19:30

Opening Ceremony

Chairs:
Manuel Battegay, Switzerland
José M. Gatell, Spain
Scientific Programme

Welcome
Manuel Battegay, Switzerland
José M. Gatell, Spain

Address
Maribel Pasarin, Spain
Jordi Casabona i Barbarà, Spain

HIV and Hepatitis - Europe Back on the Agenda
Tamás Bereczky, Hungary

Global Epidemiology in Action
Matthias Egger, Switzerland

90-90-90 by 2020 in Europe
Michel Kazatchkine, France

The EACS Awards
Nathan Clumeck, Belgium

Ceremony
19:30 - 20:30

Welcome Reception
Thursday, 22 October 2015

Meet the Expert
07:45 - 08:45

**Meet the Expert, - Vaccination for HIV-infected Patients**

*Vaccination for HIV-infected Patients*
Arkaitz Imaz, Spain
Carolynne Schwarze-Zander, Germany

Meet the Expert
07:45 - 08:45

**Meet the Expert, - ART in HIV Advanced Disease**

*ART in HIV Advanced Disease*
Félix Gutiérrez, Spain
Valérie Martinez, France

Meet the Expert
07:45 - 08:45

**Meet the Expert, - HIV-HCV Drug-Drug Interactions**

*HIV-HCV Drug-Drug Interactions*
David Back, United Kingdom
Catia Marzolini, Switzerland

Meet the Expert
07:45 - 08:45

**Meet the Expert, - Management of Opportunistic Infections**

*Management of Opportunistic Infections*
Hansjakob Furrer, Switzerland
José Miró, Spain
Scientific Programme

Plenary Session
09:00 - 09:30

PL1, Antiviral Therapy - Thinking Ahead: Implications of the DAD and START Studies - Joint Plenary with the 17th International Workshop on Co-morbidities & Adverse Drug Reactions in HIV

Chairs:
José Alcami, Spain
Caroline Sabin, United Kingdom

Antiviral Therapy - Thinking Ahead: Implications of the DAD and START Studies - Joint Plenary with the 17th International Workshop on Co-morbidities & Adverse Drug Reactions in HIV

Jens D. Lundgren, Denmark

09:30 - 10:00

PL2, Insights from HIV Pathogenesis

Chairs:
José Alcami, Spain
Caroline Sabin, United Kingdom

Insights from HIV Pathogenesis

Marcus Altfeld, Germany

10:30 - 12:30

Parallel Session

PS1, Co-morbidities I - Joint Session with the 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV

Chairs:
Esteban Martínez, Spain
Stefan Mauss, Germany

ML1 The Interplay of Atherosclerosis and Inflammation
Turner Overton, United States
10:30 - 10:45

PS1/1 Lung Function Decline in HIV: Effects of Immediate versus Deferred ART Treatment on Lung Function Decline in a Multi-site, International, Randomized Controlled Trial
Ken Kunisaki, United States
10:45 - 11:00

PS1/2 Increased Prevalence of Hypertension in HIV-infected Patients, Most with Suppressed Viraemia on Combination Antiretroviral Therapy, is Associated with Changes in Body Composition
Rosan van Zoest, Netherlands
11:00 - 11:15

ADRLH-51 HIV-infected Patients Exert Higher Residual Platelet Reactivity on DAPT Compared to Controls after Acute Coronary Syndrome
Franck Boccara, France
11:15 - 11:30
## Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 11:45</td>
<td>ML2</td>
<td>Geriatrics for HIV Physicians</td>
<td>Matteo Cesari, France</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>PS1/3</td>
<td>Fraility Predicts All-cause Mortality, Hospital Admission and Falls in HIV-infected and Uninfected Middle-aged Individuals</td>
<td>Katherine Kooij, Netherlands</td>
</tr>
<tr>
<td>12:00 - 12:15</td>
<td>ADRHL-62</td>
<td>Effects of Immediate Versus Deferred Initiation of Antiretroviral Therapy on Bone Mineral Density: A Substudy of the INSIGHT Strategic Timing of Antiretroviral Therapy (START) Study</td>
<td>Jennifer Hoy, Australia</td>
</tr>
<tr>
<td>12:15 - 12:30</td>
<td>ML3</td>
<td>Summary on Co-morbidities and Adverse Drug Reactions Workshop</td>
<td>Judy Currier, United States</td>
</tr>
</tbody>
</table>

### Parallel Session
10:30 - 12:30  
Room Cologne

**PS2, TB in HIV-infected Patients in Europe - Together We Are Stronger: An EACS-ESCMID-ECDC-WHO Joint Session**

**Chairs:**
Antonella d’Arminio Monforte, Italy  
José Miró, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>ML1</td>
<td>Epidemiology of TB in HIV-infected Patients in Europe</td>
<td>Marieke J. van der Werf, Sweden</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>PS2/1</td>
<td>HIV Viral Load as an Independent Risk Factor for Tuberculosis: the COHERE Collaboration</td>
<td>Hansjakob Furrer, Switzerland</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>ML2</td>
<td>Outcome of TB in HIV-infected Patients in Eastern Europe</td>
<td>Daria Podlekareva, Denmark</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>PS2/2</td>
<td>One-year Mortality of HIV-patients Treated for Susceptible Tuberculosis (TB) is Higher in Eastern Europe Than in Western and Southern Europe and Latin America</td>
<td>Daria Podlekareva, Denmark</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>ML3</td>
<td>Challenges Preventing TB in HIV-infected Patients (Including the Concept ART as TB Prevention)</td>
<td>Alberto Matteelli, Italy</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>PS2/3</td>
<td>Short-course Isoniazid and Pyrazinamide Compared with 6-month Isoniazid for Tuberculosis Prevention in HIV-infected Adults: The Russian Randomized Clinical Trial</td>
<td>Zinaida Zagdyn, Russian Federation</td>
</tr>
<tr>
<td>12:00 - 12:15</td>
<td>ML4</td>
<td>Pitfalls in TB Management in HIV-infected Patients: IRIS and MDR/XDR-TB</td>
<td>Anton Pozniak, United Kingdom</td>
</tr>
<tr>
<td>12:15 - 12:30</td>
<td>PS2/4</td>
<td>Target Generic Prices for Novel Treatments for Drug-resistant Tuberculosis</td>
<td>Dzintars Gotham, United Kingdom</td>
</tr>
</tbody>
</table>
15th European AIDS Conference
October 21 - 24, 2015
Barcelona, Spain

Scientific Programme

Parallel Session
10:30 - 12:30
Room Brussels

**PS3, Cost Effectiveness, Prevention and Epidemiology**

*Chairs:*
Fiona Lyons, Ireland
Yazdan Yazdanpanah, France

**ML1**
**HIV Molecular Epidemiology**
Dimitrios Paraskevis, Greece
10:30 - 10:45

**ML2**
The Community Perspective About Costs, Cost Efficacy and Generics
Giulio Maria Corbelli, Italy
10:45 - 11:00

**PS3/1**
A New Method to Estimate the First Step in the HIV Care Continuum
Ard van Sighem, Netherlands
11:00 - 11:15

**PS3/2**
Cost-effectiveness of Single-tablet Regimens versus Generic Based Multi-tablet Regimens for First-line Antiretroviral Therapy in France
Jorge Félix, Portugal
11:15 - 11:30

**PS3/3**
Cost-Effectiveness of Treating HIV-1 with Single - versus Multi-tablet Antiretroviral Regimens in Germany
Björn Vandewalle, Portugal
11:30 - 11:45

**PS3/4**
The Efficacy of Psychosocial Interventions to Reduce Sexual and Drug Blood Borne Virus Risk Behaviours among People Who Inject Drugs: A Systematic Review and Meta-analysis
Gail Gilchrist, United Kingdom
11:45 - 12:00

**PS3/5**
HIV Acquisition among Migrants Living in Europe: Results from aMASE - Advancing Migrant Access to Health Services in Europe
Debora Alvarez-del Arco, Spain
12:00 - 12:15

**PS3/6**
HIV-related Stigma in Primary Care in the UK: Findings from HIV StigmaIndexUK-2015 Survey
Claire Ferraro, United Kingdom
12:15 - 12:30

Special Session
12:00 - 14:00
Exhibition Area

**Poster Session**

**PE1/2**
Characterization of the Near Full Length Genetic Constellation of a Unique HIV 1 A1/C Recombinant Strain in South Africa
Andrew Musyoki, South Africa

**PE1/3**
APOBEC3 Host Factors Modulate Viral Production and Infectivity of HIV-2
Susana Bandarra, Portugal

**PE1/4**
Does the Presence of a Mutation at Position V179 Impact on Clinical Outcome in Patients Taking Antiretroviral Medication?
Jasper Vink, United Kingdom
Scientific Programme

PE1/5 Performance of Genotypic Algorithms for Predicting Tropism for HIV-1 CRF02_AG Subtype
Cathia Soulié, France

PE1/6 HIV-1 Subtype B Transmission Networks in Poland Indicate Frequent Clustering and Interregional Spread of Infection among Men-Having-Sex-with-Men
Milosz Parczewski, Poland

PE1/7 HIV-1 Diversity and Transmitted Drug Resistance Mutations among Heterosexuals with HIV-1 in Bulgaria
Ivailo Alexiev, Bulgaria

PE1/8 Clinical, Virological and Phylogenetic Characterization of a Multiresistant HIV-1 Strain Outbreak in Naïve Patients in Southern Spain
Isabel Viciana, Spain

PE1/9 Tumor Suppressor p53 Protein Removes the Ribonucleotides Incorporated by HIV-1 RT into DNA
Mary Bakhanashvili, Israel

PE1/10 Dolutegravir based Regimens (DBRs) Viral Load Decay at Week 4 Could Predict Sustained Viral Suppression at Week 96
Romina Quercia, United Kingdom

PE1/11 Viruses Causing Breakthrough Infections in Women Assigned to Tenofovir Gel in the CAPRISA 004 Microbicide Trial Did Not Demonstrate a Higher Replication Capacity
Philippe Selhorst, South Africa

PE1/12 Cellular Proviral HIV DNA in Patients on Stable Combination Antiretroviral Therapy: Correlation with Immunovirological Parameters and Antiretroviral Regimens
Isabella Bon, Italy

PE1/13 Evidence that an Amino Acid Substitution in the HIV-2 Env Protein Lead to a Lack of Tetherin Antagonism
François Dufrasne, Belgium

PE1/14 Characterization of HIV-1C gp120 in Recently and Chronically Infected Individuals in Botswana
Terence Mohammed, Botswana

PE1/15 Comparison of the Analytical Performance of the Cepheid Xpert HIV-1 Viral Load Real-time PCR with the Roche Cobas Amplicon/Cobas TaqMan HIV-1 Test Version 2.0 Assay
Brice Duboil, France

PE1/16 Validation of the Xpert VIH-1 Viral Load Real-time PCR (GeneXpert®, Cepheid) for Organ Transplantations
Aleksandra Maleska, France

PE1/17 HIV-1 Genetic Diversity and Divergency and its Correlation with Disease Progression among Recently Infected Individuals Using Next Generation Sequencing
Ana Rachel Leda, Brazil

PE2/1 Responses of NK Cell Subsets to Anti-HIV Antibody Mediated Activation
Irene Lisovsky, Canada
PE2/2 Influence of HLA Glycosylation on the Binding of HLA-B*57:01 to KIR3DL1
Wilhelm Salzberger, Germany

PE2/3 Optimization of KIR2DS1 Reporter Cell Assay to Identify HIV-peptide Specific Binding of HLA-C*06:02
Anais Chapel, Germany

PE2/4 Analysis of Cross-recognition of HIV-1-Nef-Specific CTL to Human FAT3 Protein
Thomas Harrer, Germany

PE2/5 Identification of HLA-C Restricted, HIV-1-Specific CTL Epitopes by Peptide Induced Upregulation of HLA-C Expression
Thomas Harrer, Germany

PE2/7 NK Cells Expressing Self-Inhibitory KIR2DL Receptors Display Reduced Ability to Inhibit HIV-1 Replication in vitro
Korner Christian, United States

PE3/1 Plasma L-carnitine and L-lysine Concentrations in HIV-infected Patients at Clinical Stages of the Disease
Evgeny Butorov, Russian Federation

PE3/2 Plasmatic Cytokine Levels in Rapid and Slow Progressors HIV-1 Infected Rúbia de Medeiros, Brazil

PE3/3 Evaluation of Some of Oxidative and Inflammatory Stress Biomarkers in People Living with HIV/AIDS before and after the Initial Antiretroviral Therapy

PE3/5 Changes in Peripheral T-cell Homeostasis, Gut Inflammation, Intestinal Permeability and Fecal Microbiota in the First Year of Combination Antiretroviral Therapy (cART)
Camilla Tincati, Italy

PE3/6 Peripheral Blood Pre-erythroidal Cells in HIV-1 Infection
Maciej Stanislaw Tarkowski, Italy

PE3/7 Frequently Low Serum Immunoglobuline M Levels on Long-term Suppressive ART - A Possible Indicator of a Functional B-cell Defect Demasked by ART
Hans-Jürgen Stellbrink, Germany

PE3/9 HIV gp120 Enhances CXCR4/SDF-1 Mediated MSC Migration through Activation of ERK and FAK Pathways
Nicholas Chew, Singapore

PE3/10 The Role of miRNA-33 in HIV-mediated Impairment of Cholesterol Efflux in THP-1 Cells
Mireia Arnedo, Spain

PE3/11 Long-Term immune Recovery in HIV-infected Patients with Candida esophagitis is Impaired Despite Combination Antiretroviral Therapy
Nina Khanna, Switzerland

PE4/1 Analysis of Gut Microbiota Diversity in Chronic AIDS Patients Living in China Using the QIME Pipeline
Yang Sun, China
PE4/2  The Impact of HLAB*5701 on Viral Replication among Patients Infected with HIV-1 B and Non-B Subtypes - Interplay between Host and HIV Genetics
Małgorzata Dawidek, Poland

PE4/3  Circulating MicroRNA Modulations in HIV-1 Patients under Long-term ARV Treatment
Marjorie Monleau, France

PE5/1  Definition of HIV-1 CTL Epitopes Designed from Archived Virus and Exhibiting Affinity to HLA Groove: The Provir Vaccine Strategy
Herve Fleury, France

PE5/2  Kinetic of Total HIV-Dna during Interferon Based Anti-HCV Therapies in Coinfected Patients
Giancarlo Orofino, Italy

PE5/3  Development of Community-led Education about Human Papillomavirus Vaccination as a Model for Future HIV Vaccination Campaigns
Karamoko Tounkara, Mali

PE5/4  Inhibitory Role of CD16+ Inflammatory Monocytes on Vaccine-induced Antibody Responses
Anne Nolting, Germany

PE5/5  Impact of Economic Crisis on Immunization of HIV-1 Population in Greece
Olga Tsachouridou, Greece

PE6/1  Novel and Effective Vaginal Microbicide Delivery System Using Nanoparticle Entrapped Microbicides
Mahesh Sherkar, India

PE6/2  Second-generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity Toward Non-B Subtype HIV-1 Viruses
Ira Dicker, United States

PE6/3  Targeted Cleavage of the HIV-1 Proviral Genome Using AAV Vector-mediated CRISPR
Manuela Nickl, Germany

PE6/4  AR-12, a Novel First in Class Host Cell Targeting Therapeutic Candidate with Potent Activity Against HIV Multidrug Resistant Strains in vitro
Stefan Proniuk, United States

PE7/1  Patient Reported Outcomes (PRO) over 48 Weeks in a Randomized, Open-label Trial of Patients with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF)
David Budd, United States

PE7/2  Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy versus Darunavir/Ritonavir with Two Nucleoside Analogue: The PROTEA Trial
Pierre-Marie Girard, France

PE7/3  Does Two-drug Therapy Show Equivalent Efficacy to Standard Three-drug Combinations? Meta-Analysis of 14 Randomised Trials in 3323 Patients
Pierre-Marie Girard, France
Scientific Programme

PE7/4 Safety and Antiviral Effect of Elpida (VM15000), a Novel NNRTI (+Truvada) in Treatment-naïve HIV-1 Infected Patients
Alexey Kravtchenko, Russian Federation

PE7/5 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-experienced Subjects: Week 48 Safety Analysis
Bonaventura Clotet, Spain

PE7/6 Dual Treatment with Atazanavir/r+3TC vs. Triple Treatment with Atazanavir/r+2 Nucleos(t)ides in Virologically Stable Patients with HIV-1 (SALT Study): 96-week Results from a Randomised, Open Label, Non-inferiority Trial
Jose Perez-Molina, Spain

PE7/7 A Switch to Once Daily Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed HIV-infected Rwandans is Non-inferior to Continued Nevirapine-based Antiretroviral Therapy
Sean Collins, United States

PE7/8 A NRTI Sparing Two-drugs Maintenance cART is Effective and is Well Tolerated (PROBE Study)
Franco Maggiolo, Italy

PE7/9 Comparative Effectiveness of Tenofovir in Treatment-naïve HIV-infected Patients: Systematic Review and Meta-analysis
Heiner Bucher, Switzerland

PE7/10 Atazanavir plus Cobicistat (ATV+c) versus Atazanavir plus Ritonavir (ATV+r), Both in Combination with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 144 Subgroup Analysis of a Phase 3, Randomized, Double-blind, Active-controlled Trial
Graeme Moyle, United Kingdom

PE7/11 Lipid Profile and Inflammatory Markers of Lipoproteins in Virologically Suppressed Patients with Triple Therapy Switching to Lopinavir/R Plus Lamivudine
Maria Saumoy, Spain

PE7/12 The MONOD-ANRS-12206 Trial: Efavirenz May Simplify a Successful Lopinavir-based Therapy Initiated before the Age of 2 in HIV-infected Children from West-Africa
Carole Seguin-Devaux, Luxembourg

PE7/13 Improved Safety and Efficacy of TAF vs. TDF Single-tablet Regimen in HIV-1 Treatment-naïve Women through Week 48
Chloe Orkin, United Kingdom

PE7/14 Switch to Maraviroc (MVC) + Darunavir/Ritonavir (DRV/r) in Virologically Suppressed Patients with R5-Tropic Virus is Associated with an Excess of Virological Failures: 48 Weeks Results of the GUSTA Study
Barbara Rossetti, Italy

PE8/1 High Efavirenz Serum Concentrations in TB/HIV Co-infected Ugandan Adults Receiving Rifampicin-Based Anti-TB Therapy
Amrei von Braun, Uganda

PE8/2 Comparison of Serum Levels of Vitamin A in HIV Positive and HIV Negative Adults in Yenagoa Nigeria
Okechukwu Anene, Nigeria
Scientific Programme

PE8/3 The Efficacy of Second-line Antiretroviral Therapy for AIDS in China: A Retrospective Study
Qingxia Zhao, China

PE8/4 Association between Estimated Cumulative Viraemia and CD4/CD8 Ratio in HIV Patients on Long Term Antiretroviral Therapy
Kenny CW Chan, China

PE8/5 Long Term Virologic Superiority of Emtricitabine over Lamivudine when Used in Fixed Dose Combination with Tenofovir/Efavirenz Among Patients with Low Baseline CD4 Counts in Resource Limited Settings (RLS)
Ameet Dravid, India

PE8/6 Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive Individuals?
Caroline Sabin, United Kingdom

PE8/7 Toll-like Receptor 4 Polymorphism Influence on the Antiretroviral Therapy Effectiveness in HIV-Positive Patients
Tetiana Kyrychenko, Ukraine

PE8/8 Cost Effectiveness of Antiretroviral Therapy in HIV-infected Patients in Kazakhstan
Rafail Kipshakbayev, Kazakhstan

PE8/9 Role of the Decentralization of ART Services in Expansion of Access for HIV-positive IDUs to Treatment
Nataliya Nizova, Ukraine

PE8/10 Real World Experience with Raltegravir and Etravirine as Dual Agent Treatment of HIV
Dillon Benson, United States

PE8/11 Darunavir-Containing Antiretroviral Regimens in Pregnancy: Findings from the Antiretroviral Pregnancy Registry
William Short, United States

PE8/12 Prevalence and Risk Factors Associated with Adherence to Antiretroviral Therapy in HIV-infected Adults in a Tertiary Care Hospital In Mexico
Juan Domínguez, Mexico

PE8/13 Once versus Twice Daily ARV Regimens: Virological and Immunological Outcomes at 48 Weeks
Guillermo Viloria, Argentina

PE8/14 Factors Associated with Unstructured Antiretroviral Therapy Interruption during the First Year of Treatment
Mariana Kundro, Argentina

PE8/15 Durability of First Antiretrovirals Treatment between 2012-2013 in HIV-patients. Has it Improved with New Drugs?
Javier De La Torre Lima, Spain

PE8/16 Analysis of Toxicity as a Cause of Change of the First Current Antiretroviral Treatments in HIV Patients
Javier De La Torre Lima, Spain
Scientific Programme

PE8/17 48 Week Data of Atripla®, Eviplera® (EPA) or Stribild® in Routine Clinical Use: Efficiency and Safety of Single Tablet Regimens (STRs) in HIV-infected Patients Included in the German STRike Cohort
Stefan Esser, Germany

PE8/18 The Determinants of HIV+ Social Costs: An Empirical Survey in the Italian Setting
Mariangela Errico, Italy

PE8/19 Non-nucleosid Reverse Transcriptase Inhibitor (NNRTI) + Integrase Inhibitor (INI): A Well-tolerated Combination for HIV Maintenance Treatment, a Combination Hypothesized to Have Few or No Long Term Side Effects
Oswald Moling, Italy

PE8/20 Dual Therapy with Lopinavir/r and Raltegravir (LPV/r+RAL) in Treatment-experienced HIV-infected Patients: Data from the German Multicenter PROTEKT Cohort
Johannes Huelsenbeck, Germany

PE8/21 Efficacy of Darunavir/Ritonavir-based Treatment in an Italian Observational Study (TMC114HIV4042)
Andrea Antinori, Italy

PE8/22 Determinants of Virological Failure in a Large French Cohort in 2014
Gwenael Le Moal, France

PE8/23 Durability of Darunavir/ritonavir-based Treatment in an Italian Observational Study (TMC114HIV4042)
Paola Meraviglia, Italy

PE8/24 The Position of Rilpivirine in Antiretroviral Therapy: Early Evaluation of its Use in the Swiss HIV Cohort Study
Delphine Sculier, Switzerland

PE8/25 Although Aging HIV-infected Patients Are Burdened with Higher Rates of Co-morbidities and Co-medications, their Response to Raltegravir-based ART is Similar to that of Younger Subjects: An Analysis of a German Real Life Cohort
Stefan Mauss, Germany

PE8/26 Effectiveness and Safety of Fixed Dose ABC/3TC plus Rilpivirine in a Multicenter Cohort of HIV-infected Patients. SIMRIKI Study, GESIDA-8314
Jesús Troya, Spain

PE8/27 Persistency of Single Tablet Regimens (STRs) in Daily Clinical Routine - a Comparison between FTC/TDF-based STRs for Treatment of HIV-infected Patients: Data from the German STRike Cohort
Eva Wolf, Germany

PE8/28 Metabolic Syndrome, Cardiovascular Risk and Renal Impairment in HIV-infected Patients Initiating Antiretroviral Therapy in Portugal
Ana Lebre, Portugal

PE8/29 Potential Cost Savings Associated with Switches from 1st & 2nd-line ART Regimens to Less Expensive Regime; Bichat-Claude Bernard University Hospital Clinic, Paris, France 2014 (ANRS-GOTA)
Emmanuelle Papot, France
Scientific Programme

PE8/30 Durability and Predictive Factors of Discontinuation of Tenofovir-containing Antiretroviral Therapy Regimens in a Cohort of HIV-positive Patients
Marco Franzetti, Italy

PE8/31 Clinical Data and Patient-Reported Outcomes (PRO) in HIV-infected Adults Switching to RPV/FTC/TDF, due to a Previous Intolerance to cART. Interim Analysis of the PRO-STR Study
Daniel Podzamczer, Spain

PE8/32 Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (STRIBILD®) in Patients Treated during Primary HIV Infection Compared to Recent HIV Infection
Silvia Nozza, Italy

PE8/33 Long-term Virological Outcomes of ART-experienced Patients Receiving Raltegravir in a Large European Cohort Study
Anna Schultze, United Kingdom

PE8/34 Maraviroc plus Protease Inhibitor as a Switching Regimen in Clinical Practice
Marianna Menozzi, Italy

PE8/35 Early Start of Antiretroviral Therapy during Primary HIV Infection is Associated with Faster Virological Suppression
Marco Ripa, Italy

PE8/36 Experience of Dolutegravir (DTG) in HIV Infected Treatment Naïve Patients from a Tertiary Care University Hospital in Ireland
John Lambert, Ireland

PE8/37 Simplification for Dolutegravir as a Mono- or Bitherapy Maintains High Proportion of Viral Suppression Even in Highly-experienced HIV-1-infected Patients
Laurent Hocqueloux, France

PE8/38 Switch to Single Tablet Regimen (STR) in Virologically Suppressed Patients: A Comparison between Co-formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir
Roberta Gagliardini, Italy

PE8/39 Immunological and Virological Responses to Combined Antiretroviral Treatment in Male and Female Migrants in Europe: Is Benefit Equal for All?
Inmaculada Jarrín, Spain

PE8/40 Boosted versus unboosted Atazanavir/Raltegravir Dual Therapy and Immunovirological, Clinical and Pharmacological Outcomes: Results from a Prospective Multicenter Cohort of HIV-infected Individuals
David Rey, France

PE8/41 Efficacy and Safety of a Kivexa® (Abacavir/Lamivudine) plus Rilpivirine Regimen for the Treatment of HIV-1 Infection in Naïve Patients (KiRiNa Study)
Adrian Curran, Spain

PE8/42 Factors Associated with Switches and Interruptions of Initial Antiretroviral Therapy in the First Year
Michaela Rappold, Austria
PE8/43 Risk and Determinants of Failure of a Mono-PI/r Simplification Strategy with LPV/r or DRV/r in Clinical Practice
Alessandro Cozzi-Lepri, United Kingdom

PE8/44 High Treatment Retention and Success Rates of Tenofovir/Emtricitabine/Rilpivirine (Eviplera) in ART-naive HIV-infected Persons in Clinical Practice: A Comparative Study on Determinants of Use and Treatment Outcome
Alessandro Cozzi-Lepri, United Kingdom

PE8/45 Perceptions of Healthcare Providers (HCPs) and Patients around the Provision of HIV Healthcare and HCP-patient Communication: A NAM Web-based Survey
Caspar Thomson, United Kingdom

PE8/46 A Year of Stribild® Use. Experience in Real Life
Maria Arrizabalaga, Spain

PE8/47 Clinical Consequences of Poor Adherence to Antiretroviral Therapy in Patients with HIV Infection - A Retrospective Cohort Study
Cátia Caldas, Portugal

PE8/48 Is Switching to Kivexa with Rilpivirine as Effective as Switching to Eviplera in Clinical Practice?
Lucy Hedley, United Kingdom

PE8/49 Factors Related to the Durability of the First Antiretroviral Treatment
Luis Force, Spain

PE8/50 Rilpivirine with Kivexa for Treatment Naïve HIV: Experience in Clinical Practice
Lucy Hedley, United Kingdom

PE8/51 Switch from AtriplaTM to EvipleraTM: Gap between Perceived vs Compared Quality of Life
Amedeo Capetti, Italy

PE8/52 Much Less Treatment Modification in Individuals Initiating Antiretroviral Therapy with Recently Approved Drugs: The Austrian HIV Cohort Study
Michaela Rappold, Austria

PE8/53 First-line Antiretroviral Therapies in HIV-infected Patients in Germany: Treatment Decisions in the PROPHET Study
Eva Wolf, Germany

PE8/54 Maraviroc Once Daily: Experience in Routine Clinical Practice
Maria Saumoy, Spain

PE8/55 Reasons for Modification and Discontinuation of Initial Antiretroviral Treatment among Recently Diagnosed Patients in HIV-TR Cohort
Volkan Korten, Turkey

PE8/56 Simplification from Unboosted Protease Inhibitor to a STR-containing Rilpivirine Improves Levels of Triglycerides
Nicolò Riccardi, Italy
Lipid Changes and Tolerability in a Cohort of Adult HIV-infected Patients Switching to RPV/FTC/TDF, due to Intolerance to Previous cART. A Substudy of PRO-STR Study
Antonio Ocampo, Spain

KReal Study - Real World Experience of a Nucleoside-sparing Regime - Raltegravir +Lopinavir/Ritonavir
Frederico Duarte, Portugal

HiPeak Study - The Most Effective Therapeutic Response to Standard Antiretroviral Therapy (ART) Schemes in Naive HIV-1 Infected Patients with High Viral Loads
Frederico Duarte, Portugal

Does starting ART as Part of a Randomised Controlled Trial (RCT) Improve Long-term Virological and Immunological Outcomes?
Mike Youle, United Kingdom

Switching from Abacavir/Lamivudine + Nevirapine to Abacavir/Lamivudine /Dolutegravir Single Tablet Regimen (STR) in Virologically Suppressed, HIV-1 Infected Subjects: 12 Weeks Outcome
Clotilde Allavena, France

Use of Abacavir+Lamivudine+Unboosted Atazanavir (ABC/3TC+ATV) in Routine Clinical Practice: Twelve Years Experience
Rocio Montejaneto, Spain

Multi-centre International Study of the Efficacy and Tolerability of Eviplera (EVA) in Routine Clinical Settings
Mark Nelson, United Kingdom

DRV/r+3TC Bitherapy: More Than Security
Javier Moreno Díaz, Spain

Real-world Persistence with Antiretroviral Therapy for HIV in the United Kingdom: A Multicentre Retrospective Cohort Study
Joseph Lewis, United Kingdom

Unboosted Atazanavir (400 mg QD) in Combination with TDF/FTC or ABC/3TC is Able to Maintain Plasma Viral Load below 1 Copy/ml during 12 Months after the Use of Boosted Azatanavir (100/300 mg QD)
Vincent Calvez, France

Efficacy and Safety of Switching to Abacavir/Lamivudine (ABC/3TC) Plus Rilpivirine (RPV) in Virologically Suppressed HIV-infected Patients on HAART. Study SAEI 00/0067
Isabel Pérez-Hernández, Spain

Raltegravir (RAL) Based Antiretroviral Therapy (ART) in HIV-infected Solid Organ Transplant (SOT) Recipients: A Single Center Experience
Christian Manzardo, Spain

Identifying Priorities for HIV Consultations among Healthcare Providers (HCPs) across Europe: Results of a Pan-European Survey
Caspar Thomson, United Kingdom

Adherence to Antiretroviral Treatment in Turkey: Results from ACTHIV-IST Study Group
Dilek Yildiz Sevgi, Turkey
# Scientific Programme

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE8/71</td>
<td>Inter-country Variability in the Degree of ART-induced HIV-RNA Suppression</td>
<td>Kamilla Laut, Denmark</td>
</tr>
<tr>
<td>PE8/72</td>
<td>Cost Savings Associated with Rapid Virologic Response in Treatment-naive HIV Patients</td>
<td>Robert Cuffe, United Kingdom</td>
</tr>
<tr>
<td>PE8/73</td>
<td>cART-Simplification and Neuro-AIDS</td>
<td>Gabriele Arendt, Germany</td>
</tr>
<tr>
<td>PE8/74</td>
<td>Reasons to Start and to Choose the Initial Antiretroviral Treatment: The Physician's and the Patient's Perspective - A Prospective Study</td>
<td>Luigia Elzi, Switzerland</td>
</tr>
<tr>
<td>PE8/75</td>
<td>Diffusion Tension Image, Fractional Anisotropy and Mean Diffusivity Comparison in Patients Receiving PI Monotherapy or Triple Therapy</td>
<td>Ignacio Pérez-Valero, Spain</td>
</tr>
<tr>
<td>PE8/76</td>
<td>Time to Viral Suppression for HIV-positive Patients Initiating cART with Very High Viraemia</td>
<td>Annabelle Gourlay, United Kingdom</td>
</tr>
<tr>
<td>PE8/77</td>
<td>First-line NNRTI-Including cART Regimens Display Faster Immune-virologic Response in Comparison to PIs: Data from the San Paolo Infectious Diseases (SPID) Cohort, 2010-2015</td>
<td>Francesca Bai, Italy</td>
</tr>
<tr>
<td>PE8/78</td>
<td>Maraviroc Use and Outcomes across Europe - The European Coreceptor (EUCO) HIV Cohort Study</td>
<td>Anna Maria Geretti, United Kingdom</td>
</tr>
<tr>
<td>PE8/80</td>
<td>Mono and Dual Antiretroviral Suppressive Strategies: Real Life Experience in Three Hospitals in Paris (COREVIH Ile-de-France-Centre)</td>
<td>Marc-Antoine Valantin, France</td>
</tr>
<tr>
<td>PE8/81</td>
<td>Dual Therapy with Dolutegravir and Lamivudine Maintains Virologic Suppression in HIV-infected HAART-treated Patients: DOLULAM Pilot Study</td>
<td>Jacques Reynes, France</td>
</tr>
<tr>
<td>PE8/82</td>
<td>Immuno-Virological Effects and Cost after Introduction of Generic Drugs of Efavirenz and Nevirapine. Are they Good, Safe and Cheap?</td>
<td>Miguel Torralba, Spain</td>
</tr>
<tr>
<td>PE8/83</td>
<td>Eviplera (EVP) as a Treatment Option in Real-life Clinical Practice: Evidence for Efficacy and Safety</td>
<td>Konstantinos Protopapas, Greece</td>
</tr>
<tr>
<td>PE8/84</td>
<td>Simplification of a 4-drug cART Started during Acute HIV Infection (Alpha study): HIV RNA and Proviral HIV DNA Levels before and after</td>
<td>Adriana Ammassari, Italy</td>
</tr>
<tr>
<td>PE8/85</td>
<td>Genotypic Susceptibility Scores (GSS) of the Therapeutic Backbone in Treatment-experienced HIV-1 Patients: what Level is Required to Achieve Viral Suppression on Dolutegravir-containing cART</td>
<td>Matthijs Raadsen, Netherlands</td>
</tr>
</tbody>
</table>
PE8/86 Successful Interferon-based Salvage Therapy in a Panresistant HIV+ Adolescent
Markus Bickel, Germany

PE9/1 High Rate of HIV-1 Drug Resistance in Treatment Failure Patients in Taiwan, 2009-2014
Hung-Chin Tsai, Taiwan, Republic of China

PE9/2 Deep Analysis of HIV-1 Natural Variability across HIV-1 Variants at Residues Associated to Integrate Inhibitors (INI) Resistance in INI-naive Patients
Teresa Llácer Delicado, Spain

PE9/3 HIV Proviral DNA is an Adequate Genetic Compartment for Detection of Resistance Mutations Associated to Integrate Strand Transfer Inhibitors (INSTIs) Therapy in Patient with Undetectable or Low HIV Viral Load
Pablo Ferrer, Chile

PE9/5 Integrated Analysis of Emergent Drug Resistance by Population and Deep Sequencing through 48 Weeks from Clinical Studies of HIV-1 Treatment-naive Subjects Receiving EVG/COBI/FTC/TAF
Michael Miller, United States

PE9/6 Cumulative Genotypic Resistance to NRTIs and NNRTIs is Associated with a Higher Risk to Loose Virological Suppression in HIV-positive Patients Switching to Tenofovir/Emtricitabine/Rilpivirine Single-tablet Regimen
Maria Mercedes Santoro, Italy

PE9/7 Prevalence of Transmitted Drug Mutations to Rilpivirine in HIV-infected Treatment-naive Persons: Systematic Review of 64,466 Samples from 138 Studies
Vincent Calvez, France

PE9/8 What if a New HIV Integrase Inhibitor was not Prone to the Problem of Drug Resistance?
Mark Wainberg, Canada

PE9/9 Emerging Resistance Mutations in Protease Inhibitor Naive Patients Failing Atazanavir Based Regimen (ANRS Multicentre Observational Study)
Laurence Morand-Joubert, France

PE9/10 APOBEC Could Explain Low Viral Load in HIV Patient with Highly Active Therapy (HAART) with Nucleoside Analog Reverse-transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse-transcriptase Inhibitors (NNRTIs) Resistance but without Clinical Consequences
Pablo Ferrer, Chile

PE9/11 Comparison of the Risk of Resistance Accumulation According to ART Switching Strategies after Virological Failure >200 Copies/mL to First cART Using the g-computation Procedure
Alessandro Cozzi-Lepri, United Kingdom

PE9/12 HIV Drug Resistance among Children and Adolescents in Asia after First-line NNRTI-based Treatment Failure
Wanatpreeya Phongsamart, Thailand
Scientific Programme

PE9/13  **Protease Inhibitor Monotherapy: Effectiveness and Resistance in Clinical Practice**
Kate El Bouzidi, United Kingdom

PE9/14  **Characterization of HIV Resistance in Peripheral Blood Mononuclear Cells (PBMC-DNA) in Patients with Suppressed or Low Level Viremia**
Mauro Zaccarelli, Italy

PE9/15  **Prediction of Virological Failure by a Single Quantifiable Viral Load Below 200 Copies/mL in Treated HIV-infected Patients**
Gisela Leierer, Austria

PE9/16  **Impact of Baseline NRTI Resistance Mutations on Virological Suppression of HIV-1 Infected Patients Treated by Elvitegravir/Cobicistat/Emtricitabine/Tenofovir**
Nolwenn Hall, France

PE9/17  **Transmitted Drug Resistance (TDR) in Drug-naive HIV-2 Infected Patients**
Frederico Duarte, Portugal

PE9/18  **Patterns of Viral Resistance in Patients with Virologic Failure on a Dual Agent Antiretroviral Regimen**
Dillon Benson, United States

PE9/19  **Antiretroviral Resistance Mutations and Molecular Surveillance of HIV-1 in the Comunidad Valenciana (Spain), 2011-2013**
Manoli Torres-Puente, Spain

PE9/20  **Evolution of Resistance Rates to RT and Protease Inhibitors in Antiretroviral-experienced HIV-infected Patients**
Anne-Geneviève Marcelin, France

PE9/21  **Integrated Analysis of Emergent Drug Resistance through 96 & 144 Weeks from Clinical Studies of HIV-1 Treatment-naive Subjects Receiving Dolutegavir Based Regimens**
James Demarest, United States

PE9/22  **E138A - Natural Polymorphism or Selected by 2nd Generation NNRTIs?**
Martin Obermeier, Germany

PE9/23  **Decline in Resistance Mutations’ Prevalences, Namely K65R: Frankfurt HIV-1 Database, 2005-2013**
Christoph Stephan, Germany

PE10/1  **Discovery of Novel Diaryltriazines (DATAs) as Non-nucleoside Reverse Transcriptase Inhibitors via Extension into the Entrance Channel of HIV-1 Reverse Transcriptase**
Udaya Pratap Singh, India

PE10/2  **Design and Discovery of Potent Hybrid 1,3,5-Triazine-1,3-Thiazine Analogs Clubbed via Amine Bridge: A Novel Lead for Next Generation NNRTI**
Amita Verma, India

PE10/3  **Pharmacogenetic: Screening Relevant Polymorphisms on Antiretroviral Therapy in an HIV Portuguese Population**
Ana Fernandes, Portugal
Scientific Programme

**PE10/4**  Impact of Decentralized Drug Purchase on Antiretroviral Treatment Costs in Spain  
Yaiza Rivero-Montesdeoca, Spain

**PE10/5**  Impact of UGT1A1*28 Polymorphism on Raltegravir Metabolism  
Leïla Belkhir, Belgium

**PE10/6**  The Rilpivirine/Emtricitabine/Tenofovir Alafenamide (RPV/FTC/TAF) Single Tablet Regimen (STR) is Bioequivalent to Elvitegravir/Cobicistat/FTC/TAF (E/C/F/TAF) and RPV  
Julia Zack, United States

**PE10/7**  Co-medication in an Irish Infectious Diseases Clinic: The Level of Accurate Recording of co-medication and the Significance of Interactions between co-medication and Antiretrovirals (ARVs)  
Paul Hollywood, Ireland

**PE10/8**  Differential Pharmacological Impact of Abacavir Sulphate and Tenofovir on Platelet Aggregation Independent of HIV Infection  
Erica Smyth, United Kingdom

**PE10/9**  The Effect of Food on the Rilpivirine/Emtricitabine/Tenofovir Alafenamide (RPV/FTC/TAF) Single Tablet Regimen (STR) Tablet  
Julia Zack, United States

**PE10/10**  Impact of Tenofovir’ (TDF) Dose Adjustment on the Estimated Glomerular Filtration Rate (eGFR) and TDF trough Concentration (C\text{trough-TDF})  
Sylvie Bregigeon, France

**PE10/11**  Assessment of CYP3A5 Genotype on Maraviroc Exposure and Efficacy in a Phase 3 Study  
Manoli Vourvahis, United States

**PE10/12**  Frequency and Severity of Drug Interactions in a Cohort of HIV-infected Patients Identified through a Multidisciplinary Team  
Hernando Knobel, Spain

**PE10/13**  The Effect of Food on the Pharmacokinetics of Unboosted and Boosted Tenofovir Alafenamide  
Joseph Custodio, United States

**PE10/14**  Evaluation of Tenofovir Alafenamide Pharmacokinetics: No Influence of Demographic or HIV Disease Factors  
Joseph Custodio, United States

**PE10/15**  Pharmacology Drug Interactions and Adherence in Patients on Polypharmacy in our Hospital  
Sheila Ruiz, Spain

**PE10/16**  Risk Factors Associated with Hypersensitivity Reactions to Antiretroviral Drugs in Patients Infected with HIV  
José Antonio Mata-Marín, Mexico

**PE10/17**  What Minimal Concentration of Darunavir in Maintenance Darunavir/Ritonavir 800/100 mg Once-daily with 2 NRTIs (DAMAR study)?  
Minh Lê, France
Scientific Programme

PE10/18  Comparison of the in vitro Dissolution and in vivo Pharmacokinetics of Branded versus Generic Efavirenz Formulation in HIV Patients
  Cristina Gervasoni, Italy

PE10/19  Neuro+3 Study: Baseline Characteristics with Pharmacologic Results of HIV Patients with Neurocognitive Disorders Despite Effective Antiretroviral Therapy
  Gilles Force, France

PE11/1  Renal Toxicity Following Exposure to Tenofovir and Inhibitors of Tenofovir’s Renal Efflux Drug Transporters in HIV-1 Patients
  Casper Rokx, Netherlands

PE11/2  Simple and Practical Screening Approach to Identify HIV-infected Individuals with Current Depression or Risk of Developing Depression
  Lotte Rodkjær, Denmark

PE11/3  Analysis of Neurocognitive Function and CNS Endpoints at Week 96 in the PROTEA Trial: Darunavir/Ritonavir with or without Nucleoside Analogues
  Amanda Clarke, United Kingdom

PE11/4  Safety, Sensory Function and Analgesic Effectiveness Following Capsaicin 8% Patch (Qutenza®) Repeat Treatment in Peripheral Neuropathic Pain: Stride Study
  Graeme Moyle, United Kingdom

PE11/5  Tenofovir-associated Nephrotoxicity and Hypophosphatemia in HIV-infected Patients: A Single-centre Cohort Study
  Chien-Yu Cheng, Taiwan, Republic of China

PE11/6  Hepatotoxicity and Skin Rash of non-nucleoside Reverse Transcriptase Inhibitor (nNRTI) plus Nucleoside Reverse-Transcriptase Inhibitors in HIV-infected Taiwanese
  Pei-Ying Wu, Taiwan, Republic of China

PE11/7  Health State Utilities of Risks Associated with Antiretroviral Treatment (ART) for Human Immunodeficiency Virus (HIV)
  Louis Matza, United States

PE11/8  Discontinuation of Tenofovir due to Nefrotoxicity: Insight into 12 Years of Clinical Practice
  Elżbieta Bakowska, Poland

PE11/9  Incidence of Cancer in Individuals treated with Raltegravir-based and Non-raltegravir-based cART Regimens
  Daniel Grint, United Kingdom

PE11/10 Cross-sectional Multi-centre Study of Bone Mineral Density in HIV-1 Infected Patients on Antiretroviral Treatment at Risk for Osteopenia/Osteoporosis
  Frank Post, United Kingdom

PE11/11 Osteonecrosis and HIV Infection: The Experience of a Portuguese Center
  Rosário Serrão, Portugal

PE11/12 Prevalence of Sleep Disorders, Anxiety and Depression in HIV/AIDS Patients under Antiretroviral Treatment in China
  Wu Hao, China
Scientific Programme

PE11/13  Risk Factors of Anxiety and Depression in HIV-infected Patients during Antiretroviral Treatment  
Wu Hao, China

PE11/14  Abacavir Does Not Produce Vascular Inflammatory Effects in ATP Receptor-deficient Mice  
Samuel Orden, Spain

PE11/15  The Vascular Pro-inflammatory Effects of Abacavir Involve Interference with the Purinergic System  
Víctor Collado Díaz, Spain

PE11/16  Abacavir Induces Platelet Adhesion to Endothelial Cells  
César Ríos-Navarro, Spain

PE11/17  Hepatic Safety of Maraviroc in HIV Infected Patients with HCV and/or HBV Co-infection. The Maraviroc Cohort Spanish Group  
Manuel Crespo, Spain

PE11/18  Breast Density Assessment in Women Living with HIV/AIDS  
Mónica Mendes, Brazil

PE11/19  Differences in HIV Symptom Index Questionnaire (SIQ) and Sleep/Wake Activity Inventory (SWAI) after Switching to a Rilpivirine (RPV)-containing Regimens in Combination Antiretroviral Therapy (cART)-experienced HIV-infected Patients  
Manuela Colafigli, Italy

PE12/1  Risk Factors for Mortality in HIV-infected Patients with CMV Disease in the Combination Antiretroviral Era  
Rafael Perello, Spain

PE12/2  Hospitalizations of HIV Patients in a Major Israeli HIV/AIDS Center in the Years 2000-2012  
Keren Mahlab-Guri, Israel

PE12/3  Low Bone Fracture Risk Measured by Frax Index in HIV Patients  
Carmen Hidalgo-Tenorio, Spain

PE12/4  HIV-associated versus Classic Fever of Unknown Origin 25 Years on: Spectrum and Criteria Revisited  
Paul De Munter, Belgium

PE12/5  Impact of Late Presentation on Short, Mid and Long-term Mortality and on Causes of Death in Spain (2004-2013)  
Paz Sobrino-Vegas, Spain

PE12/6  Cardiovascular-specific Mortality in HIV-positive Patients with Alcohol Use Disorders  
Robert Muga, Spain

PE12/7  Ongoing Contribution of AIDS Deaths in the HAART Era: Data from the UK CHIC Study  
Sophie Jose, United Kingdom

PE12/8  American College of Cardiology Pooled Equations and DAD Algorithm to Predict Freedom from Cardiovascular Events in HIV Patients  
Giovanni Guaraldi, Italy
Scientific Programme

PE12/9  Cardiovascular Risk Factors and Recommended LDL Cholesterol Goals Attainment among HIV Positive Patients: The Impact of the Metabolic Syndrome
Elisabetta Schiaroli, Italy

PE12/10  Persistent HIV Low-level Viremia and Cardiovascular Risk
Silvia Costarelli, Italy

PE12/11  Heart Transplantation in HIV-infected Patients: A Report of Three Cases from a Single Institution
Fernando Agüero, Spain

PE12/12  Prognostic Value of DLCO in a Cohort of Middle Aged HIV Infected Patients in Terms of Mortality and Incidence of Cardiovascular Events after 6 Years of Prospective Follow-up
Francisco Fanjul, Spain

PE12/13  Lower CD4/CD8 Ratio
Francisco Fanjul, Spain

PE12/14  Trends in Cardiovascular Surgery in HIV-infected Patients: A 30-year Single Center Experience
Juan M Pericás, Spain

Sharanjit Dhoot, United Kingdom

PE12/16  Cardiovascular Events in HIV-positive Patients over the Last Decade. The Experience of Brescia from 2000 to 2012
Elena Raffetti, Italy

PE12/17  Rare Case of Adult Onset Still’s Disease Inducing Hemophagocytic Lymphohistiocytosis (HLH) during Early HIV Infection: Emerging Treatment Controversies and Dilemmas
Garyfalia Poulakou, Greece

PE13/1  Characteristics of the Active Drug Users Recently Infected with Hepatitis C in a Shantytown with a High Prevalence of HCV
Pablo Ryan, Spain

PE13/2  Hepatic Safety of RPV/FTC/TDF Single Tablet Regimen in HIV/HCV-coinfected Subjects. The hEPAtic Study
Karin Neukam, Spain

PE13/3  Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-experienced Subjects with HCV Genotype 1 and HIV-co-infection (ANRS HC31 SOFTRIH Study)
Eric Rosenthal, France

PE13/4  Uptake of Tenofovir-based Combination Antiretroviral Therapy (cART) among HIV/HBV Co-infected Patients in the EuroSIDA Study
Lars Peters, Denmark

PE13/5  Ledipasvir/Sofosbuvir with or without Ribavirin for the Treatment of Patients with Genotype 2-6 Chronic HCV Infection: Summary Results from Four Phase II Studies
Armand Abergel, France
Scientific Programme

PE13/6  The Treatment Cascade of Chronic Hepatitis C In HIV Co-infected Patients: Data from the Clinic of Infectious Diseases in Modena, Italy
Gianluca Cuomo, Italy

PE13/7  Factors Associated with Changes in Liver Stiffness in HIV/HCV Co-infected Patients along 5 Years of Follow-up: Effect of Treatment Response to HCV-therapy on Liver Fibrosis
Eva Van den Eynde, Spain

PE13/8  Does treatment of HCV with DAAs Affect Renal Function? Findings from the German Multicenter Cohort on Direct Antiviral Agents in HCV- and HIV/HCV-infected Patients (GECCO)
Stefan Mauss, Germany

PE13/9  Co-morbidities and Co-medications in HIV Patients with Hepatitis C in the Era of New Agents
Lise Cuzin, France

PE13/10  Efficiency of an Integrated Management of New Treatments of HCV
Julie Chas, France

PE13/11  Differential Regulation of Primary Natural Killer Cell Function by Sequence Variations in HCV Core-derived Epitope through Altered Binding of KIR2DL3 to HLA-C*03:04
Sebastian Lunemann, Germany

PE13/12  CD4 and CD4/CD8 Ratio Progression in HIV-HCV Infected Patients after Achievement of SVR
Annalisa Saracino, Italy

PE13/13  Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-infected Patients
Sanjay Bhagani, United Kingdom

PE13/14  Incidence and Recurrence of Hepatitis C Virus Reinfection after Sustained Virological Response in a Large Cohort of Prisoners
Andrés Marco, Spain

PE13/15  Differences in HCV Genotype 1a and 1b Molecular Epidemiology and NS3A Resistance Associated Variant Frequency among HIV-coinfected Patients from Poland
Milosz Parczewski, Poland

PE13/16  Prognostic Value of Transient Elastography in HIV-infected Patients with Chronic Hepatitis C
Juan Berenguer, Spain

PE13/17  Acute Hepatitis C in HIV Co-infected Patients in Barcelona: A Rising Epidemics
Maria Martínez-Rebollar, Spain

PE13/18  Prognostic Value of Liver Stiffness in HIV/HCV-coinfected Patients with Decompensated Cirrhosis
Juan Berenguer, Spain

PE13/19  Determinants and Impact of Late HCV Diagnosis among Persons with Newly Diagnosed HIV Infection
Enrico Girardi, Italy
Sci\textbf{entific Programme}

PE13/20 \textbf{HCV-RNA Profiles among HIV/HCV-coinfected Individuals in the ESPRIT Study: Spontaneous HCV-RNA Clearance Documented in 9 Individuals}
\textit{Daniel Grint, United Kingdom}

PE13/21 \textbf{Seroclearance of Hepatitis B Surface Antigen is Associated with Immune Reconstitution Inflammatory Syndrome among HIV and HBV Coinfected Individuals}
\textit{Takashi Muramatsu, Japan}

PE13/22 \textbf{Boceprevir Plus Peginterferon/Ribavirin to Retreat HCV Genotype-1 in HIV-HCV coinfected Patients. Final Results of BOC HIV-HCV Spanish Study Group}
\textit{Montserrat Laguno, Spain}

PE13/23 \textbf{HIV/HCV-coinfection across Europe}
\textit{Lars Peters, Denmark}

PE13/24 \textbf{Prevalence and Clinical Determinants of Hepatitis Delta Co-infection in a Rural Tanzanian HIV Cohort}
\textit{Annja Winter, Switzerland}

PE13/25 \textbf{Challenges of Anti HCV Treatment in Persons Living with HIV in the Era of Directly Acting Antivirals (DAA)}
\textit{Massimo Puoti, Italy}

PE13/26 \textbf{Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectiveness And Impact on Liver Fibrosis (MASTER Cohort)}
\textit{Paola Nasta, Italy}

PE13/27 \textbf{Awareness of HCV-coinfection among Newly Diagnosed HIV Individuals}
\textit{Paola Scognamiglio, Italy}

PE13/28 \textbf{Monocytes and Dendritic Cells Subsets during New Anti-HCV Treatments: IFN free and IFN Based Regimen}
\textit{Stefano Savinelli, Italy}

PE13/29 \textbf{High Efficacy of Grazoprevir/Elbasvir in HCV Genotype 1, 4, and 6-infected Patients with HIV-co-infection: The phase 3 C-EDGE Co-infection Study}
\textit{Christine Katlama, France}

PE13/30 \textbf{Safety and Efficacy of combinations of Direct Antiviral Agents (DAAs) against Hepatitis C Virus (HCV) in HIV Co-infected Patients}
\textit{Daniela Buccione, Spain}

PE13/31 \textbf{Safety and Efficacy of IFN-free, DAAs-based Therapy in HIV/HCV Solid Organ Transplanted Patients}
\textit{Ana Moreno, Spain}

PE13/32 \textbf{Real-world Effectiveness of Ledipasvir/sofosbuvir 8 Weeks Chronic Hepatitis C Treatment}
\textit{Karsten Wursthorn, Germany}

PE13/33 \textbf{Interferon-gamma (IFN-\textgreek{g})-inducible Protein-10 (IP-10) and sCD163 in HCV Monoinfected and HIV/HCV-coinfected Subjects: A Potential Role as Markers of Fibrosis and Response to Therapy}
\textit{Claudia Mascia, Italy}
Scientific Programme

PE13/34  Safety and Efficacy of SOF-based Therapy in HIV/HCV-coinfected Patients with Chronic Kidney Disease (CKD) in “Real Life”
David Nicolás, Spain

PE13/35  Reduced CD4 Monitoring in Stable and Virally Suppressed HIV/HCV-coinfected Patients from the PISCIS Cohort (Spain)
David Nicolás, Spain

PE13/36  Linkage to Care after Routine HIV, Hepatitis B (HBV) & C (HCV) Testing in the Emergency Department (ED) - The ‘Going Viral’ Campaign
Rageshri Dhairyawan, United Kingdom

PE13/37  Prevalence of Hepatitis B Virus and Hepatic Fibrosis Progression after ART Initiation among ART-naïve Individuals in a Rural Tanzanian HIV Cohort
Adrià Ramírez-Mena, Spain

PE13/38  Effectiveness of New Direct-acting Antivirals in a Real-life Cohort of Difficult-to-Treat HCV and HIV/HCV-coinfected Patients
María Jesús Vivancos Gallego, Spain

PE13/39  Directly-acting Agents against the Hepatitis C Virus (HCV) for HCV-coinfected and HIV-HCV-coinfected Patients with HCV Genotypes 1, 2, 3 and 4 - Results from the German Hepatitis C Cohort (GECCO)
Stefan Christensen, Germany

PE13/40  High Proportion of Advanced Liver Fibrosis and Cirrhosis Requiring Hepatitis C Treatment in HIV-HCV Coinfected Patients in Hai Phong, Northern Vietnam
Tam Nguyen Truong, Viet Nam

PE13/41  Are there any Variables that Predict a Rapid Progression to Liver Fibrosis in HIV-HCV infected patients?
David Rial, Spain

PE13/42  Spontaneous Hepatitis C Virus (HCV) Clearance: Epidemiological and Clinical Characterization and Identification of Predictive Factors of Clearance in a Portuguese Cohort
Nina Fernandes, Portugal

PE13/43  Significant Reductions in Costs of Generic Production of Sofosbuvir and Daclatasvir for Hepatitis C Treatment in Low- and Middle-income Countries
Andrew Hill, United Kingdom

PE13/44  Differential Effects of HCV Therapy with Direct Acting Antiviral Agents on Lipids in the German Multicenter Cohort on Direct Antiviral Agents in HCV- and HIV/HCV-infected Patients (GECCO)
Stefan Mauss, Germany

PE13/45  Correlates of Successful HCV Treatment in HIV Co-infected Vulnerable Populations
Syune Hakobyan, Canada

PE13/46  High Prevalence of Undiagnosed Hepatitis C Virus (HCV) Infection in Attendees of the Emergency Department of a Central London Hospital
Daniel Bradshaw, United Kingdom
Scientific Programme

PE14/1  Infectious Complication Rate in a Cohort of HIV-infected Kidney Transplant Recipients
        Oana Ailioaie, Romania

PE14/2  Antiretroviral and Cotrimoxazole Prophylactic Therapies among HIV-TB Co-infected Patients
        Olatunji Adetokunboh, South Africa

PE14/3  Resistance to Antituberculous Drugs and Outcome among TB/HIV Co-infected Adults in Ghana - Detect HIV/TB study
        Stephanie Bjerrum, Denmark

PE14/4  HIV/TB Coinfection
        Mariana Hualde, Argentina

PE14/5  Use of IGRA Tests for Heavy Immunosuppressed HIV-patients
        Aleksander Panteleev, Russian Federation

PE14/6  FDG-PET/CT: A Non-invasive Tool in Diagnosis and Monitoring of Therapeutic Response in HIV Patients with Extra-pulmonary Tuberculosis
        Charlotte Martin, Belgium

PE14/7  Drug Resistant TB in HIV-infected Patients in St Petersburg: Problems and Perspectives
        Aleksander Panteleev, Russian Federation

PE14/8  Has Tuberculosis in HIV-infected Patients the Same Clinical and Epidemiological Features than Tuberculosis in HIV-negative Patients?
        Javier Martinez-Sanz, Spain

PE14/9  Consecutive Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis in a Spanish cohort of HIV-infected Individuals
        Adrià Ramírez-Mena, Spain

PE14/10 Computed Tomography in the Diagnosis of Bowel Diseases in Patients with HIV/Tuberculosis co-infection
        Irina Sokolina, Russian Federation

PE15/1  Human Immunodeficiency Virus Infection and Stroke: A Case-control Study in a Portuguese Hospital
        André Silva-Pinto, Portugal

PE15/2  Prevalence of Hypertension and Obesity among HIV Patients in a Care Program in Nairobi: A Case for Integration of Care
        Moses Masika, Kenya

PE15/3  Brain-related Voice Emotion Processing Deficits in HIV-infected Patients
        Alicia González-Baeza, Spain

PE15/4  Burden of Chronic Obstructive Pulmonary Disease (COPD) and its Determinants in an African HIV Cohort
        Attannon Arnauld Fiogbé, Togo

PE15/5  Ageing with HIV: Do Comorbidities and Poly-medication Drive Treatment Optimizations?
        Lise Cuzin, France
<table>
<thead>
<tr>
<th>PE15/6</th>
<th>Central Obesity and Correlating Factors in Vojvodina’s Cohort</th>
<th>Daniela Maric, Serbia</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE15/7</td>
<td>Prevalence and Risk Factors for Chronic Kidney Disease (CKD) among Ambulatory ART Naive HIV-1 Infected Patients in a Rural Kenyan Population</td>
<td>Paul Yonga, Kenya</td>
</tr>
<tr>
<td>PE15/8</td>
<td>Has CXCL13 an Added Value in the Diagnosis of Neurosyphilis?</td>
<td>Khutso Mothapo, Netherlands</td>
</tr>
<tr>
<td>PE15/9</td>
<td>Associations between Cognitive Impairment and Patient-reported Measures of Physical/Mental Functioning in Older People Living with HIV</td>
<td>Jonathan Underwood, United Kingdom</td>
</tr>
<tr>
<td>PE15/10</td>
<td>Metabolic Syndrome and Sub Clinical Cardiovascular Disease Detected on Cardiac MRI in HIV Infected Patients</td>
<td>Aisling Loy, Ireland</td>
</tr>
<tr>
<td>PE15/11</td>
<td>Increased Markers of Endothelial Dysfunction in Untreated HIV Infection Are Associated with Viral Replication but Not with Platelet Aggregation</td>
<td>Judith Haissman, Denmark</td>
</tr>
<tr>
<td>PE15/12</td>
<td>Evaluation of a Physiotherapy-led Group Rehabilitation Intervention for Adults Living with HIV: Referrals, Adherence and Outcomes</td>
<td>Darren Brown, United Kingdom</td>
</tr>
<tr>
<td>PE15/13</td>
<td>Aging on cART: No Worsening of Bone Mineral Density over 12 Years</td>
<td>Clotilde Allavena, France</td>
</tr>
<tr>
<td>PE15/14</td>
<td>Gastroesophageal Reflux Disease among Adults with HIV: Prevalence and Risk Factors of Severe or Frequent Symptoms</td>
<td>Mazen Bader, Canada</td>
</tr>
<tr>
<td>PE15/15</td>
<td>Evaluation and Management of Fracture Risk of HIV Patients in the US Veterans Health Care System</td>
<td>Roger Bedimo, United States</td>
</tr>
<tr>
<td>PE15/16</td>
<td>Nephrology Consultations Incorporated into HIV Care - Non-compliance is an Important Issue</td>
<td>Bartłomiej Matosz, Poland</td>
</tr>
<tr>
<td>PE15/17</td>
<td>Cardiovascular Risk Assessment in HIV-1 Infected Patients and a Comparison of Framingham, SCORE, and DAD Risk Methods</td>
<td>Zev Sthoeger, Israel</td>
</tr>
<tr>
<td>PE15/18</td>
<td>Absence of Pneumocystis jirovecii Colonization in HIV-infected Persons</td>
<td>Andreas Ronit, Denmark</td>
</tr>
<tr>
<td>PE15/19</td>
<td>COPD Symptom and Disease Screening in an HIV Population</td>
<td>Nadine Kronfli, Canada</td>
</tr>
<tr>
<td>PE15/20</td>
<td>Epidemiology and Costs for Comorbidities in People Living with Human Immunodeficiency Virus (PLWHIV) - A Systematic Review</td>
<td>Julie Glanville, United Kingdom</td>
</tr>
</tbody>
</table>
Scientific Programme

PE15/21  A Calibration of the Framingham Coronary Risk Function Adapted to the Characteristics of Spanish HIV-infected Patients  
Vicente Estrada, Spain

PE15/22  Evaluation of HIV Testing Recommendations In Specialty Guidelines for the Management of HIV Indicator Conditions  
Emily Lord, United Kingdom

PE15/23  The Prevalence and Outcome of HIV-associated Neurocognitive Impairment in a Clinical Setting  
Francesca Ferretti, United Kingdom

PE15/24  Characteristics and Outcome of Patients Diagnosed with HIV at Older Age  
Ilan Asher, Israel

PE15/25  Improvement of the Estimation Performance of Ischemic Heart Events Risk in Mediterranean HIV-infected Patients by Means of the Adapted Framingham Function (REGICOR)  
Hernando Knobel, Spain

PE15/26  Analysis of Co-morbidities in HIV Infection  
Svetlana Buzunova, Russian Federation

PE15/27  Comorbidities and Disability Experienced among Adults Living with HIV in Canada: Results from the HIV Health and Rehabilitation Survey  
Kelly O’Brien, Canada

PE15/28  Clinical Evaluation is Better than Risk Prediction Algorithms to Identify Patients who Need Statin Therapy  
Giovanni Guaraldi, Italy

PE15/29  cIMT Progression in 90 Patients Starting Their First Highly Active Antiretroviral Therapy: 48 Months Observation  
Sergio Ferrara, Italy

PE15/30  Cannabis Exposure Increases the Risk of Liver Fibrosis in HIV-infected Patients  
Olivia Zaegel-Faucher, France

PE15/31  Epidemiology of Acute Myocardial Infarction in HIV-infected Patients in Spain during the Combination Antiretroviral Therapy Era (1997-2011)  
Juan Berenguer, Spain

PE15/32  Ageing Perception and Attitudes in HIV Patients in Italy  
Mariangela Errico, Italy

PE15/33  Impact of Maraviroc, Dolutegravir and Darunavir/Ritonavir on Human Coronary Endothelial Cell Functions According to Age  
Jacqueline Capeau, France

PE15/34  Statins and Aspirin in HIV-infected People: Gap between Guidelines and Clinical Practice. The Results of the HIV-HY Study  

PE15/35  The Metabolome in HIV-associated Chronic Obstructive Pulmonary Disease  
Chris Wendt, United States
<table>
<thead>
<tr>
<th>PE15/36</th>
<th>Low Prevalence of HIV-associated Neurocognitive Disorder (HAND) in a Swedish Cohort of HIV-1 Infected Individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Åsa Mellgren, Sweden</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/37</th>
<th>Non-viral Liver Disease Burden in HIV Positive Individuals. A Prospective Cohort Study: Preliminary Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yishi Tan, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/38</th>
<th>Impact of HIV and Type 2 Diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hedda Hoel, Norway</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/39</th>
<th>Apolipoprotein E (ApoE) e2 Genetic Variant is Associated with Favorable Lipid Profile on cART among HIV-1 Infected Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magdalena Wiltak-Jedra, Poland</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/40</th>
<th>CD4/CD8 Ratio for Monitoring the Immunological Response to Combined Antiretroviral Therapy in Ageing HIV+ Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria Nikolova, Bulgaria</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/41</th>
<th>Description of a Male to Female Transgender HIV Positive Population in the North-West of France in 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeremie Leporrier, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/42</th>
<th>Lack of Association between Liver Stiffness and Bone Mineral Density in HIV/HCV-coinfected Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Juan Berenguer, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/43</th>
<th>Should We Screen for NAFLD/NASH in HIV Patients?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giovanni Guaraldi, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/44</th>
<th>Human Papillomavirus Infection in HIV Positive and HIV Negative Men Who Have Sex with Men in Non Metropolitan Area of Central Italy: Prevalence and Genotypes Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Claudio Ucciferri, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/45</th>
<th>The Characteristics, Prevalence and Progression of Insulin Resistance in Patients with HIV and HIV/HCV Coinfection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opas Putcharoen, Thailand</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/46</th>
<th>Trends in Myocardial Infarction among HIV-1-infected Individuals in France between 2000 and 2009 Compared to the General Population: Results from FHDH-ANRS CO4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dominique Costagliola, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/47</th>
<th>Assessment of Associations between Markers of Renal Function and Bone Mineral Density in HIV-positive and HIV-negative Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elena Alvarez, Ireland</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/48</th>
<th>Effectiveness of Progressive Resistive Exercise for Adults Living with HIV: A Cochrane Collaboration Systematic Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kelly O'Brien, Canada</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE15/49</th>
<th>Relationship between Surface Activation Markers on Peripheral Monocyte/Macrophage and Evolution of Cognitive Performance in HIV-infected Patients under Suppressive Antiretroviral Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alessandra Bandera, Italy</td>
<td></td>
</tr>
</tbody>
</table>
PE15/50  A Systematic Review of Psychiatric Illness and Sleep Disturbance Prevalence as Comorbidity with HIV in the UK, with Comparison to the UK General Population
Masautso Chaponda, United Kingdom

PE15/51  Vaginal Shedding of Herpesviridae Does Not Influence the Coronary Microcirculation in HIV-infected Women
Andreas Knudsen, Denmark

PE15/52  Prevalence of Central Obesity and Metabolic Complications among Adults Living with HIV in Ireland
Laura Kelly, Ireland

PE15/53  Association with Statin Use in Individuals with and without Cardiovascular Disease
Gisela Leierer, Austria

PE15/54  A Study of the Effect of Early, Untreated HIV on Cerebral Perfusion and Arterial Transit Time in the Basal Ganglia Using Arterial Spin Labelling
Lewis Haddow, United Kingdom

PE15/55  Plasma Osteoprotegerin Concentration in HIV Infected Men and its Association with Hypertriglyceridemia
Anita Olczak, Poland

PE15/56  Anaemia and HIV - An Old New Study Opportunity

PE15/57  Increased Incidence of Cancer and Cancer-related Mortality among HIV/HCV-coinfected Patients, 1993-2014
Alvaro Mena, Spain

PE15/58  Neuroimaging Findings in Effectively Suppressed HIV+ Patients with Symptomatic Neurocognitive Dysfunction: A Cross-sectional Sub-study from the PIVOT Trial
Alejandro Arenas-Pinto, United Kingdom

PE15/59  Age-related Polypharmacy in HIV-infected Patients in a Spanish University Hospital
Angels Andreu - Crespo, Spain

PE15/60  The “Bone Status” in under 40 HIV Positive Patients
Ermelinda Guerra, Italy

PE15/61  White Matter Abnormalities Are Associated with Neurocognitive Disorders in HIV-positive Patients
Andrea Calcagno, Italy

PE15/62  Blood Brain Barrier Impairment is Associated with CSF Neopterine in Late-presenters and with Neurodegeneration and Astrocytosis in Patients with CSF HIV RNA
Andrea Calcagno, Italy

PE15/63  Weight Loss as a Potential Benefit of Liraglutide for Treatment of Diabetes Mellitus in HIV Patients
Amanda McAneny, United States

PE15/64  How do Frailty Mediate and Moderate Pathway Leading to Disability
Andrea Malagoli, Italy
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE15/65</td>
<td>Loss of Bone Mineral Density on Long-term Antiretroviral Therapy: Protective Effect of Nevirapine?</td>
<td>François Raffi, France</td>
</tr>
<tr>
<td>PE15/66</td>
<td>Neurological Complications in HIV+ Patients</td>
<td>Goffredo Angioni, Italy</td>
</tr>
<tr>
<td>PE15/67</td>
<td>Should We Still Use the “Three Questions Test” as a Screening of HIV-associated Neurocognitive Disorders? Evaluation of Sensitivity, Specificity, Positive and Negative Predictive Value and Association with Altered Quality of Life</td>
<td>Francesca Bai, Italy</td>
</tr>
<tr>
<td>PE15/68</td>
<td>HIV Infection is Associated with Reduced Bone Quality Independently of Bone Mineral Density and Antiretroviral Treatment</td>
<td>Robert Güerri-Fernández, Spain</td>
</tr>
<tr>
<td>PE15/69</td>
<td>Increased Urinary Albumin-to-creatinine Ratio and the Metabolic Syndrome Contribute to Endothelial Dysfunction in HIV+ Patients with Normal Renal Function</td>
<td>Elisabetta Schiaroli, Italy</td>
</tr>
<tr>
<td>PE15/70</td>
<td>Dyslipidemia and Fasting Glucose Impairment among HIV-infected Patients 48-weeks after the First Antiretroviral Regimen</td>
<td>José Antonio Mata-Marín, Mexico</td>
</tr>
<tr>
<td>PE15/71</td>
<td>Risk Factors for Chronic Kidney Disease in HIV-1 Infected Mexican Patients Initiating Antiretroviral Therapy</td>
<td>Ricardo Rojas-Agualar, Mexico</td>
</tr>
<tr>
<td>PE15/73</td>
<td>A Cross-sectional Study of Co-morbidities in HIV-infected Patients Receiving cART in Taiwan: A Nationwide Surveillance</td>
<td>Chia-Jui Yang, Taiwan, Republic of China</td>
</tr>
<tr>
<td>PE15/74</td>
<td>Prevalence of Low 25-hydroxy-vitamin D levels and Factors Associated with 25-hydroxy-vitamin D Insufficiency in a Large European HIV Cohort</td>
<td>Rocio Montejano, Spain</td>
</tr>
<tr>
<td>PE15/75</td>
<td>Prevalence of Respiratory Symptoms and Screening for Chronic Obstructive Pulmonary Disease: Results from an Italian Multicenter Study</td>
<td>Giordano Madeddu, Italy</td>
</tr>
<tr>
<td>PE15/76</td>
<td>Cerebrospinal Fluid (CSF) HIV Escape is Associated with Progressive Neurologic Deterioration in Patients on Virologically Suppressive Antiretroviral Therapy (ART) in Western India</td>
<td>Ameet Dravid, India</td>
</tr>
<tr>
<td>PE15/77</td>
<td>Health Transitions in HIV-seropositive Individuals Undergoing NRTI-based and NRTI-sparing Treatment Strategies</td>
<td>Stefano Zona, Italy</td>
</tr>
<tr>
<td>PE15/78</td>
<td>Brain Functioning and Neurocognitive Disorders among Young HIV-positive MSM Treated with cART. Preliminary Results</td>
<td>Bogna Szymańska, Poland</td>
</tr>
<tr>
<td>PE15/79</td>
<td>Lopinavir Alone and Ritonavir-boosted Lopinavir Induce Adipocyte Toxicity at Nanomolar Concentrations in vitro</td>
<td>Robert Maughan, Ireland</td>
</tr>
</tbody>
</table>
Scientific Programme

PE15/80  Active HCV Replication is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV
Andrea De Luca, Italy

PE15/81  Improvement of Bone Mineral Density after Switching from Triple Therapy with Lopinavir and Ritonavir Plus Two Nucleos(t)ide Reverse Transcriptase Inhibitors to Lopinavir and Ritonavir Plus Lamivudine: OLE-lip Substudy
Manuel Crespo, Spain

PE15/82  Neuropsychological Performance and Self-Reported Function in HIV Positive Patients in Five European Clinics
Lewis Haddow, United Kingdom

PE15/83  Secondary Hyperparathyroidism in Patients Presenting Low 25-hydroxy-vitamin D: Prevalence and Associated Factors
Ignacio Pérez-Valero, Spain

PE15/84  Effect of Aging in the Neuropsychological Profile of HIV-infected Patients
Alicia González-Baeza, Spain

PE15/85  Prospective Assessment of Bone Mineral Density among a Cohort of Middle-aged HIV-infected and Uninfected Women: Evaluation of a Population at High Risk
Anna Pia Lassandro, Italy

PE15/86  HIV and Subclinical Atherosclerosis
Argyro Lazarini, Greece

PE15/87  Higher HIV Viral Load is Associated with Lower Levels of Vitamin D in Treatment-naive HIV Patients
María Elena Ceballos, Chile

PE15/88  Self-Reported Prevalence of Co-morbidities and Use of Non-HIV Related Medications among People Living with HIV in England and Wales: Results from the Positive Voices Survey
Meaghan Kall, United Kingdom

PE15/89  Relapse of Cerebrospinal Fluid Escape Following Optimization and Subsequent Simplification of Antiretroviral Therapy
Francesca Ferretti, United Kingdom

PE15/90  Study of Comorbidities in HIV Patients over 50 Years Old
Violeta Alastrué del Castaño, Spain

PE15/91  Will the Next Generation of Rehabilitation Professionals Be Ready to Treat People Living with HIV? Results of a Survey of UK Higher Education Institutions
Will Chegwidden, United Kingdom

PE15/92  Changes in Renal Biomarkers Following Tenofovir Discontinuation in HIV-infected Viral-suppressed Patients, Montreal, Canada
Annie Talbot, Canada

PE16/1  Cervical Squamous Intraepithelial Lesion and Risk Factors among HIV-infected Nigerian Women
Chidinma Vivian Gab-Okafor, Nigeria
PE16/2  Diagnostic Value of Anal Cytology, HPV Testing and High Resolution Anoscopy (HRA) in Screening for Anal Intraepithelial Neoplasia (AIN) in HIV Positive Individuals  
Deepa Grover, United Kingdom

PE16/3  Low Clearance and High Acquisition Rate of High-risk Human Papillomavirus (HR-HPV) in a Cohort of 260 Spanish HIV-positive Men Who have Sex With Men (MSM)  
Carmen Hidalgo-Tenorio, Spain

PE16/4  Low High-density Lipoprotein Cholesterol (HDL) is Associated with the Risk of Non-AIDS Defining Malignancies  
Nicola Squillace, Italy

PE16/5  Value of Prostate-specific Antigen (PSA) Screening for Prostate Cancer Detection in aging People Living with HIV (PLWHIV)  
David Zucman, France

PE16/6  Incidence and Survival in HIV Infected patients with Malignancies: A 7 Year Romanian Single Center Experience  
Cristiana Oprea, Romania

PE16/7  Detection of High Risk HPV in HIV Positive MSM Using Multiple Technologies - Implications for Immunisation and Disease Prevention  
Deepa Grover, United Kingdom

PE16/8  Increased risk of Radiation Induced Adverse Effects in Patients on NNRTI Based Antiretroviral Treatment  
Markus Hecht, Germany

PE16/9  Maintaining Dose Intensity of R-CHOP Improves Survival in HIV Associated Lymphoma  
Alessia Dalla Pria, United Kingdom

PE16/10 Incident of Cancer in HIV-infected Patients along 30 Years (1983-2013)  
Carolina Tudela, Spain

PE16/11 CD4+ and CDB+ T-Cell Kinetics in Aviremic HIV-infected Patients Developing Hodgkin or Non Hodgkin Lymphoma  
Christian Hoffmann, Germany

PE16/12 Prevalence and Incidence of Anal Dysplasia and High-risk Human Papillomavirus (HR-HPV) in a Prospective Cohort of Spanish Women Living with HIV (WLHIV)  
Carmen Hidalgo-Tenorio, Spain

PE16/13 Is There Evidence for T-cell Activation Prior to HIV-associated Lymphoma in Aviremic Patients?  
Christian Hoffmann, Germany

PE16/14 Evaluation of Hematologic and Hepatic Toxicity in HIV-associated Non-Hodgkin Lymphoma: A Cohort Study  
Alessandra Bandera, Italy

PE16/15 Prevalence and Persistence of HPV Infection and Citological Abnormalities in a Cohort of HIV Infected Patients  
Nicola Squillace, Italy
**Scientific Programme**

**PE16/16**
**Screening for Anal Intraepithelial Neoplasia (AIN) in HIV-positive Patients: The Practical Uptake of a New Guideline**  
Robert Jablonka, Germany

**PE17/1**
**Health Seeking Behaviour among Youth with Sexually Transmitted Infection in Nigeria**  
Orobosa Enadeghe, Nigeria

**PE17/2**
"A One Stop Shop" STD Service for MSM in Croatia/South East Europe - A New Approach  
Šime Zekan, Croatia

**PE17/3**
**Factors Associated with Urinary Tract Infections among HIV-1 Infected Patients - Is Active HCV Infection a Risk Factor?**  
Agata Skrzat-Wojdacz, Poland

**PE17/4**
**Anal Cytology (AC) and Sexually Transmitted Infection (STI) Screening in Ageing People Living with HIV (PLWH)**  
Malika Mohabeer Hart, United Kingdom

**PE17/5**
**HIV-1 Vaginal Shedding is Suppressed among HIV-1 Infected Women on Modern Combined Antiretroviral Therapy**  
Sara Grignolo, Italy

**PE17/6**
**Human Papillomavirus 58: An Emerging High-risk Genotype in Italian HIV-infected Men Who Have Sex with Men?**  
Claudio Ucciferri, Italy

**PE17/7**
**Men Who Have Sex with Men from Paris. Argument for Universal HPV Vaccination**  
Hugues Cordel, France

**PE17/8**
**High Rates of Sexually Transmitted Infections (STIs) and Recreational Drug Use (RDU) amongst HIV-positive Men Who Have Sex with Men (MSM) Attending Outpatients across London (UK)**  
Selena Singh, United Kingdom

**PE17/9**
**Long-term Hepatic Safety and Impact of Maraviroc on Fibrosis Progression: A 148 week Randomised, Double-blind Study of Maraviroc versus Placebo in Combination with Other Antiretroviral Agents in HIV-1 Patients Co-infected with Hepatitis C and/or Hepatitis B Virus**  
Frank Plonski, United States

**PE17/10**
**HIV and Syphilis: When Do we Need to Perform a Lumbar Puncture?**  
Agnès Libois, Belgium

**PE17/11**
**Detection of Anal HPV Infection by Two Techniques in HIV+ MSM Individuals and Correlation with Pathologic Findings in Cytology and Biopsy**  
Elena Ferrer, Spain

**PE17/12**
**Should Screening of Asymptomatic Sexually Transmitted Infections Be Performed to All HIV-infected Men Who Have Sex with Men?**  
Irene Sanchez, Spain

**PE17/13**
**Prevalence of Anal High-risk Human Papillomavirus Infections among HIV-positive Men Who Have Sex With Men in Istanbul**  
Alper Gündüz, Turkey
Scientific Programme

PE17/14  Acute Kidney Injury in Shigella Infection in an HIV-positive Cohort
Nadia Ahmed, United Kingdom

PE17/15  The Serum TRUST Titer ≥1:16 is a Predictor for Asymptomatic Neurosyphilis among HIV/Syphilis Co-infected Patients
Jianjun Sun, China

PE18/1   Sexual Risk and Sexually Transmitted Infections among Chinese HIV-positive MSM after Engagement in Care
Kenny CW Chan, China

PE18/2   "One Shouldn’t Convict People for Hypothetical Risks": Developments in European Criminal Law and Policy following Increased Knowledge and Awareness of the Additional Prevention Benefit of Antiretroviral Therapy
Edwin Bernard, United Kingdom

PE18/3   A Finger-stick Whole Blood HIV Self-test as an HIV Screening Tool Adapted to the General Public
Thierry Prazuck, France

PE18/4   Choice of nPEP Regimens and Completion Rates in a MSM Population in Sydney, Australia: Provision of Drugs at what Cost?
Rohan Bopage, Australia

PE18/5   Acceptability of Pre-exposure Prophylaxis (PrEP) and Reported Adherence to Non HIV Medication Regimens in HIV Negative Portuguese Men who Have Sex with Men (MSM) Eligible to PrEP
Luis-Miguel Rocha, Portugal

PE18/6   Human Immunodeficiency Virus (HIV): Continuum of Care in Europe and Central Asia
Teymur Noori, Sweden

PE18/7   Predictors of Knowledge of Non-occupational HIV Post Exposure Prophylaxis among Men Who Have Sex with Men Attending a Suburban Sexual Health Clinic in Sydney, Australia
Rasanga Liyanage, Australia

PE18/8   Acceptable Rates of Acute HIV Detection Using a Fourth-generation Point of Care HIV Test
Naomi Fitzgerald, United Kingdom

PE18/9   Evaluation of a Strategy to Improve Linkage to Care in Newly Diagnosed HIV Patients
Miguel Raffo, Spain

PE18/10  A New Strategy to Avoid HIV Patient’s Loss of Follow-up: Intervention at First Visit Failure
Jose Fajardo, Spain

PE18/11  Randomised Controlled Trial of the Tolerability and Completion of Maraviroc Compared to Kaletra® in Combination with Truvada® for HIV Post Exposure Prophylaxis (MiPEP Trial)
Ana Milinkovic, United Kingdom

PE18/12  Recording of the Professional Exposure to Blood Transmitted Agents at a Tertiary University Hospital in Greece, during 2007-2013
Anestis Ganitis, Greece
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE18/13</td>
<td>Knowledge and Use of Post-exposure Prophylaxis (PEP) among Men Who Have Sex with Men (MSM) in Portugal</td>
<td>Maria-José Campos, Portugal</td>
</tr>
<tr>
<td>PE18/14</td>
<td>Cohort for MSM as a Useful Tool to Assure Cost Effectiveness during the Implementation of PrEP</td>
<td>Michael Meulbroek, Spain</td>
</tr>
<tr>
<td>PE19/1</td>
<td>Using Quality Improvement to Address High Default from PMTCT Services (Early Infant Diagnosis) at State Hospital Ijebu Ode, Nigeria</td>
<td>Foluwaso Olaoluwa-Moronkeji, Nigeria</td>
</tr>
<tr>
<td>PE19/2</td>
<td>Higher Risks of Mother-to-Child HIV Transmission (MTCT) in Countries with Lower Prevalence: UNAIDS 2013 Results for 33 Countries with Generalised Epidemics</td>
<td>Andrew Hill, United Kingdom</td>
</tr>
<tr>
<td>PE19/3</td>
<td>Experience of Prevention of Mother to Child Transmission of HIV in Georgia</td>
<td>Ketevan Shermadini, Georgia</td>
</tr>
<tr>
<td>PE19/4</td>
<td>Regional Disparity of Maternal-paediatric Antiretroviral Coverage among African Priority Countries</td>
<td>Olatunji Adetokunboh, South Africa</td>
</tr>
<tr>
<td>PE19/5</td>
<td>UK National Clinical Audit 2014: Management of Pregnancies in Women with HIV</td>
<td>Sonia Raffe, United Kingdom</td>
</tr>
<tr>
<td>PE19/7</td>
<td>Drug Resistance Mutations (DRM) among Pregnant HIV-positive Women in the Duesseldorf University Hospital, Germany, 2009-2015</td>
<td>Ulrike Haars, Germany</td>
</tr>
<tr>
<td>PE19/8</td>
<td>Mode of Delivery in Pregnant Women Living with HIV in Denmark: A Risk Assessment of Emergency Caesarean Sections</td>
<td>Mathilde Ørbæk, Denmark</td>
</tr>
<tr>
<td>PE19/9</td>
<td>Evaluation of 10 Years of a Mother to Child Transmission Prevention Program in a Community Health Center in Bamako, Mali</td>
<td>Karamoko Tounkara, Mali</td>
</tr>
<tr>
<td>PE19/10</td>
<td>HIV Perinatally Exposed Children in Romania - Review</td>
<td>Alina Maria Cibea, Romania</td>
</tr>
<tr>
<td>PE20/1</td>
<td>The Effects of Toxic Impact of Tenofovir on the Bone Mineral Density in Children</td>
<td>Natalya Rymarenko, Ukraine</td>
</tr>
<tr>
<td>PE20/2</td>
<td>Prevalence and Characteristics of Group B Streptococcus Colonization in HIV-infected Pregnant Women in Belgium</td>
<td>Nicolas Dauby, Belgium</td>
</tr>
<tr>
<td>PE20/3</td>
<td>Resistance Mutations to Antiretroviral Drugs on HIV Strains of Treated HIV-1 Infectious Pediatric Patients in Venezuela</td>
<td>Diana Lopez, Venezuela</td>
</tr>
</tbody>
</table>
PE20/4  Associations between Paediatric HIV Clients, Their Caregivers and Retention: Evidence from the EMBRACE Cohort, Eastern Cape, South Africa
Hugh Adler, Ireland

PE20/5  The One-stop Clinic of Ifakara: Implementing a Bundle of Measures for Paediatric HIV Services in Rural Africa to Reach the UNAIDS’ Target “90-90-90”
Anna Gamell, Switzerland

PE20/6  Long-term Prognosis of Children Born to HIV-1 Infected Mothers in Japan
Mizue Tanaka, Japan

PE20/7  Abnormal Neurometabolite Levels Reflect Poorer Cognitive Performance in HIV-infected Children
Yvonne Wilma van Dalen, Netherlands

PE20/8  The Eye as a Window to the Brain: Retinal Structure Associated with Cerebral Injury in Perinatally HIV-infected Children
Charlotte Blokhuis, Netherlands

PE20/9  Threatening Levels of Acquired HIV Drug Resistance and Virologic Failure in Children and Adolescents in Rural Tanzania – An Emerging Public Health Concern
Lukas Muri, Switzerland

PE20/11  Educational Intervention Increases Acceptability and Knowledge of Newborn Male Circumcision (NMC) among Parents of Newborn Boys in Port-au-Prince, Haiti
Jessy Dévieux, United States

PE21/1  Evolution of HIV-infected Injecting Drug Users in Spain during 2004-2013: Persistence of Poor Engagement to Care and Worse Clinical Outcomes
Inés Suárez-García, Spain

PE21/2  Are Immigrant Men who Have Sex with Men (MSM) who Visited an HIV Checkpoint (Actuel-sur-Rue) in Montreal, Canada, More Vulnerable to HIV?
David Lessard, Canada

PE21/3  Weight Changes and Prognosis for People Living with HIV Initiating Highly Active Antiretroviral Therapy in the APROCO Cohort Study
Victoire Fokom Defo, Cameroon

PE21/4  Expansion of the CRF19_cpx Variant in Spain
Fernando Gonzalez-Candelas, Spain

PE21/5  A Decade of HIV Care and Treatment in Rural Tanzania: Trends in Treatment, Opportunistic Infections and Laboratory Abnormalities among HIV-positive Adults
Tracy Glass, Switzerland

PE21/6  Missed Opportunities for Earlier HIV Diagnosis in Men who Have Sex with Men (MSM) - A Service Evaluation of HIV Testing in UK Sexual Health Clinics
Emily Clarke, United Kingdom
PE21/7  A Universal Testing Programme for Blood Borne Viruses (BBV) in an Urban Emergency Department (ED) - A Call for Widespread Testing in Ireland
Sarah O’Connell, Ireland

PE21/8  Missed Opportunities for HIV Testing and Factors Associated with Delayed Diagnosis
Rosa de Miguel Buckley, Spain

PE21/9  Intervention Packages against HIV and HCV Infections for People who Inject Drug in Georgia: A Modeling and Cost-effectiveness Study
Guillaume Mabileau, France

PE21/10  The Continuum of HIV Care in Catalonia
Colin Campbell, Spain

PE21/11  From Pills to Patients: Determination of the Number of People Living with HIV who Are Receiving Antiretroviral Therapy, Costs and Potential Cost-savings in Germany
Daniel Schmidt, Germany

PE21/12  HIV Infection among Persons Aged 50 Years and over in the EU, 2004-2013: Missed Opportunities for Earlier Diagnosis?
Lara Tavoschi, Sweden

PE21/13  Use of 3 HIV Testing Methods in French Primary Care: Classical ELISA Laboratory Screening versus 2 Rapid Finger-stick HIV Tests with Result under 5 Minutes (INSTI) and up to 30 Minutes (VIKIA)
Angela Daiana Papadima, France

PE21/14  CD4+T-cell Count at cART Initiation among Migrant Men and Women Living in Western Europe
Susana Monge, Spain

PE21/15  Linkage to Care Following HIV Diagnosis in Europe: A Review of the Literature
Sara Croxford, United Kingdom

PE21/16  Comparing a ‘Multi Assay Algorithm’ with the BED Capture Enzyme Immunoassay for the Testing of Recent HIV-1 Infections in Germany
Andrea Hauser, Germany

PE21/17  Coverage and Acceptability of a Targeted Testing Strategy, Resourced by an External Program Intervention, DRIVE Study (Rapid Diagnosis of HIV infection in Spain)
María Jesús Pérez Elías, Spain

PE21/18  Unselected, Emergency Department-based Rapid HIV Screening Detects High Proportion of Early, Asymptomatic HIV Infection
Marilia Rita Pinzone, Italy

PE21/19  Recreational Drug Consumption in People Living with HIV in Europe: A Systematic Review
Cesar Velasco, Spain

PE21/20  HIV Late Presentation in Southern Sardinia, Italy
Goffredo Angioni, Italy
Scientific Programme

PE21/21  Travel to the Tropics and its Impact on Viral Control in HIV Patients in the Swiss HIV Cohort Study
Hiwot Gebreselassie, Switzerland

PE21/22  Recent HIV-infections in Germany 2008-2014: What Do we Know?
Andrea Hauser, Germany

PE21/23  High Rate of Transmission Clusters among Men Who Have Sex with Men (MSM) with Acute-recent HIV Infection in Barcelona
Juan Ambrosioni, Spain

PE21/24  Developments in the Delay of HIV Detection and Treatment Initiation in Recent Years
Borja Carmelo Gracia Tello, Spain

PE21/25  Transmission Clustering among Kiev HIV Sequences
Esther Fearnhill, United Kingdom

PE21/26  HIV Subtypes: The Same Disease, Different Stories?
Claudia Afonso, Portugal

PE21/27  HIV Testing in Innovative Environments Mexico
Nalleli Delgadillo, Mexico

PE21/28  Ongoing Mononucleosis-like Illness - A Clear Indicator Condition for HIV Testing: Results from the HIDES 2 Study - Single Arm Extension
Dorthe Raben, Denmark

PE21/29  The Acute/Recent HIV Infection Cohort from Hospital Clinic, Barcelona: Epidemiological and Virological Trends from 1997 to 2014
David Nicolás, Spain

PE21/30  Healthcare Related Costs of Missed Opportunities for HIV Diagnosis: A Potential Driver to Increase Indicator Condition Guided HIV Testing
Caroline Rae, United Kingdom

PE21/31  Current Epidemiology and Outcomes of HIV-infected Patients Admitted to an Intensive Care Unit (ICU) in Barcelona, Spain
Veronica Rico, Spain

PE21/32  Over Half of People in HIV Care in the United Kingdom by 2028 Will Be Aged 50 Years or Above
Zheng Yin, United Kingdom

PE21/33  Trends and Causes of Hospitalization among HIV-infected People from 1998 to 2015 in a Single Italian Tertiary Care Centre
Alberto Borghetti, Italy

PE21/34  Recent HIV Infection: Epidemiologic, Clinical and Therapeutic Evolution of a Portuguese Cohort
Bernardo Neves, Portugal

PE21/35  Retention in Care of a Population of Migrant HIV-infected IDUs in Greece (Single Center Experience)
Eleni Kakalou, Greece
Scientific Programme

PE21/36  Is It Feasible to Reduce the Number of Determinations Performed on Viral Load and CD4 T-lymphocytes in an HIV Specialized Consultation Unit?  
Alberto Díaz-De Santiago, Spain

PE21/37  Clinical and Epidemiological Characteristics of HIV Infection Newly Diagnosed in People over 59 Years of the Spanish Cohort VACH  
Dolores Merino Muñoz, Spain

PE21/38  Asymptomatic Late Presenters: 12 Years Trend in CD4+ Cell Counts at HIV Diagnosis in a Single Testing Site in Buenos Aires  
Mariana Kundro, Argentina

PE21/39  Analysis of New HIV Diagnoses among Young People  
Borja Carmelo Gracia Tello, Spain

PE21/40  Dynamics of Transmission Trends in 30 Years of HIV Epidemic in Romania  
Mariana Mardarescu, Romania

PE22/2  Late HIV Diagnosis in Georgia: Public Health and Economic Implications  
Nikoloz Chkhartishvili, Georgia

PE22/4  Using Mixed-methods to Understand HIV Treatment Cascade among OST Patients and PWIDs in Five Ukrainian Cities  
Alyona Mazhnaya, Ukraine

PE22/5  High Proportion of Viral Suppression with Frequent Changes of Antiretroviral Treatment in Newly Diagnosed Patients in Santo Andre Aids Program, Sao Paulo, Brazil  
Elaine Matsuda, Brazil

PE22/6  High Proportion of Virological Failure and HIV Drug Resistance among TB/HIV Co-infected Ugandan Adults  
Amrei von Braun, Uganda

PE22/7  First-line Antiretroviral Therapy in Resource-limited Settings: the Experience of Serbia  
Gordana Dragovic, Serbia

PE22/8  Direct Costs of HIV/AIDS Care in Estonia  
Liis Lemsalu, Estonia

PE22/9  Treating HCV with Interferon-free Regimens in Correctional Settings: An Italian Experience  
Antonella Foschi, Italy

PE22/11  Deferring CD4 Cell Count Monitoring in HIV+ Treated Patients with More than 350 or 500 CD4 Lymphocyte/μl is a Safe and Cheap Strategy  
Benedetto Celesia, Italy

PE23/1  Sexual Risk Behaviours of High School Students in an Urban Town of Cameroon  
Tarkang Elvis, Cameroon

PE23/2  Assessing Parental Knowledge and Attitudes towards Disclosure of HIV  
Conor Lyons, Ireland
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE23/3</td>
<td>HIV Prevalence and Factors Associated with HIV Infection among Injection Drug Users, Uzbekistan</td>
<td>Shukhrat Umarkhojaev, Uzbekistan</td>
</tr>
<tr>
<td>PE23/4</td>
<td>Stigma towards People Living with HIV/AIDS among Healthcare Practitioners and Medical Students</td>
<td>Julia Dabravolskaj, Canada</td>
</tr>
<tr>
<td>PE23/5</td>
<td>Lost Opportunities for Early ART</td>
<td>Anastasia Pokrovskaya, Russian Federation</td>
</tr>
<tr>
<td>PE23/6</td>
<td>SM@RT-@IDS: The Digital Prevention for the Smart Generations</td>
<td>Carmine Falanga, Italy</td>
</tr>
<tr>
<td>PE23/7</td>
<td>HIV Disclosure and Stigma among Women Living with HIV in Denmark - Results from the SHADE Cohort</td>
<td>Maria Wessman, Denmark</td>
</tr>
<tr>
<td>PE23/8</td>
<td>Barriers to Accessing HIV Testing, Treatment and Healthcare for Migrants Living with HIV in Europe</td>
<td>Ibidun Fakoya, United Kingdom</td>
</tr>
<tr>
<td>PE23/9</td>
<td>Barriers to HIV Routine Screening in Primary Care: What Do Patients Think about it?</td>
<td>Guillaume Conort, France</td>
</tr>
<tr>
<td>PE23/10</td>
<td>Disutilities Associated with Central Nervous System (CNS) Side Effects of Antiretroviral Therapy (ART) in HIV: Results from the UK, France and Spain</td>
<td>Rodolphe Perard, United Kingdom</td>
</tr>
<tr>
<td>PE23/11</td>
<td>The StigmaIndexUK-2015: A New Methodology for Measuring the Experiences of Stigma among People Living with HIV</td>
<td>Jo Jefferies, United Kingdom</td>
</tr>
<tr>
<td>PE23/12</td>
<td>Differences in Patients and Physicians Adherence Evaluation - Results from the German Adherence Cohort Study</td>
<td>Christoph Spinner, Germany</td>
</tr>
<tr>
<td>PE23/13</td>
<td>The Impact of Antiretroviral Therapy on Treatment Satisfaction and Quality of Life of PLWH in Europe</td>
<td>Miranda Murray, United Kingdom</td>
</tr>
<tr>
<td>PE23/14</td>
<td>HIV/AIDS-related Knowledge and Behaviors of Precarised Migrants in the Geneva Area, Switzerland</td>
<td>Deborah Glejser, Switzerland</td>
</tr>
<tr>
<td>PE23/15</td>
<td>Health Workers in B&amp;H and HIV Stigma and Discrimination</td>
<td>Stela Stojisavljevic, Bosnia and Herzegovina</td>
</tr>
<tr>
<td>PE23/16</td>
<td>A New International Questionnaire to Assess Health-related Quality of Life (HRQL) Specific to Viral Hepatitis C: Proqol-HCV</td>
<td>Martin Duracinsky, France</td>
</tr>
<tr>
<td>PE23/17</td>
<td>Reduced CD4 Count Monitoring: Potential for Large Cost Savings but is it Acceptable to Patients?</td>
<td>Sophie Flavell, United Kingdom</td>
</tr>
</tbody>
</table>
Scientific Programme

PE23/18  Prediction of the Factors Influencing the HIV Test Utilisation among Young People Aged between 17-25 Years in Saudi Arabia
Abdullah Almilaiibary, United Kingdom

PE23/19  Clinical and Community Views of the Instant Result HIV Self-testing: Barriers and Facilitators for Effective Implementation amongst MSM (Men who Have Sex with Men)
Jamie Frankis, United Kingdom

PE23/20  Clinical, Psychological and Behavioural Barriers to HIV Testing amongst MSM (Men who Have Sex with Men) who Use Social and Sociosexual Media: Implications for HIV Prevention Programmes
Jamie Frankis, United Kingdom

PE24/1  Integrated HIV and Gynaecological Services for HIV-positive Women in Warsaw - A Luxury or Standard of Care?
Justyna Kowalska, Poland

PE24/2  Gender Differences in Baseline Epidemiological Profile and Clinical Characteristics and its Evolution in the Spanish AIDS Research Network Cohort (CoRIS)
Constanza Muñoz, Spain

PE24/3  Facts on Contraception Use and Unintended Pregnancies in HIV-infected Women on Antiretroviral Therapy in Switzerland
Valentina Mercanti, Switzerland

PE24/4  Epidemiological Trends of HIV Infection in Women Spanish Cohort Vach
Dolores Merino Muñoz, Spain

Special Session
13:00 - 14:00
Room Barcelona

BPD1, Best Poster Discussion 1 - Clinical Science - Treatment

Chairs:
Pedro Cahn, Argentina
Linos Vandekerckhove, Belgium

BPD1/1  Patients´ Characteristics and Prescription Practices of Post-exposure Prophylaxis for HIV in a Large Metropolitan Emergency Room in Switzerland, 2007-2013
Alex Marzel, Switzerland 13:00 - 13:06

BPD1/2  People Living with HIV who Visited AIDS Centers in Russia
Anastasia Pokrovskaya, Russian Federation 13:06 - 13:12

BPD1/3  Healthcare Provider Communication Training Program Improves Adherence Assessment in HIV-infected Patients Treated with Antiretroviral Therapy (ART) in Rural Tanzania
Stefan Erb, Switzerland 13:12 - 13:18
Scientific Programme

BPD1/4
The Efficacy and Safety of Elvitegravir (EVG)/Cobicistat (COBI)/Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) and Ritonavir (RTV) Boosted Atazanavir (ATV) plus FTC/TDF in Treatment Naïve Women with HIV-1 Infection: Week 48 Analysis of the Phase 3, Randomized, Double Blind Study
Cissy Kityo, Uganda
13:18 - 13:24

LBBPD1/1
A Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF), Each Coformulated with Elvitegravir, Cobicistat and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 96 Results
David Wohl, United States
13:24 - 13:30

BPD1/5
Week 48 Results of the Randomised, Multicentre Maraviroc Switch Study (MARCH)
Sarah Pett, Australia
13:30 - 13:36

BPD1/6
Simplification to Atazanavir/Ritonavir + Lamivudine versus Maintaining Atazanavir/Ritonavir + 2NRTIs in Virologically Suppressed HIV-infected Patients: 48-weeks Data of the ATLAS-M Trial
Andrea De Luca, Italy
13:36 - 13:42

BPD1/7
Estimation of Renal Function by CKD-EPI versus MDRD Equations in a Cohort of HIV-infected Patients: A Cross-sectional Analysis
Marina Cristelli, Brazil
13:42 - 13:48

LBBPD1/2
High SVR12 Results after 12-week Boceprevir, Peginterferon and Ribavirin in the Dutch Acute Hepatitis C in HIV Study (DAHHS)
Sebastiaan Hullegie, Netherlands
13:48 - 13:54

Special Session
Room Cologne
13:00 - 14:00

BPD2, Best Poster Discussion 2 - Clinical Science - Epidemiology

Chairs:
Stéphane De Wit, Belgium
Anne-Geneviève Marcelin, France

ML1
HIV Resistance - Where Are We Heading
Mark Wainberg, Canada
13:00 - 13:06

BPD2/1
Regional Differences in Transmission of HIV Drug Resistance Mutations in Europe
Laura Marije Hofstra, Netherlands
13:06 - 13:12

BPD2/2
The Mater-Bronx Rapid HIV Testing (M-BRIHT): A Randomized, Controlled Study Exploring Factors Associated with Decision to undergo HIV Testing
Marilia Rita Pinzone, Italy
13:12 - 13:18

BPD2/4
Age, Gender, Risk Group, Cohort Size and Year of Study Effect on the Performance Indicator of CD4 Count at HIV Presentation: A UK CHIC Study on Late Diagnosis Performance
Skevi Michael, United Kingdom
13:18 - 13:24
Scientific Programme


BPD2/6  HIV-1 Local Transmission Networks in 9 European Countries and Canada: Association with Demographic and Clinical Factors  13:30 - 13:36  Dimitrios Paraskevis, Greece

BPD2/7  No Decline in Hepatitis C Virus (HCV) Incidence among HIV-positive Men who Have Sex with Men (MSM) within CASCADE: 1990-2014  13:36 - 13:42  Maria Prins, Netherlands


Special Session
13:00 - 14:00  Room Brussels

BPD3, Best Poster Discussion 3 - Basic Science

Chairs:
Maria Buzon, Spain
Marylyn Addo, Germany

BPD3/1  Pre-cART Pro-inflammatory milieu, Microbial Translocation (MT) and Risk of Disease Progression in HIV-infected Patients Starting Their First cART: Data from the Icona Foundation Cohort  13:00 - 13:06  Giulia Marchetti, Italy

BPD3/2  MicroRNA-210, microRNA-7 and miRNA-331 is Upregulated in HIV Infection and Associated with Systemic Inflammation  13:06 - 13:12  Vibe Ballegaard, Denmark

BPD3/3  Immunological Ageing in HIV-1 Positive Individuals on Combination Antiretroviral Therapy (cART) Compared to Appropriately Selected Controls and Blood Bank Donors  13:12 - 13:18  Neeltje Kootstra, Netherlands


BPD3/5  Selection of an HLA-C*03:04-restricted HIV-1 p24 Gag sequence variant is associated with viral escape from KIR2DL3pos NK cells  13:24 - 13:30  Angelique Hoelzemer, United States

BPD3/6  Soluble TLR2 and 4 Are Associated with HIV/SIV Related Neuroinflammation and Neuropathology  13:30 - 13:36  Khutso Mothapo, Netherlands

BPD3/7  Plasma Interferon-inducible Protein-10 Levels, T-cell Activation and Regulation Are Increased in HIV Immunological Non-responders  13:36 - 13:42  Birgitte Stiksrud, Norway
**Scientific Programme**

**BPD3/8**  
**Restoration of B Cell Phenotype and Function on ART during Chronic HIV Infection**  
Ramla Tanko, South Africa  
13:42 - 13:48

**BPD3/9**  
**HIV-1 CRF02_AG Infected Patients Show a Lower Response to a PI Based First Line HAART: A Role of Specific Natural Polymorphisms**  
Daniele Armenia, Italy  
13:48 - 13:54

**Special Session**  
13:00 - 14:00  
Room Belgrade

**Is Europe Buying into PrEP? The New Prevention Landscape from a Community Perspective - Session Convened by EATG**

**Chairs:**  
Cristina Mussini, Italy  
Rebekah Webb, United Kingdom

- **Is PrEP for HIV Prevention Cost-Effective in MSM?**  
  Valentina Cambiano, United Kingdom  
  13:00 - 13:15

- **Challenges to Implementing PrEP in European Health Systems**  
  Anastasia Pharris, Sweden  
  13:15 - 13:30

- **Community Involvement in the IPERGAY Study**  
  Daniela Rojas Castro, France  
  13:30 - 13:45

- **Q&A Community Panel on National Initiatives on PrEP in Europe**  
  Gus Cairns, United Kingdom  
  Nicholas Feustel, Germany  
  Michael Meulbroek, Spain  
  Rebecca Mbewe, United Kingdom  
  13:45 - 14:00

**Special Session**  
13:00 - 14:00  
Room Madrid

**EACS General Assembly**

**Parallel Session**  
14:00 - 16:00  
Room Barcelona

**PS4, Antiretroviral Therapy I**

**Chairs:**  
Georg Behrens, Germany  
Annemarie Wensing, Netherlands

- **ML1 Cost Efficacy of Recommended ART Regimes (GESIDA)**  
  José M. Gatell, Spain  
  14:00 - 14:15
Scientific Programme

PS4/1 Integrated and Total HIV-1 DNA Correlate Well and Predict ex vivo Viral Outgrowth
Linos Vandekerckhove, Belgium
14:15 - 14:30

PS4/2 Low-level Viremia (LLV) Ranging from 50 to 500 Copies/mL is Associated to an Increased Risk of AIDS Events in the Icona Foundation Cohort
Andrea Antinori, Italy
14:30 - 14:45

PS4/3 Effectiveness of Maintenance Combination Antiretroviral Therapy Using Half-dose Efavirenz Plus 2 Nucleoside Reverse-transcriptase Inhibitors with the Guidance of Therapeutic Drug Monitoring
Chien-Ching Hung, Taiwan, Republic of China
14:45 - 15:00

LBPS4/1 Dolutegravir-Lamivudine as Initial Therapy in HIV-infected, ARV Naive Patients: First Results of the PADDLE Trial
Pedro Cahn, Argentina
15:00 - 15:15

LBPS4/2 Dolutegravir Monotherapy in HIV-infected Patients with Sustained Viral Suppression: A 24-week Pilot Study
Esteban Martínez, Spain
15:15 - 15:30

PS4/4 Dolutegravir Monotherapy in HIV-infected Patients with Suppressed HIV Viremia
Christine Katlama, France
15:30 - 15:45

ML2 Should We Lower Drug Burden (Pro/Con Debate, Virological/Clinical Point of View)
Andrea De Luca, Italy
Christoph Wyen, Germany
15:45 - 16:00

Parallel Session
14:00 - 16:00
Room Cologne

PS5, Opportunistic Infections and Tumours

Chairs:
Vincent Calvez, France
Cristina Mussini, Italy

ML1 Who is at Risk for Opportunistic Infections
Nina Khanna, Switzerland
14:00 - 14:15

PS5/1 AIDS Defining Opportunistic Diseases in the Swiss HIV Cohort Study: A Comprehensive Review 1988-2013
Hansjakob Furrer, Switzerland
14:15 - 14:30

PS5/2 HIV Replication is a Major Predictor of Primary and Recurrent Pneumocystis Pneumonia - Implications for Prophylaxis Recommendations
Hansjakob Furrer, Switzerland
14:30 - 14:45

PS5/3 Recurrent Disease in HIV-infected Patients with Hodgkin Lymphoma (HL) or Non-Hodgkin Lymphoma (NHL) in the German AIDS-related Lymphoma Cohort Study
Philipp Schommers, Germany
14:45 - 15:00
Scientific Programme

**PS5/4**
**Long Lasting Viral Suppression and Immune Reconstitution of a Great Magnitude Reduce the Risk of Cervical Dysplasia in HIV-positive Women**
Déborah Konopnicki, Belgium
15:00 - 15:15

**PS5/5**
**Prostate-specific Antigen (PSA) Testing Patterns for Prostate Cancer (PCa) in HIV+ Men. Does One Size Fit All?**
Leah Shepherd, United Kingdom
15:15 - 15:30

**PS5/6**
**Prevalence and Distribution of Cervical Human Papillomavirus and Dysplasia in Women Living with HIV in Denmark - Results from the SHADE Cohort**
Kristina Thorsteinsson, Denmark
15:30 - 15:45

**ML2**
**HPV - To Vaccinate or Not? (Pro/Con Debate)**
Déborah Konopnicki, Belgium
Maarten Schim van der Loeff, Netherlands
15:45 - 16:00

Parallel Session
14:00 - 16:00

**Room Brussels**

**PS6, Gender Issues in HIV**

**Chairs:**
Anna Maria Geretti, United Kingdom
Fiona Mulcahy, Ireland

**ML1**
**Models of Care: The Way Forward**
Fiona Lyons, Ireland
14:00 - 14:15

**PS6/1**
**Key Interventions and Populations to Target to Facilitate Engagement in HIV Care among Women Living with HIV: Findings from the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS)**
Nadine Kronfli, Canada
14:15 - 14:30

**PS6/2**
**Sex-specific Regulation of Type I Interferons in pDC Upon TLR7 Stimulation**
Susanne Ziegler, Germany
14:30 - 14:45

**PS6/3**
**Is the Gender Difference in Viral Load Response to ART Narrowing over Time?**
Lisa Burch, United Kingdom
14:45 - 15:00

**PS6/4**
**Outcomes after 2 Years on Antiretroviral Therapy (ART): Comparison of Women who were ART-naive and Women who Previously Used Short-course ART in Pregnancy**
Susie Huntington, United Kingdom
15:00 - 15:15

**PS6/5**
**Do Socio-economic Factors Explain Gender Differences in Virological Response to ART in the UK?**
Rebecca O’Connell, United Kingdom
15:15 - 15:30

**PS6/6**
**Sex Differences in Depressive Symptoms: Data from the Frankfurt HIV-cohort**
Claus Philippe Küpper-Tetzel, Germany
15:30 - 15:45
**Scientific Programme**

**ML2**  
*Making WAVEs - Women Against Viruses in Europe*  
Anna Maria Geretti, United Kingdom  
15:45 - 16:00

Industry Sponsored Session  
16:30 - 18:00  
Room Cologne

**Industry Sponsored Session**  
(For more details, please visit the [EACS Conference website](http://www.eacs-conference2015.com/index.php?article_id=47))

Industry Sponsored Session  
18:15 - 19:45  
Room Cologne

**Industry Sponsored Session**  
(For more details, please visit the [EACS Conference website](http://www.eacs-conference2015.com/index.php?article_id=47))

---

15th European AIDS Conference  
October 21 - 24, 2015  
Barcelona, Spain

Page 55 / 100
Meet the Expert
07:45 - 08:45
Room Madrid

Meet the Expert, - Management of TB in HIV Patients
Management of TB in HIV Patients
Roxana Cernat, Romania
Santiago Moreno, Spain

Meet the Expert, - Pitfalls in Neurocognitive Disease
Pitfalls in Neurocognitive Disease
Jordi Blanch, Spain
Paola Cinque, Italy

Meet the Expert, - Prevention of Bone Disease in HIV
Prevention of Bone Disease in HIV
Eugenia Negredo, Spain
Philip Tarr, Switzerland

Meet the Expert, - Management of Co-morbidities in HIV Aging Patients
Management of Co-morbidities in HIV Aging Patients
Giovanni Guaraldi, Italy
Ana Milinkovic, United Kingdom
Scientific Programme

Plenary Session
09:00 - 09:30

**PL3, PrEP ! - From Science to Implementation**

Prof. Martin Fisher in Memoriam Lecture

**Chairs:**
Jean-Michel Molina, France
Jürgen Rockstroh, Germany

**PrEP ! - From Science to Implementation**
Sheena McCormack, United Kingdom

09:00 - 09:30

Plenary Session
09:30 - 10:00

**PL4, HCV DAAs in Europe - Making it Happen**

**Chairs:**
Jean-Michel Molina, France
Jürgen Rockstroh, Germany

**HCV DAAs in Europe - Making it Happen**
Markus Peck, Austria

09:30 - 10:00

Parallel Session
10:30 - 12:30

**PS7, Liver Disease and Hepatitis in HIV-infected Patients**

**Chairs:**
José Mallolas, Spain
Massimo Puoti, Italy

**ML1**

**Hepatitis B Cure Strategies**
Mala Maini, United Kingdom

10:30 - 10:45

**PS7/1**

**Hepatitis Delta in the Swiss HIV Cohort Study (SHCS): Clinical Characteristics and Long-term Outcomes**
Charles Béguelin, Switzerland

10:45 - 11:00

**PS7/2**

**Trends in Incidence and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus Co-infected Individuals from 2001 to 2014: A Multi-cohort Study**
Lars Iversen Gjærde, Denmark

11:00 - 11:15

**PS7/3**

**How Many Patients Treated? The Number of Patients with Statutory Health Insurance Receiving Antiviral Hepatitis C Therapy Determined by Drug Prescriptions Data**
Daniel Schmidt, Germany

11:15 - 11:30

**PS7/4**

**Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients?**
Lars Peters, Denmark

11:30 - 11:45
Scientific Programme

LBPS7/1  TURQUOISE-I Study: Use of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + Ribavirin in Patients with HCV/HIV-1 Co-infection on Stable Darunavir-containing Antiretroviral Therapy
Roger Trinh, United States
11:45 - 12:00

PS7/5  Sofosbuvir Plus Ledipasvir for 8 Weeks in HCV-mono- and HIV-HCV-coinfected Patients - Results from the German Hepatitis C Cohort (GECCO)
Patrik Ingiliz, Germany
12:00 - 12:15

ML2  HCV Eradication - Everything Solved? (Pro/Con Debate)
Juan Berenguer, Spain
Stefan Mauss, Germany
12:15 - 12:30

Parallel Session
10:30 - 12:30  Room Cologne

PS8, Cohort Studies - Contribution to Clinical Care

Chairs:
Dominique Costagliola, France
Ian Weller, United Kingdom

ML1  What Cohort Studies Contribute to Clinical Care in Adults
Stéphane De Wit, Belgium
10:30 - 10:45

ML2  What Cohort Studies Contribute to Clinical Care in Children
Claire Thorne, United Kingdom
10:45 - 11:00

PS8/1  Long-Term Evolution and Determinants for the Restoration of the CD4/CD8 Ratio in HIV-1 Infected Individuals on Efficient Antiretroviral Therapy
Fabienne Caby, France
11:00 - 11:15

PS8/2  Transient Viral Rebounds as a Prognostic Factor for Control Loss among 1075 HIV-controllers Followed in COHERE Collaboration
Fanny Chereau, France
11:15 - 11:30

PS8/3  Current Stage of HIV Epidemic in Ukraine: HIV in Men who Acquired HIV through Heterosexual Mode of Transmission
Nataliya Nizova, Ukraine
11:30 - 11:45

PS8/4  Poor Linkage to Care Despite Significant Improvement in Access To Early cART - Data from Test and Keep in Care (TAK) Project
Justyna Kowalska, Poland
11:45 - 12:00

PS8/5  Excess of Short and Long-term overall and Cause-specific Mortality in HIV Positive Subjects Compared to the General Population: Differences by HCV-coinfection
Belén Alejos, Spain
12:00 - 12:15

PS8/6  Where is the Greatest Impact of Uncontrolled HIV Infection on Clinical Disease Progression?
Amanda Mocroft, United Kingdom
12:15 - 12:30
PS9, Pharmacology, Pharmacogenomics and Drug-Drug Interactions

Chairs:
Saye Khoo, United Kingdom
Catia Marzolini, Switzerland

ML1  The Prospect of Long-Acting Agents
Marco Siccardi, United Kingdom
10:30 - 10:45

PS9/1  A Population Pharmacokinetic Model for a Long-acting Injectable Nanosuspension of Rilpivirine for Intramuscular Injection
Herta Crauwels, Belgium
10:45 - 11:00

ML2  Drug-Drug Interactions - Still Complex
Caroline Solas, France
11:00 - 11:15

PS9/2  Assessment of Drug-Drug Interaction between New Antiretroviral Drugs and Combined Oral Contraceptives
Emilie Blavier, Belgium
11:15 - 11:30

PS9/3  Efavirenz Simultaneous Induction and Inhibition of Multiple Cytochromes Impacts the Magnitude of Drug-Drug Interactions
Catia Marzolini, Switzerland
11:30 - 11:45

ML3  Recreational Drugs - An Uprising Issue
Marta Boffito, United Kingdom
11:45 - 12:00

PS9/4  Elvitegravir Concentrations in Seminal Plasma in HIV-1 Infected Patients
Arkaitz Imaz, Spain
12:00 - 12:07

PS9/5  HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen
Arkaitz Imaz, Spain
12:07 - 12:14

PS9/6  Pharmacokinetics of Once-daily Ritonavir Boosted Atazanavir or Darunavir in Combination with a Dual Nucleos(t)ide Analogs Backbone among HIV-1-naive Patients with Severe Immunosuppression: IMEA 040-DATA Sub-study
Minh Lê, France
12:14 - 12:29

Poster Session

PE1/2  Characterization of the Near Full Length Genetic Constellation of a Unique HIV 1 A1/C Recombinant Strain in South Africa
Andrew Musyoki, South Africa

PE1/3  APOBEC3 Host Factors Modulate Viral Production and Infectivity of HIV-2
Susana Bandarra, Portugal

PE1/4  Does the Presence of a Mutation at Position V179 Impact on Clinical Outcome in Patients Taking Antiretroviral Medication?
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenting Author</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE1/5</td>
<td>Performance of Genotypic Algorithms for Predicting Tropism for HIV-1 CRF02_AG Subtype</td>
<td>Cathia Soulié, France</td>
<td>France</td>
</tr>
<tr>
<td>PE1/6</td>
<td>HIV-1 Subtype B Transmission Networks in Poland Indicate Frequent Clustering and Interregional Spread of Infection among Men-Having-Sex-with-Men</td>
<td>Milosz Parczewski, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>PE1/7</td>
<td>HIV-1 Diversity and Transmitted Drug Resistance Mutations among Heterosexuals with HIV-1 in Bulgaria</td>
<td>Ivailo Alexiev, Bulgaria</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>PE1/8</td>
<td>Clinical, Virological and Phylogenetic Characterization of a Multiresistant HIV-1 Strain Outbreak in Naïve Patients in Southern Spain</td>
<td>Isabel Viciana, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>PE1/9</td>
<td>Tumor Suppressor p53 Protein Removes the Ribonucleotides Incorporated by HIV-1 RT into DNA</td>
<td>Mary Bakhanashvili, Israel</td>
<td>Israel</td>
</tr>
<tr>
<td>PE1/10</td>
<td>Dolutegravir based Regimens (DBRs) Viral Load Decay at Week 4 Could Predict Sustained Viral Suppression at Week 96</td>
<td>Romina Quercia, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>PE1/11</td>
<td>Viruses Causing Breakthrough Infections in Women Assigned to Tenofovir Gel in the CAPRISA 004 Microbicide Trial Did Not Demonstrate a Higher Replication Capacity</td>
<td>Philippe Selhorst, South Africa</td>
<td>South Africa</td>
</tr>
<tr>
<td>PE1/12</td>
<td>Cellular Proviral HIV DNA in Patients on Stable Combination Antiretroviral Therapy: Correlation with Immunovirological Parameters and Antiretroviral Regimens</td>
<td>Isabella Bon, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>PE1/13</td>
<td>Evidence that an Amino Acid Substitution in the HIV-2 Env Protein Lead to a Lack of Tetherin Antagonism</td>
<td>François Dufrasne, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>PE1/14</td>
<td>Characterization of HIV-1C gp120 in Recently and Chronically Infected Individuals in Botswana</td>
<td>Terence Mohammed, Botswana</td>
<td>Botswana</td>
</tr>
<tr>
<td>PE1/15</td>
<td>Comparison of the Analytical Performance of the Cepheid Xpert HIV-1 Viral Load Real-time PCR with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test Version 2.0 Assay</td>
<td>Brice Dubouil, France</td>
<td>France</td>
</tr>
<tr>
<td>PE1/16</td>
<td>Validation of the Xpert VIH-1 Viral Load Real-time PCR (GeneXpert®, Cepheid) for Organ Transplantations</td>
<td>Aleksandra Maleska, France</td>
<td>France</td>
</tr>
<tr>
<td>PE1/17</td>
<td>HIV-1 Genetic Diversity and Divergency and its Correlation with Disease Progression among Recently Infected Individuals Using Next Generation Sequencing</td>
<td>Ana Rachel Leda, Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td>PE2/1</td>
<td>Responses of NK Cell Subsets to Anti-HIV Antibody Mediated Activation</td>
<td>Irene Lisovsky, Canada</td>
<td>Canada</td>
</tr>
</tbody>
</table>
Scientific Programme

PE2/2  Influence of HLA Glycosylation on the Binding of HLA-B*57:01 to KIR3DL1  
Wilhelm Salzberger, Germany

PE2/3  Optimization of KIR2DS1 Reporter Cell Assay to Identify HIV-peptide Specific Binding of HLA-C*06:02  
Anais Chapel, Germany

PE2/4  Analysis of Cross-recognition of HIV-1-Nef-Specific CTL to Human FAT3 Protein  
Thomas Harrer, Germany

PE2/5  Identification of HLA-C Restricted, HIV-1-Specific CTL Epitopes by Peptide Induced Upregulation of HLA-C Expression  
Thomas Harrer, Germany

PE2/7  NK Cells Expressing Self-Inhibitory KIR2DL Receptors Display Reduced Ability to Inhibit HIV-1 Replication in vitro  
Korner Christian, United States

PE3/1  Plasma L-carnitine and L-lysine Concentrations in HIV-infected Patients at Clinical Stages of the Disease  
Evgeny Butorov, Russian Federation

PE3/2  Plasmatic Cytokine Levels in Rapid and Slow Progressors HIV-1 Infected  
Rúbia de Medeiros, Brazil

PE3/3  Evaluation of Some of Oxidative and Inflammatory Stress Biomarkers in People Living with HIV/AIDS before and after the Initial Antiretroviral Therapy  
Mônica Mendes, Brazil

PE3/5  Changes in Peripheral T-cell Homeostasis, Gut Inflammation, Intestinal Permeability and Fecal Microbiota in the First Year of Combination Antiretroviral Therapy (cART)  
Camilla Tincati, Italy

PE3/6  Peripheral Blood Pre-erythroidal Cells in HIV-1 Infection  
Maciej Stanislaw Tarkowski, Italy

PE3/7  Frequently Low Serum Immunoglobuline M Levels on Long-term Suppressive ART - A Possible Indicator of a Functional B-cell Defect Demasked by ART  
Hans-Jürgen Stellbrink, Germany

PE3/9  HIV gp120 Enhances CXCR4/SDF-1 Mediated MSC Migration through Activation of ERK and FAK Pathways  
Nicholas Chew, Singapore

PE3/10  The Role of miRNA-33 in HIV-mediated Impairment of Cholesterol Efflux in THP-1 Cells  
Mireia Arnedo, Spain

PE3/11  Long-Term Immune Recovery in HIV-infected Patients with Candida esophagitis is Impaired Despite Combination Antiretroviral Therapy  
Nina Khanna, Switzerland
**Scientific Programme**

**PE4/1**  
**Analysis of Gut Microbiota Diversity in Chronic AIDS Patients Living in China Using the QIIME Pipeline**  
Yang Sun, China

**PE4/2**  
**The Impact of HLAB*5701 on Viral Replication among Patients Infected with HIV-1 B and Non-B Subtypes - Interplay between Host and HIV Genetics**  
Małgorzata Dawidek, Poland

**PE4/3**  
**Circulating MicroRNA Modulations in HIV-1 Patients under Long-term ARV Treatment**  
Marjorie Monleau, France

**PE5/1**  
**Definition of HIV-1 CTL Epitopes Designed from Archived Virus and Exhibiting Affinity to HLA Groove: The Provir Vaccine Strategy**  
Herve Fleury, France

**PE5/2**  
**Kinetic of Total HIV-Dna during Interferon Based Anti-HCV Therapies in Coinfected Patients**  
Giancarlo Orofino, Italy

**PE5/3**  
**Development of Community-led Education about Human Papillomavirus Vaccination as a Model for Future HIV Vaccination Campaigns**  
Karamoko Tounkara, Mali

**PE5/4**  
**Inhibitory Role of CD16+ Inflammatory Monocytes on Vaccine-induced Antibody Responses**  
Anne Nolting, Germany

**PE5/5**  
**Impact of Economic Crisis on Immunization of HIV-1 Population in Greece**  
Olga Tsachouridou, Greece

**PE6/1**  
**Novel and Effective Vaginal Microbicide Delivery System Using Nanoparticle Entrapped Microbicides**  
Mahesh Sherkar, India

**PE6/2**  
**Second-generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity Toward Non-B Subtype HIV-1 Viruses**  
Ira Dicker, United States

**PE6/3**  
**Targeted Cleavage of the HIV-1 Proviral Genome Using AAV Vector-mediated CRISPR**  
Manuela Nickl, Germany

**PE6/4**  
**AR-12, a Novel First in Class Host Cell Targeting Therapeutic Candidate with Potent Activity Against HIV Multidrug Resistant Strains in vitro**  
Stefan Proniuk, United States

**PE7/1**  
**Patient Reported Outcomes (PRO) over 48 Weeks in a Randomized, Open-label Trial of Patients with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF)**  
David Budd, United States

**PE7/2**  
**Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy versus Darunavir/Ritonavir with Two Nucleoside Analogue: The PROTEA Trial**  
Pierre-Marie Girard, France
Does Two-drug Therapy Show Equivalent Efficacy to Standard Three-drug Combinations? Meta-Analysis of 14 Randomised Trials in 3323 Patients
Pierre-Marie Girard, France

Safety and Antiviral Effect of Elpida (VM15000), a Novel NNRTI (+Truvada) in Treatment-naive HIV-1 Infected Patients
Alexey Kravtchenko, Russian Federation

HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-experienced Subjects: Week 48 Safety Analysis
Bonaventura Clotet, Spain

Dual Treatment with Atazanavir/r+3TC vs. Triple Treatment with Atazanavir/r+2 Nucleos(t)ides in Virologically Stable Patients with HIV-1 (SALT Study): 96-week Results from a Randomised, Open Label, Non-inferiority Trial
Jose Perez-Molina, Spain

A Switch to Once Daily Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed HIV-infected Rwandans is Non-inferior to Continued Nevirapine-based Antiretroviral Therapy
Sean Collins, United States

A NRTI Sparing Two-drugs Maintenance cART is Effective and is Well Tolerated (PROBE Study)
Franco Maggiolo, Italy

Comparative Effectiveness of Tenofovir in Treatment-naive HIV-infected Patients: Systematic Review and Meta-analysis
Heiner Bucher, Switzerland

Atazanavir plus Cobicistat (ATV+c) versus Atazanavir plus Ritonavir (ATV+r), Both in Combination with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 144 Subgroup Analysis of a Phase 3, Randomized, Double-blind, Active-controlled Trial
Graeme Moyle, United Kingdom

Lipid Profile and Inflammatory Markers of Lipoproteins in Virologically Suppressed Patients with Triple Therapy Switching to Lopinavir/R Plus Lamivudine
Maria Saumoy, Spain

The MONOD-ANRS-12206 Trial: Efavirenz May Simplify a Successful Lopinavir-based Therapy Initiated before the Age of 2 in HIV-infected Children from West-Africa
Carole Seguin-Devaux, Luxembourg

Improved Safety and Efficacy of TAF vs. TDF Single-tablet Regimen in HIV-1 Treatment-naive Women through Week 48
Chloe Orkin, United Kingdom

Switch to Maraviroc (MVC) + Darunavir/Ritonavir (DRV/r) in Virologically Suppressed Patients with R5-Tropic Virus is Associated with an Excess of Virological Failures: 48 Weeks Results of the GUSTA Study
Barbara Rossetti, Italy

High Efavirenz Serum Concentrations in TB/HIV Co-infected Ugandan Adults Receiving Rifampicin-Based Anti-TB Therapy
Amrei von Braun, Uganda
PE8/2 Comparison of Serum Levels of Vitamin A in HIV Positive and HIV Negative Adults in Yenagoa Nigeria
Okechukwu Anene, Nigeria

PE8/3 The Efficacy of Second-line Antiretroviral Therapy for AIDS in China: A Retrospective Study
Qingxia Zhao, China

PE8/4 Association between Estimated Cumulative Viraemia and CD4/CD8 Ratio in HIV Patients on Long Term Antiretroviral Therapy
Kenny CW Chan, China

PE8/5 Long Term Virologic Superiority of Emtricitabine over Lamivudine when Used in Fixed Dose Combination with Tenofovir/Efavirenz Among Patients with Low Baseline CD4 Counts in Resource Limited Settings (RLS)
Ameet Dravid, India

PE8/6 Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive Individuals?

PE8/7 Toll-like Receptor 4 Polymorphism Influence on the Antiretroviral Therapy Effectiveness in HIV-Positive Patients
Tetiana Kyrychenko, Ukraine

PE8/8 Cost Effectiveness of Antiretroviral Therapy in HIV-infected Patients in Kazakhstan
Rafail Kipshakbayev, Kazakhstan

PE8/9 Role of the Decentralization of ART Services in Expansion of Access for HIV-positive IDUs to Treatment
Nataliya Nizova, Ukraine

PE8/10 Real World Experience with Raltegravir and Etravirine as Dual Agent Treatment of HIV
Dillon Benson, United States

PE8/11 Darunavir-Containing Antiretroviral Regimens in Pregnancy: Findings from the Antiretroviral Pregnancy Registry
William Short, United States

PE8/12 Prevalence and Risk Factors Associated with Adherence to Antiretroviral Therapy in HIV-infected Adults in a Tertiary Care Hospital In Mexico
Juan Dominguez, Mexico

PE8/13 Once versus Twice Daily ARV Regimens: Virological and Immunological Outcomes at 48 Weeks
Guillermo Viloria, Argentina

PE8/14 Factors Associated with Unstructured Antiretroviral Therapy Interruption during the First Year of Treatment
Mariana Kundro, Argentina

PE8/15 Durability of First Antiretrovirals Treatment between 2012-2013 in HIV-patients. Has it Improved with New Drugs?
Javier De La Torre Lima, Spain

PE8/16 Analysis of Toxicity as a Cause of Change of the First Current Antiretroviral Treatments in HIV Patients
Javier De La Torre Lima, Spain
Scientific Programme

PE8/17 48 Week Data of Atripla®, Eviplera® (EPA) or Stribild® in Routine Clinical Use: Efficiency and Safety of Single Tablet Regimens (STRs) in HIV-infected Patients Included in the German STRiKe Cohort
Stefan Esser, Germany

PE8/18 The Determinants of HIV+ Social Costs: An Empirical Survey in the Italian Setting
Mariangela Errico, Italy

PE8/19 Non-nucleosid Reverse Transcriptase Inhibitor (NNRTI) + Integrase Inhibitor (INI): A Well-tolerated Combination for HIV Maintenance Treatment, a Combination Hypothesized to Have Few or No Long Term Side Effects
Oswald Moling, Italy

PE8/20 Dual Therapy with Lopinavir/r and Raltegravir (LPV/r+RAL) in Treatment-experienced HIV-infected Patients: Data from the German Multicenter PROTEKT Cohort
Johannes Huelsenbeck, Germany

PE8/21 Efficacy of Darunavir/Ritonavir-based Treatment in an Italian Observational Study (TMC114HIV4042)
Andrea Antinori, Italy

PE8/22 Determinants of Virological Failure in a Large French Cohort in 2014
Gwenaël Le Moal, France

PE8/23 Durability of Darunavir/ritonavir-based Treatment in an Italian Observational Study (TMC114HIV4042)
Paola Meraviglia, Italy

PE8/24 The Position of Rilpivirine in Antiretroviral Therapy: Early Evaluation of its Use in the Swiss HIV Cohort Study
Delphine Sculier, Switzerland

PE8/25 Although Aging HIV-infected Patients Are Burdened with Higher Rates of Co-morbidities and Co-medications, their Response to Raltegravir-based ART is Similar to that of Younger Subjects: An Analysis of a German Real Life Cohort
Stefan Mauss, Germany

PE8/26 Effectiveness and Safety of Fixed Dose ABC/3TC plus Rilpivirine in a Multicenter Cohort of HIV-infected Patients. SIMRIKI Study, GESIDA-8314
Jesús Troya, Spain

PE8/27 Persistency of Single Tablet Regimens (STRs) in Daily Clinical Routine - a Comparison between FTC/TDF-based STRs for Treatment of HIV-infected Patients: Data from the German STRiKe Cohort
Eva Wolf, Germany

PE8/28 Metabolic Syndrome, Cardiovascular Risk and Renal Impairment in HIV-infected Patients Initiating Antiretroviral Therapy in Portugal
Ana Lebre, Portugal

PE8/29 Potential Cost Savings Associated with Switches from 1st & 2nd-line ART Regimens to Less Expensive Regime; Bichat-Claude Bernard University Hospital Clinic, Paris, France 2014 (ANRS-GOTA)
Emmanuelle Papot, France
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE8/30</td>
<td>Durability and Predictive Factors of Discontinuation of Tenofovir-</td>
<td>Marco Franzetti, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td>containing Antiretroviral Therapy Regimens in a Cohort of HIV-positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/31</td>
<td>Clinical Data and Patient-Reported Outcomes (PRO) in HIV-infected</td>
<td>Daniel Podzamczer, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td></td>
<td>Adults Switching to RPV/FTC/TDF, due to a Previous Intolerance to cART.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interim Analysis of the PRO-STR Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/32</td>
<td>Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil</td>
<td>Silvia Nozza, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td>Fumarate (STRIBILD®) in Patients Treated during Primary HIV Infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Compared to Recent HIV Infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/33</td>
<td>Long-term Virological Outcomes of ART-experienced Patients Receiving</td>
<td>Anna Schultze, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Raltegravir in a Large European Cohort Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/34</td>
<td>Maraviroc plus Protease Inhibitor as a Switching Regimen in Clinical</td>
<td>Marianna Menozzi, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td>Practice</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/35</td>
<td>Early Start of Antiretroviral Therapy during Primary HIV Infection is</td>
<td>Marco Ripa, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td>Associated with Faster Virological Suppression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/36</td>
<td>Experience of Dolutegravir (DTG) in HIV Infected Treatment Naïve</td>
<td>John Lambert, Ireland</td>
<td>Ireland</td>
</tr>
<tr>
<td></td>
<td>Patients from a Tertiary Care University Hospital in Ireland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/37</td>
<td>Simplification for Dolutegravir as a Mono- or Bitherapy Maintains High</td>
<td>Laurent Hocqueloux, France</td>
<td>France</td>
</tr>
<tr>
<td></td>
<td>Proportion of Viral Suppression Even in Highly-experienced HIV-1-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>infected Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/38</td>
<td>Switch to Single Tablet Regimen (STR) in Virologically Suppressed</td>
<td>Roberta Gagliardini, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td>Patients: A Comparison between Co-formulated</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/39</td>
<td>Immunological and Virological Responses to Combined Antiretroviral</td>
<td>Inmaculada Jarrín, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td></td>
<td>Treatment in Male and Female Migrants in Europe: Is Benefit Equal for</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/40</td>
<td>Boosted versus unboosted Atazanavir/Raltegravir Dual Therapy and</td>
<td>David Rey, France</td>
<td>France</td>
</tr>
<tr>
<td></td>
<td>Immunovirological, Clinical and Pharmacological Outcomes: Results from</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a Prospective Multicenter Cohort of HIV-infected Individuals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/41</td>
<td>Efficacy and Safety of a Kivexa® (Abacavir/Lamivudine) plus Rilpivirine</td>
<td>Adrian Curran, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td></td>
<td>Regimen for the Treatment of HIV-1 Infection in Naïve Patients (KiRiNa</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE8/42</td>
<td>Factors Associated with Switches and Interruptions of Initial</td>
<td>Michaela Rappold, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td></td>
<td>Antiretroviral Therapy in the First Year</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Scientific Programme

PE8/43 Risk and Determinants of Failure of a Mono-PI/r Simplification Strategy with LPV/r or DRV/r in Clinical Practice
Alessandro Cozzi-Lepri, United Kingdom

PE8/44 High Treatment Retention and Success Rates of Tenofovir/Emtricitabine/Rilpivirine (Eviplera) in ART-naive HIV-infected Persons in Clinical Practice: A Comparative Study on Determinants of Use and Treatment Outcome
Alessandro Cozzi-Lepri, United Kingdom

PE8/45 Perceptions of Healthcare Providers (HCPs) and Patients around the Provision of HIV Healthcare and HCP-patient Communication: A NAM Web-based Survey
Caspar Thomson, United Kingdom

PE8/46 A Year of StriBild® Use. Experience in Real Life
Maria Arribalagla, Spain

PE8/47 Clinical Consequences of Poor Adherence to Antiretroviral Therapy in Patients with HIV Infection - A Retrospective Cohort Study
Cátia Caldas, Portugal

PE8/48 Is Switching to Kivexa with Rilpivirine as Effective as Switching to Eviplera in Clinical Practice?
Lucy Hedley, United Kingdom

PE8/49 Factors Related to the Durability of the First Antiretroviral Treatment
Luis Force, Spain

PE8/50 Rilpivirine with Kivexa for Treatment Naïve HIV: Experience in Clinical Practice
Lucy Hedley, United Kingdom

PE8/51 Switch from AtriplaTM to EvipleraTM: Gap between Perceived vs Compared Quality of Life
Amedeo Capetti, Italy

PE8/52 Much Less Treatment Modification in Individuals Initiating Antiretroviral Therapy with Recently Approved Drugs: The Austrian HIV Cohort Study
Michaela Rappold, Austria

PE8/53 First-line Antiretroviral Therapies in HIV-infected Patients in Germany: Treatment Decisions in the PROPHET Study
Eva Wolf, Germany

PE8/54 Maraviroc Once Daily: Experience in Routine Clinical Practice
Maria Saumoy, Spain

PE8/55 Reasons for Modification and Discontinuation of Initial Antiretroviral Treatment among Recently Diagnosed Patients in HIV-TR Cohort
Volkan Korten, Turkey

PE8/56 Simplification from Unboosted Protease Inhibitor to a STR-containing Rilpivirine Improves Levels of Triglycerides
Niccolò Riccardi, Italy
Lipid Changes and Tolerability in a Cohort of Adult HIV-infected Patients Switching to RPV/FTC/TDF, due to Intolerance to Previous cART. A Substudy of PRO-STR Study
Antonio Ocampo, Spain

KReal Study - Real World Experience of a Nucleoside-sparing Regime - Raltegravir + Lopinavir/Ritonavir
Frederico Duarte, Portugal

HiPeak Study - The Most Effective Therapeutic Response to Standard Antiretroviral Therapy (ART) Schemes in Naïve HIV-1 Infected Patients with High Viral Loads
Frederico Duarte, Portugal

Does starting ART as Part of a Randomised Controlled Trial (RCT) Improve Long-term Virological and Immunological Outcomes?
Mike Youle, United Kingdom

Switching from Abacavir/Lamivudine + Nevirapine to Abacavir/Lamivudine /Dolutegravir Single Tablet Regimen (STR) in Virologically Suppressed, HIV-1 Infected Subjects: 12 Weeks Outcome
Clotilde Allavena, France

Use of Abacavir+Lamivudine+Unboosted Atazanavir (ABC/3TC+ATV) in Routine Clinical Practice: Twelve Years Experience
Rocio Montejano, Spain

Multi-centre International Study of the Efficacy and Tolerability of Eviplera (EVA) in Routine Clinical Settings
Mark Nelson, United Kingdom

DRV/r+3TC Bitherapy: More Than Security
Javier Moreno Díaz, Spain

Real-world Persistence with Antiretroviral Therapy for HIV in the United Kingdom: A Multicentre Retrospective Cohort Study
Joseph Lewis, United Kingdom

Unboosted Atazanavir (400 mg QD) in Combination with TDF/FTC or ABC/3TC is Able to Maintain Plasma Viral Load below 1 Copy/ml during 12 Months after the Use of Boosted Azatanavir (100/300 mg QD)
Vincent Calvez, France

Efficacy and Safety of Switching to Abacavir/Lamivudine (ABC/3TC) Plus Rilpivirine (RPV) in Virologically Suppressed HIV-infected Patients on HAART. Study SAEI 00/0067
Isabel Pérez-Hernández, Spain

Raltegravir (RAL) Based Antiretroviral Therapy (ART) in HIV-infected Solid Organ Transplant (SOT) Recipients: A Single Center Experience
Christian Manzardo, Spain

Identifying Priorities for HIV Consultations among Healthcare Providers (HCPs) across Europe: Results of a Pan-European Survey
Caspar Thomson, United Kingdom

Adherence to Antiretroviral Treatment in Turkey: Results from ACTHIV-IST Study Group
Dilek Yildiz Sevgi, Turkey
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE8/71</td>
<td>Inter-country Variability in the Degree of ART-induced HIV-RNA Suppression</td>
<td>Kamilla Laut, Denmark</td>
</tr>
<tr>
<td>PE8/72</td>
<td>Cost Savings Associated with Rapid Virologic Response in Treatment-naive HIV Patients</td>
<td>Robert Cuffe, United Kingdom</td>
</tr>
<tr>
<td>PE8/73</td>
<td>cART-Simplification and Neuro-AIDS</td>
<td>Gabriele Arendt, Germany</td>
</tr>
<tr>
<td>PE8/74</td>
<td>Reasons to Start and to Choose the Initial Antiretroviral Treatment: The Physician’s and the Patient’s Perspective - A Prospective Study</td>
<td>Luigia Elzi, Switzerland</td>
</tr>
<tr>
<td>PE8/75</td>
<td>Diffusion Tension Image, Fractional Anisotropy and Mean Diffusivity Comparison in Patients Receiving PI Monotherapy or Triple Therapy</td>
<td>Ignacio Pérez-Valero, Spain</td>
</tr>
<tr>
<td>PE8/76</td>
<td>Time to Viral Suppression for HIV-positive Patients Initiating cART with Very High Viraemia</td>
<td>Annabelle Gourlay, United Kingdom</td>
</tr>
<tr>
<td>PE8/77</td>
<td>First-line NNRTI-Including cART Regimens Display Faster Immune-virologic Response in Comparison to PIs: Data from the San Paolo Infectious Diseases (SPID) Cohort, 2010-2015</td>
<td>Francesca Bai, Italy</td>
</tr>
<tr>
<td>PE8/78</td>
<td>Maraviroc Use and Outcomes across Europe - The European Coreceptor (EUCO) HIV Cohort Study</td>
<td>Anna Maria Geretti, United Kingdom</td>
</tr>
<tr>
<td>PE8/80</td>
<td>Mono and Dual Antiretroviral Suppressive Strategies: Real Life Experience in Three Hospitals in Paris (COREVIH Ile-de-France-Centre)</td>
<td>Marc-Antoine Valantin, France</td>
</tr>
<tr>
<td>PE8/81</td>
<td>Dual Therapy with Dolutegravir and Lamivudine Maintains Virologic Suppression in HIV-infected HAART-treated Patients: DOLULAM Pilot Study</td>
<td>Jacques Reynes, France</td>
</tr>
<tr>
<td>PE8/82</td>
<td>Immuno-Virological Effects and Cost after Introduction of Generic Drugs of Efavirenz and Nevirapine. Are they Good, Safe and Cheap?</td>
<td>Miguel Torralba, Spain</td>
</tr>
<tr>
<td>PE8/83</td>
<td>Eviplera (EVP) as a Treatment Option in Real-life Clinical Practice: Evidence for Efficacy and Safety</td>
<td>Konstantinos Protopapas, Greece</td>
</tr>
<tr>
<td>PE8/84</td>
<td>Simplification of a 4-drug cART Started during Acute HIV Infection (Alpha study): HIV RNA and Proviral HIV DNA Levels before and after</td>
<td>Adriana Ammassari, Italy</td>
</tr>
<tr>
<td>PE8/85</td>
<td>Genotypic Susceptibility Scores (GSS) of the Therapeutic Backbone in Treatment-experienced HIV-1 Patients: what Level is Required to Achieve Viral Suppression on Dolutegravir-containing cART</td>
<td>Matthijs Raadsen, Netherlands</td>
</tr>
</tbody>
</table>
PE8/86  Successful Interferon-based Salvage Therapy in a Panresistant HIV+ Adolescent
Markus Bickel, Germany

PE9/1  High Rate of HIV-1 Drug Resistance in Treatment Failure Patients in Taiwan, 2009-2014
Hung-Chin Tsai, Taiwan, Republic of China

PE9/2  Deep Analysis of HIV-1 Natural Variability across HIV-1 Variants at Residues Associated to Integrase Inhibitors (INI) Resistance in INI-naive Patients
Teresa Llácer Delicado, Spain

PE9/3  HIV Proviral DNA is an Adequate Genetic Compartment for Detection of Resistance Mutations Associated to Integrase Strand Transfer Inhibitors (INSTIs) Therapy in Patient with Undetectable or Low HIV Viral Load
Pablo Ferrer, Chile

PE9/5  Integrated Analysis of Emergent Drug Resistance by Population and Deep Sequencing through 48 Weeks from Clinical Studies of HIV-1 Treatment-naive Subjects Receiving EVG/COBI/FTC/TAF
Michael Miller, United States

PE9/6  Cumulative Genotypic Resistance to NRTIs and NNRTIs is Associated with a Higher Risk to Loose Virological Suppression in HIV-positive Patients Switching to Tenofovir/Emtricitabine/Rilpivirine Single-tablet Regimen
Maria Mercedes Santoro, Italy

PE9/7  Prevalence of Transmitted Drug Mutations to Rilpivirine in HIV-infected Treatment-naive Persons: Systematic Review of 64,466 Samples from 138 Studies
Vincent Calvez, France

PE9/8  What if a New HIV Integrase Inhibitor was not Prone to the Problem of Drug Resistance?
Mark Wainberg, Canada

PE9/9  Emerging ResistanceMutations in Protease Inhibitor Naive Patients Failing Atazanavir Based Regimen (ANRS Multicentre Observational Study)
Laurence Morand-Joubert, France

PE9/10  APOBEC Could Explain Low Viral Load in HIV Patient with Highly Active Therapy (HAART) with Nucleoside Analog Reverse-transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse-transcriptase Inhibitors (NNRTIs) Resistance but without Clinical Consequences
Pablo Ferrer, Chile

PE9/11  Comparison of the Risk of Resistance Accumulation According to ART Switching Strategies after Virological Failure >200 Copies/mL to First cART Using the g-computation Procedure
Alessandro Cozzi-Lepri, United Kingdom

PE9/12  HIV Drug Resistance among Children and Adolescents in Asia after First-line NNRTI-based Treatment Failure
Wanatpreeya Phongsamart, Thailand
**Scientific Programme**

**PE9/13**
Protease Inhibitor Monotherapy: Effectiveness and Resistance in Clinical Practice  
Kate El Bouzidi, United Kingdom

**PE9/14**
Characterization of HIV Resistance in Peripheral Blood Mononuclear Cells (PBMC-DNA) in Patients with Suppressed or Low Level Viremia  
Mauro Zaccarelli, Italy

**PE9/15**
Prediction of Virological Failure by a Single Quantifiable Viral Load Below 200 Copies/mL in Treated HIV-infected Patients  
Gisela Leierer, Austria

**PE9/16**
Impact of Baseline NRTI Resistance Mutations on Virological Suppression of HIV-1 Infected Patients Treated by Elvitegravir/Cobicistat/Emtricitabine/Tenofovir  
Nolwenn Hall, France

**PE9/17**
Transmitted Drug Resistance (TDR) in Drug-naive HIV-2 Infected Patients  
Frederico Duarte, Portugal

**PE9/18**
Patterns of Viral Resistance in Patients with Virologic Failure on a Dual Agent Antiretroviral Regimen  
Dillon Benson, United States

**PE9/19**
Antiretroviral Resistance Mutations and Molecular Surveillance of HIV-1 in the Comunidad Valenciana (Spain), 2011-2013  
Manoli Torres-Puente, Spain

**PE9/20**
Evolution of Resistance Rates to RT and Protease Inhibitors in Antiretroviral-experienced HIV-infected Patients  
Anne-Geneviève Marcelin, France

**PE9/21**
Integrated Analysis of Emergent Drug Resistance through 96 & 144 Weeks from Clinical Studies of HIV-1 Treatment-naive Subjects Receiving Dolutegravir Based Regimens  
James Demarest, United States

**PE9/22**
E138A – Natural Polymorphism or Selected by 2nd Generation NNRTIs?  
Martin Obermeier, Germany

**PE9/23**
Decline in Resistance Mutations’ Prevalences, Namely K65R: Frankfurt HIV-1 Database, 2005-2013  
Christoph Stephan, Germany

**PE10/1**
Discovery of Novel Diaryltriazines (DATAs) as Non-nucleoside Reverse Transcriptase Inhibitors via Extension into the Entrance Channel of HIV-1 Reverse Transcriptase  
Udaya Pratap Singh, India

**PE10/2**
Design and Discovery of Potent Hybrid 1,3,5-Triazine-1,3-Thiazine Analogs Clubbed via Amine Bridge: A Novel Lead for Next Generation NNRTI  
Amita Verma, India

**PE10/3**
Pharmacogenetic: Screening Relevant Polymorphisms on Antiretroviral Therapy in an HIV Portuguese Population  
Ana Fernandes, Portugal
Scientific Programme

PE10/4 Impact of Decentralized Drug Purchase on Antiretroviral Treatment Costs in Spain
Yaiza Rivero-Montesdeoca, Spain

PE10/5 Impact of UGT1A1*28 Polymorphism on Raltegravir Metabolism
Leïla Belkhir, Belgium

PE10/6 The Rilpivirine/Emtricitabine/Tenofovir Alafenamide (RPV/FTC/TAF) Single Tablet Regimen (STR) is Bioequivalent to Elvitegravir/Cobicistat/FTC/TAF (E/C/F/TAF) and RPV
Julia Zack, United States

PE10/7 Co-medication in an Irish Infectious Diseases Clinic: The Level of Accurate Recording of co-medication and the Significance of Interactions between co-medication and Antiretrovirals (ARVs)

PE10/8 Differential Pharmacological Impact of Abacavir Sulphate and Tenofovir on Platelet Aggregation Independent of HIV Infection
Erica Smyth, United Kingdom

PE10/9 The Effect of Food on the Rilpivirine/Emtricitabine/Tenofovir Alafenamide (RPV/FTC/TAF) Single Tablet Regimen (STR) Tablet

PE10/10 Impact of Tenofovir' (TDF) Dose Adjustment on the Estimated Glomerular Filtration Rate (eGFR) and TDF trough Concentration (C\text{trough-TDF})
Sylvie Bregigeon, France

PE10/11 Assessment of CYP3A5 Genotype on Maraviroc Exposure and Efficacy in a Phase 3 Study
Manoli Vourvahis, United States

PE10/12 Frequency and Severity of Drug Interactions in a Cohort of HIV-infected Patients Identified through a Multidisciplinary Team
Hernando Knobel, Spain

PE10/13 The Effect of Food on the Pharmacokinetics of Unboosted and Boosted Tenofovir Alafenamide
Joseph Custodio, United States

PE10/14 Evaluation of Tenofovir Alafenamide Pharmacokinetics: No Influence of Demographic or HIV Disease Factors
Joseph Custodio, United States

PE10/15 Pharmacology Drug Interactions and Adherence in Patients on Polypharmacy in our Hospital
Sheila Ruiz, Spain

PE10/16 Risk Factors Associated with Hypersensitivity Reactions to Antiretroviral Drugs in Patients Infected with HIV
José Antonio Mata-Marín, Mexico

PE10/17 What Minimal Concentration of Darunavir in Maintenance Darunavir/Ritonavir 800/100 mg Once-daily with 2 NRTIs (DAMAR study)?
Minh Lê, France

PE10/18 Comparison of the in vitro Dissolution and in vivo Pharmacokinetics of Branded versus Generic Efavirenz Formulation in HIV Patients
Cristina Gervasoni, Italy
Scientific Programme

PE10/19 Neuro+3 Study: Baseline Characteristics with Pharmacologic Results of HIV Patients with Neurocognitive Disorders Despite Effective Antiretroviral Therapy
Gilles Force, France

PE11/1 Renal Toxicity Following Exposure to Tenofovir and Inhibitors of Tenofovir’s Renal Efflux Drug Transporters in HIV-1 Patients
Casper Rokx, Netherlands

PE11/2 Simple and Practical Screening Approach to Identify HIV-infected Individuals with Current Depression or Risk of Developing Depression
Lotte Rodkjær, Denmark

PE11/3 Analysis of Neurocognitive Function and CNS Endpoints at Week 96 in the PROTEA Trial: Darunavir/Ritonavir with or without Nucleoside Analogues
Amanda Clarke, United Kingdom

PE11/4 Safety, Sensory Function and Analgesic Effectiveness Following Capsaicin 8% Patch (Quenzatm) Repeat Treatment in Peripheral Neuropathic Pain: Stride Study
Graeme Moyle, United Kingdom

PE11/5 Tenofovir-associated Nephrotoxicity and Hypophosphatemia in HIV-infected Patients: A Single-centre Cohort Study
Chien-Yu Cheng, Taiwan, Republic of China

PE11/6 Hepatotoxicity and Skin Rash of non-nucleoside Reverse Transcriptase Inhibitor (nNRTI) plus Nucleoside Reverse-Transcriptase Inhibitors in HIV-infected Taiwanese
Pei-Ying Wu, Taiwan, Republic of China

PE11/7 Health State Utilities of Risks Associated with Antiretroviral Treatment (ART) for Human Immunodeficiency Virus (HIV)
Louis Matza, United States

PE11/8 Discontinuation of Tenofovir due to Nefrotoxicity: Insight into 12 Years of Clinical Practice
Elzbieta Bakowska, Poland

PE11/9 Incidence of Cancer in Individuals treated with Raltegravir-based and Non-raltegravir-based cART Regimens
Daniel Grint, United Kingdom

PE11/10 Cross-sectional Multi-centre Study of Bone Mineral Density in HIV-1 Infected Patients on Antiretroviral Treatment at Risk for Osteopenia/Osteoporosis
Frank Post, United Kingdom

PE11/11 Osteonecrosis and HIV Infection: The Experience of a Portuguese Center
Rosário Serrão, Portugal

PE11/12 Prevalence of Sleep Disorders, Anxiety and Depression in HIV/AIDS Patients under Antiretroviral Treatment in China
Wu Hao, China

PE11/13 Risk Factors of Anxiety and Depression in HIV-infected Patients during Antiretroviral Treatment
Wu Hao, China
**Scientific Programme**

**PE11/14**  
**Abacavir Does Not Produce Vascular Inflammatory Effects in ATP Receptor-deficient Mice**  
Samuel Orden, Spain

**PE11/15**  
**The Vascular Pro-inflammatory Effects of Abacavir Involve Interference with the Purinergic System**  
Víctor Collado Díaz, Spain

**PE11/16**  
**Abacavir Induces Platelet Adhesion to Endothelial Cells**  
César Ríos-Navarro, Spain

**PE11/17**  
**Hepatic Safety of Maraviroc in HIV Infected Patients with HCV and/or HBV Co-infection. The Maraviroc Cohort Spanish Group**  
Manuel Crespo, Spain

**PE11/18**  
**Breast Density Assessment in Women Living with HIV/AIDS**  
Mónica Mendes, Brazil

**PE11/19**  
**Differences in HIV Symptom Index Questionnaire (SIQ) and Sleep/Wake Activity Inventory (SWAI) after Switching to a Rilpivirine (RPV)-containing Regimens in Combination Antiretroviral Therapy (cART)-experienced HIV-infected Patients**  
Manuela Colafigilii, Italy

**PE12/1**  
**Risk Factors for Mortality in HIV-infected Patients with CMV Disease in the Combination Antiretroviral Era**  
Rafael Perello, Spain

**PE12/2**  
**Hospitalizations of HIV Patients in a Major Israeli HIV/AIDS Center in the Years 2000-2012**  
Keren Mahlab-Guri, Israel

**PE12/3**  
**Low Bone Fracture Risk Measured by Frax Index in HIV Patients**  
Carmen Hidalgo-Tenorio, Spain

**PE12/4**  
**HIV-associated versus Classic Fever of Unknown Origin 25 Years on: Spectrum and Criteria Revisited**  
Paul De Munter, Belgium

**PE12/5**  
**Impact of Late Presentation on Short, Mid and Long-term Mortality and on Causes of Death in Spain (2004-2013)**  
Paz Sobrino-Vegas, Spain

**PE12/6**  
**Cardiovascular-specific Mortality in HIV-positive Patients with Alcohol Use Disorders**  
Robert Muga, Spain

**PE12/7**  
**Ongoing Contribution of AIDS Deaths in the HAART Era: Data from the UK CHIC Study**  
Sophie Jose, United Kingdom

**PE12/8**  
**American College of Cardiology Pooled Equations and DAD Algorithm to Predict Freedom from Cardiovascular Events in HIV Patients**  
Giovanni Guaraldi, Italy
**Scientific Programme**

**PE12/9**  
Cardiovascular Risk Factors and Recommended LDL Cholesterol Goals Attainment among HIV Positive Patients: The Impact of the Metabolic Syndrome  
Elisabetta Schiaroli, Italy

**PE12/10**  
Persistent HIV Low-level Viremia and Cardiovascular Risk  
Silvia Costarelli, Italy

**PE12/11**  
Heart Transplantation in HIV-infected Patients: A Report of Three Cases from a Single Institution  
Fernando Agüero, Spain

**PE12/12**  
Prognostic Value of DLCO in a Cohort of Middle Aged HIV Infected Patients in Terms of Mortality and Incidence of Cardiovascular Events after 6 Years of Prospective Follow-up  
Francisco Fanjul, Spain

**PE12/13**  
Lower CD4/CD8 Ratio (  
Francisco Fanjul, Spain

**PE12/14**  
Trends in Cardiovascular Surgery in HIV-infected Patients: A 30-year Single Center Experience  
Juan M Pericás, Spain

**PE12/15**  
Sharanjit Dhoot, United Kingdom

**PE12/16**  
Cardiovascular Events in HIV-positive Patients over the Last Decade. The Experience of Brescia from 2000 to 2012  
Elena Raffetti, Italy

**PE12/17**  
Rare Case of Adult Onset Still’s Disease Inducing Hemophagocytic Lymphohistiocytosis (HLH) during Early HIV Infection: Emerging Treatment Controversies and Dilemmas  
Garyfalia Poulakou, Greece

**PE13/1**  
Characteristics of the Active Drug Users Recently Infected with Hepatitis C in a Shantytown with a High Prevalence of HCV  
Pablo Ryan, Spain

**PE13/2**  
Hepatic Safety of RPV/FTC/TDF Single Tablet Regimen in HIV/HCV-coinfected Subjects. The hEPAtic Study  
Karin Neukam, Spain

**PE13/3**  
Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-experienced Subjects with HCV Genotype 1 and HIV-co-infection (ANRS HC31 SOFTRIH Study)  
Eric Rosenthal, France

**PE13/4**  
Uptake of Tenofovir-based Combination Antiretroviral Therapy (cART) among HIV/HBV Co-infected Patients in the EuroSIDA Study  
Lars Peters, Denmark

**PE13/5**  
Ledipasvir/Sofosbuvir with or without Ribavirin for the Treatment of Patients with Genotype 2-6 Chronic HCV Infection: Summary Results from Four Phase II Studies  
Armand Abergel, France
The Treatment Cascade of Chronic Hepatitis C In HIV Co-infected Patients: Data from the Clinic of Infectious Diseases in Modena, Italy
Gianluca Cuomo, Italy

Factors Associated with Changes in Liver Stiffness in HIV/HCV Co-infected Patients along 5 Years of Follow-up: Effect of Treatment Response to HCV-therapy on Liver Fibrosis
Eva Van den Eynde, Spain

Does treatment of HCV with DAAs Affect Renal Function? Findings from the German Multicenter Cohort on Direct Antiviral Agents in HCV- and HIV/HCV-infected Patients (GECCO)
Stefan Mauss, Germany

Co-morbidities and Co-medications in HIV Patients with Hepatitis C in the Era of New Agents
Lise Cuzin, France

Efficiency of an Integrated Management of New Treatments of HCV
Julie Chas, France

Differential Regulation of Primary Natural Killer Cell Function by Sequence Variations in HCV Core-derived Epitope through Altered Binding of KIR2DL3 to HLA-C*03:04
Sebastian Lunemann, Germany

CD4 and CD4/CD8 Ratio Progression in HIV-HCV Infected Patients after Achievement of SVR
Annalisa Saracino, Italy

Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-infected Patients
Sanjay Bhagani, United Kingdom

Incidence and Recurrence of Hepatitis C Virus Reinfection after Sustained Virological Response in a Large Cohort of Prisoners
Andrés Marco, Spain

Differences in HCV Genotype 1a and 1b Molecular Epidemiology and NS3A Resistance Associated Variant Frequency among HIV-coinfected Patients from Poland
Milosz Parczewski, Poland

Prognostic Value of Transient Elastography in HIV-infected Patients with Chronic Hepatitis C
Juan Berenguer, Spain

Acute Hepatitis C in HIV Co-infected Patients in Barcelona: A Rising Epidemics
Maria Martínez-Rebollar, Spain

Prognostic Value of Liver Stiffness in HIV/HCV-coinfected Patients with Decompensated Cirrhosis
Juan Berenguer, Spain

Determinants and Impact of Late HCV Diagnosis among Persons with Newly Diagnosed HIV Infection
Enrico Girardi, Italy
**Scientific Programme**

**PE13/20**  
HCV-RNA Profiles among HIV/HCV-coinfected Individuals in the ESPRIT Study: Spontaneous HCV-RNA Clearance Documented in 9 Individuals  
Daniel Grint, United Kingdom

**PE13/21**  
Seroclearance of Hepatitis B Surface Antigen is Associated with Immune Reconstitution Inflammatory Syndrome among HIV and HBV Coinfected Individuals  
Takashi Muramatsu, Japan

**PE13/22**  
Boceprevir Plus Peginterferon/Ribavirin to Retreat HCV Genotype-1 in HIV-HCV coinfected Patients. Final Results of BOC HIV-HCV Spanish Study Group  
Montserrat Laguno, Spain

**PE13/23**  
HIV/HCV-coinfection across Europe  
Lars Peters, Denmark

**PE13/24**  
Prevalence and Clinical Determinants of Hepatitis Delta Co-infection in a Rural Tanzanian HIV Cohort  
Annja Winter, Switzerland

**PE13/25**  
Challenges of Anti HCV Treatment in Persons Living with HIV in the Era of Directly Acting Antiviralss (DAA)  
Massimo Puoti, Italy

**PE13/26**  
Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV coinfected Patients: Evaluation of Safety, Effectiveness And Impact on Liver Fibrosis (MASTER Cohort)  
Paola Nasta, Italy

**PE13/27**  
Awareness of HCV-coinfection among Newly Diagnosed HIV Individuals  
Paola Scognamiglio, Italy

**PE13/28**  
Monocytes and Dendritic Cells Subsets during New Anti-HCV Treatments: IFN free and IFN Based Regimen  
Stefano Savinelli, Italy

**PE13/29**  
High Efficacy of Grazoprevir/Elbasvir in HCV Genotype 1, 4, and 6-infected Patients with HIV-co-infection: The phase 3 C-EDGE Co-infection Study  
Christine Katlama, France

**PE13/30**  
Safety and Efficacy of combinations of Direct Antiviral Agents (DAAs) against Hepatitis C Virus (HCV) in HIV Co-infected Patients  
Daniela Buccione, Spain

**PE13/31**  
Safety and Efficacy of IFN-free, DAAs-based Therapy in HIV/HCV Solid Organ Transplanted Patients  
Ana Moreno, Spain

**PE13/32**  
Real-world Effectiveness of Ledipasvir/sofosbuvir 8 Weeks Chronic Hepatitis C Treatment  
Karsten Wursthorn, Germany

**PE13/33**  
Interferon-gamma (IFN-γ)-inducible Protein-10 (IP-10) and sCD163 in HCV Monoinfected and HIV/HCV-coinfected Subjects: A Potential Role as Markers of Fibrosis and Response to Therapy  
Claudia Mascia, Italy
Scientific Programme

PE13/34  Safety and Efficacy of SOF-based Therapy in HIV/HCV-coinfected Patients with Chronic Kidney Disease (CKD) in “Real Life”

PE13/35  Reduced CD4 Monitoring in Stable and Virally Suppressed HIV/HCV-coinfected Patients from the PISCIS Cohort (Spain)
David Nicolás, Spain

PE13/36  Linkage to Care after Routine HIV, Hepatitis B (HBV) & C (HCV) Testing in the Emergency Department (ED) - The ‘Going Viral’ Campaign
Rageshri Dhairyawan, United Kingdom

PE13/37  Prevalence of Hepatitis B Virus and Hepatic Fibrosis Progression after ART Initiation among ART-naïve Individuals in a Rural Tanzanian HIV Cohort
Adrià Ramírez-Mena, Spain

PE13/38  Effectiveness of New Direct-acting Antivirals in a Real-life Cohort of Difficult-to-Treat HCV and HIV/HCV-coinfected Patients
María Jesús Vivancos Gallego, Spain

PE13/39  Directly-acting Agents against the Hepatitis C Virus (HCV) for HCV-monoinfected and HIV-HCV-coinfected Patients with HCV Genotypes 1, 2, 3 and 4 - Results from the German Hepatitis C Cohort (GECCO)
Stefan Christensen, Germany

PE13/40  High Proportion of Advanced Liver Fibrosis and Cirrhosis Requiring Hepatitis C Treatment in HIV-HCV Coinfected Patients in Hai Phong, Northern Vietnam
Tam Nguyen Truong, Viet Nam

PE13/41  Are there any Variables that Predict a Rapid Progression to Liver Fibrosis in HIV-HCV infected patients?
David Rial, Spain

PE13/42  Spontaneous Hepatitis C Virus (HCV) Clearance: Epidemiological and Clinical Characterization and Identification of Predictive Factors of Clearance in a Portuguese Cohort
Nina Fernandes, Portugal

PE13/43  Significant Reductions in Costs of Generic Production of Sofosbuvir and Daclatasvir for Hepatitis C Treatment in Low- and Middle-income Countries
Andrew Hill, United Kingdom

PE13/44  Differential Effects of HCV Therapy with Direct Acting Antiviral Agents on Lipids in the German Multicenter Cohort on Direct Antiviral Agents in HCV- and HIV/HCV-infected Patients (GECCO)
Stefan Mauss, Germany

PE13/45  Correlates of Successful HCV Treatment in HIV Co-infected Vulnerable Populations
Syune Hakobyan, Canada

PE13/46  High Prevalence of Undiagnosed Hepatitis C Virus (HCV) Infection in Attendees of the Emergency Department of a Central London Hospital
Daniel Bradshaw, United Kingdom
<table>
<thead>
<tr>
<th>PE14/1</th>
<th>Infectious Complication Rate in a Cohort of HIV-infected Kidney Transplant Recipients</th>
<th>Oana Ailioaie, Romania</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE14/2</td>
<td>Antiretroviral and Cotrimoxazole Prophylactic Therapies among HIV-TB Co-infected Patients</td>
<td>Olatunji Adetokunboh, South Africa</td>
</tr>
<tr>
<td>PE14/3</td>
<td>Resistance to Antituberculous Drugs and Outcome among TB/HIV Co-infected Adults in Ghana - Detect HIV/TB study</td>
<td>Stephanie Bjerrum, Denmark</td>
</tr>
<tr>
<td>PE14/4</td>
<td>HIV/TB Coinfection</td>
<td>Mariana Hualde, Argentina</td>
</tr>
<tr>
<td>PE14/5</td>
<td>Use of IGRA Tests for Heavy Immunosuppressed HIV-patients</td>
<td>Aleksander Panteleev, Russian Federation</td>
</tr>
<tr>
<td>PE14/6</td>
<td>FDG-PET/CT: A Non-invasive Tool in Diagnosis and Monitoring of Therapeutic Response in HIV Patients with Extra-pulmonary Tuberculosis</td>
<td>Charlotte Martin, Belgium</td>
</tr>
<tr>
<td>PE14/7</td>
<td>Drug Resistant TB in HIV-infected Patients in St Petersburg: Problems and Perspectives</td>
<td>Aleksander Panteleev, Russian Federation</td>
</tr>
<tr>
<td>PE14/8</td>
<td>Has Tuberculosis in HIV-infected Patients the Same Clinical and Epidemiological Features than Tuberculosis in HIV-negative Patients?</td>
<td>Javier Martinez-Sanz, Spain</td>
</tr>
<tr>
<td>PE14/9</td>
<td>Consecutive Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis in a Spanish cohort of HIV-infected Individuals</td>
<td>Adrià Ramírez-Mena, Spain</td>
</tr>
<tr>
<td>PE14/10</td>
<td>Computed Tomography in the Diagnosis of Bowel Diseases in Patients with HIV/Tuberculosis co-infection</td>
<td>Irina Sokolina, Russian Federation</td>
</tr>
<tr>
<td>PE15/1</td>
<td>Human Immunodeficiency Virus Infection and Stroke: A Case-control Study in a Portuguese Hospital</td>
<td>André Silva-Pinto, Portugal</td>
</tr>
<tr>
<td>PE15/2</td>
<td>Prevalence of Hypertension and Obesity among HIV Patients in a Care Program in Nairobi: A Case for Integration of Care</td>
<td>Moses Masika, Kenya</td>
</tr>
<tr>
<td>PE15/3</td>
<td>Brain-related Voice Emotion Processing Deficits in HIV-infected Patients</td>
<td>Alicia González-Baeza, Spain</td>
</tr>
<tr>
<td>PE15/4</td>
<td>Burden of Chronic Obstructive Pulmonary Disease (COPD) and its Determinants in an African HIV Cohort</td>
<td>Attannon Arnauld Fiogbé, Togo</td>
</tr>
<tr>
<td>PE15/5</td>
<td>Ageing with HIV: Do Comorbidities and Poly-medication Drive Treatment Optimizations?</td>
<td>Lise Cuzin, France</td>
</tr>
</tbody>
</table>
Scientific Programme

PE15/6  Central Obesity and Correlating Factors in Vojvodina’s Cohort
        Daniela Maric, Serbia

PE15/7  Prevalence and Risk Factors for Chronic Kidney Disease (CKD) among
        Ambulatory ART Naïve HIV-1 Infected Patients in a Rural Kenyan
        Population
        Paul Yonga, Kenya

PE15/8  Has CXCL13 an Added Value in the Diagnosis of Neurosyphilis?
        Khutso Mothapo, Netherlands

PE15/9  Associations between Cognitive Impairment and Patient-reported
        Measures of Physical/Mental Functioning in Older People Living with HIV
        Jonathan Underwood, United Kingdom

PE15/10  Metabolic Syndrome and Sub Clinical Cardiovascular Disease Detected on
         Cardiac MRI in HIV Infected Patients
         Aisling Loy, Ireland

PE15/11  Increased Markers of Endothelial Dysfunction in Untreated HIV Infection
         Are Associated with Viral Replication but Not with Platelet Aggregation
         Judith Haissman, Denmark

PE15/12  Evaluation of a Physiotherapy-led Group Rehabilitation Intervention for
         Adults Living with HIV: Referrals, Adherence and Outcomes
         Darren Brown, United Kingdom

PE15/13  Aging on cART: No Worsening of Bone Mineral Density over 12 Years
         Clotilde Allavena, France

PE15/14  Gastroesophageal Reflux Disease among Adults with HIV: Prevalence and
         Risk Factors of Severe or Frequent Symptoms
         Mazen Bader, Canada

PE15/15  Evaluation and Management of Fracture Risk of HIV Patients in the US
         Veterans Health Care System
         Roger Bedimo, United States

PE15/16  Nephrology Consultations Incorporated into HIV Care - Non-compliance is
         an Important Issue
         Bartłomiej Matosz, Poland

PE15/17  Cardiovascular Risk Assessment in HIV-1 Infected Patients and a
         Comparison of Framingham, SCORE, and DAD Risk Methods
         Zev Sthoeeger, Israel

PE15/18  Absence of Pneumocystis jirovecii Colonization in HIV-infected Persons
         Andreas Ronit, Denmark

PE15/19  COPD Symptom and Disease Screening in an HIV Population
         Nadine Kronfli, Canada

PE15/20  Epidemiology and Costs for Comorbidities in People Living with Human
         Immunodeficiency Virus (PLWHIV) - A Systematic Review
         Julie Glanville, United Kingdom
A Calibration of the Framingham Coronary Risk Function Adapted to the Characteristics of Spanish HIV-infected Patients
Vicente Estrada, Spain

Evaluation of HIV Testing Recommendations In Specialty Guidelines for the Management of HIV Indicator Conditions
Emily Lord, United Kingdom

The Prevalence and Outcome of HIV-associated Neurocognitive Impairment in a Clinical Setting
Francesca Ferretti, United Kingdom

Characteristics and Outcome of Patients Diagnosed with HIV at Older Age
Ilan Asher, Israel

Improvement of the Estimation Performance of Ischemic Heart Events Risk in Mediterranean HIV-infected Patients by Means of the Adapted Framingham Function (REGICOR)
Hernando Knobel, Spain

Analysis of Co-morbidities in HIV Infection
Svetlana Buzunova, Russian Federation

Comorbidities and Disability Experienced among Adults Living with HIV in Canada: Results from the HIV Health and Rehabilitation Survey
Kelly O’Brien, Canada

Clinical Evaluation is Better than Risk Prediction Algorithms to Identify Patients who Need Statin Therapy
Giovanni Guaraldi, Italy

cIMT Progression in 90 Patients Starting Their First Highly Active Antiretroviral Therapy: 48 Months Observation
Sergio Ferrara, Italy

Cannabis Exposure Increases the Risk of Liver Fibrosis in HIV-infected Patients
Olivia Zaegel-Faucher, France

Epidemiology of Acute Myocardial Infarction in HIV-infected Patients in Spain during the Combination Antiretroviral Therapy Era (1997-2011)
Juan Berenguer, Spain

Ageing Perception and Attitudes in HIV Patients in Italy
Mariangela Errico, Italy

Impact of Maraviroc, Dolutegravir and Darunavir/Ritonavir on Human Coronary Endothelial Cell Functions According to Age
Jacqueline Capeau, France

Statins and Aspirin in HIV-infected People: Gap between Guidelines and Clinical Practice. The Results of the HIV-HY Study
Paolo Bonfanti, Italy

The Metabolome in HIV-associated Chronic Obstructive Pulmonary Disease
Chris Wendt, United States
**Scientific Programme**

**PE15/36**  
Low Prevalence of HIV-associated Neurocognitive Disorder (HAND) in a Swedish Cohort of HIV-1 Infected Individuals  
Åsa Mellgren, Sweden

**PE15/37**  
Non-viral Liver Disease Burden in HIV Positive Individuals. A Prospective Cohort Study: Preliminary Results  
Yishi Tan, United Kingdom

**PE15/38**  
Impact of HIV and Type 2 Diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction  
Hedda Hoel, Norway

**PE15/39**  
Apolipoprotein E (ApoE) e2 Genetic Variant is Associated with Favorable Lipid Profile on cART among HIV-1 Infected Patients  
Magdalena Witak-Jedra, Poland

**PE15/40**  
CD4/CD8 Ratio for Monitoring the Immunological Response to Combined Antiretroviral Therapy in Ageing HIV+ Patients  
Maria Nikolova, Bulgaria

**PE15/41**  
Description of a Male to Female Transgender HIV Positive Population in the North-West of France in 2013  
Jeremie Leporrier, France

**PE15/42**  
Lack of Association between Liver Stiffness and Bone Mineral Density in HIV/HCV-coinfected Patients  
Juan Berenguer, Spain

**PE15/43**  
Should We Screen for NAFLD/NASH in HIV Patients?  
Giovanni Guaraldi, Italy

**PE15/44**  
Human Papillomavirus Infection in HIV Positive and HIV Negative Men Who Have Sex with Men in Non Metropolitan Area of Central Italy: Prevalence and Genotypes Distribution  
Claudio Ucciferri, Italy

**PE15/45**  
The Characteristics, Prevalence and Progression of Insulin Resistance in Patients with HIV and HIV/HCV Coinfection  
Opas Putcharoen, Thailand

**PE15/46**  
Trends in Myocardial Infarction among HIV-1-infected Individuals in France between 2000 and 2009 Compared to the General Population: Results from FHDH-ANRS CO4  
Dominique Costagliola, France

**PE15/47**  
Assessment of Associations between Markers of Renal Function and Bone Mineral Density in HIV-positive and HIV-negative Subjects  
Elena Alvarez, Ireland

**PE15/48**  
Effectiveness of Progressive Resistive Exercise for Adults Living with HIV: A Cochrane Collaboration Systematic Review  
Kelly O'Brien, Canada

**PE15/49**  
Relationship between Surface Activation Markers on Peripheral Monocyte/Macrophage and Evolution of Cognitive Performance in HIV-infected Patients under Suppressive Antiretroviral Therapy  
Alessandra Bandera, Italy
Scientific Programme

PE15/50  A Systematic Review of Psychiatric Illness and Sleep Disturbance Prevalence as Comorbidity with HIV in the UK, with Comparison to the UK General Population
Masautso Chaponda, United Kingdom

PE15/51  Vaginal Shedding of Herpesviridae Does Not Influence the Coronary Microcirculation in HIV-infected Women
Andreas Knudsen, Denmark

PE15/52  Prevalence of Central Obesity and Metabolic Complications among Adults Living with HIV in Ireland
Laura Kelly, Ireland

PE15/53  Association with Statin Use in Individuals with and without Cardiovascular Disease
Gisela Leierer, Austria

PE15/54  A Study of the Effect of Early, Untreated HIV on Cerebral Perfusion and Arterial Transit Time in the Basal Ganglia Using Arterial Spin Labelling
Lewis Haddow, United Kingdom

PE15/55  Plasma Osteoprotegerin Concentration in HIV Infected Men and its Association with Hypertriglyceridemia
Anita Olczak, Poland

PE15/56  Anaemia and HIV - An Old New Study Opportunity
Joana Silva, Portugal

PE15/57  Increased Incidence of Cancer and Cancer-related Mortality among HIV/HCV-coinfected Patients, 1993-2014
Alvaro Mena, Spain

PE15/58  Neuroimaging Findings in Effectively Suppressed HIV+ Patients with Symptomatic Neurocognitive Dysfunction: A Cross-sectional Sub-study from the PIVOT Trial
Alejandro Arenas-Pinto, United Kingdom

PE15/59  Age-related Polypharmacy in HIV-infected Patients in a Spanish University Hospital
Angels Andreu - Crespo, Spain

PE15/60  The “Bone Status” in under 40 HIV Positive Patients
Ermelinda Guerra, Italy

PE15/61  White Matter Abnormalities Are Associated with Neurocognitive Disorders in HIV-positive Patients
Andrea Calcagno, Italy

PE15/62  Blood Brain Barrier Impairment is Associated with CSF Neopterine in Late-presenter’s and with Neurodegeneration and Astrocytosis in Patients with CSF HIV RNA
Andrea Calcagno, Italy

PE15/63  Weight Loss as a Potential Benefit of Liraglutide for Treatment of Diabetes Mellitus in HIV Patients
Amanda McAneny, United States
PE15/64  How do Frailty Mediate and Moderate Pathway Leading to Disability
Andrea Malagoli, Italy

PE15/65  Loss of Bone Mineral Density on Long-term Antiretroviral Therapy: Protective Effect of Nevirapine?
François Raffi, France

PE15/66  Neurological Complications in HIV+ Patients
Goffredo Angioni, Italy

PE15/67  Should We Still Use the “Three Questions Test” as a Screening of HIV-associated Neurocognitive Disorders? Evaluation of Sensitivity, Specificity, Positive and Negative Predictive Value and Association with Altered Quality of Life
Francesca Bai, Italy

PE15/68  HIV Infection is Associated with Reduced Bone Quality Independently of Bone Mineral Density and Antiretroviral Treatment
Robert Güerri-Fernández, Spain

PE15/69  Increased Urinary Albumin-to-creatinine Ratio and the Metabolic Syndrome Contribute to Endothelial Dysfunction in HIV+ Patients with Normal Renal Function
Elisabetta Schiaroli, Italy

PE15/70  Dyslipidemia and Fasting Glucose Impairment among HIV-infected Patients 48-weeks after the First Antiretroviral Regimen
José Antonio Mata-Marín, Mexico

PE15/71  Risk Factors for Chronic Kidney Disease in HIV-1 Infected Mexican Patients Initiating Antiretroviral Therapy
Ricardo Rojas-Aguilar, Mexico

PE15/73  A Cross-sectional Study of Co-morbidities in HIV-infected Patients Receiving cART in Taiwan: A Nationwide Surveillance
Chia-Jui Yang, Taiwan, Republic of China

PE15/74  Prevalence of Low 25-hydroxy-vitamin D levels and Factors Associated with 25-hydroxy-vitamin D Insufficiency in a Large European HIV Cohort
Rocio Montejano, Spain

PE15/75  Prevalence of Respiratory Symptoms and Screening for Chronic Obstructive Pulmonary Disease: Results from an Italian Multicenter Study
Giordano Madeddu, Italy

PE15/76  Cerebrospinal Fluid (CSF) HIV Escape is Associated with Progressive Neurologic Deterioration in Patients on Virologically Suppressive Antiretroviral Therapy (ART) in Western India
Ameet Dravid, India

PE15/77  Health Transitions in HIV-seropositive Individuals Undergoing NRTI-based and NRTI-sparing Treatment Strategies
Stefano Zona, Italy

PE15/78  Brain Functioning and Neurocognitive Disorders among Young HIV-positive MSM Treated with cART. Preliminary Results
Bogna Szymańska, Poland
Scientific Programme

PE15/79  Lopinavir Alone and Ritonavir-boosted Lopinavir Induce Adipocyte Toxicity at Nanomolar Concentrations in vitro
Robert Maughan, Ireland

PE15/80  Active HCV Replication is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV
Andrea De Luca, Italy

PE15/81  Improvement of Bone Mineral Density after Switching from Triple Therapy with Lopinavir and Ritonavir Plus Two Nucleos(t)ide Reverse Transcriptase Inhibitors to Lopinavir and Ritonavir Plus Lamivudine: OLE-lip Substudy
Manuel Crespo, Spain

PE15/82  Neuropsychological Performance and Self-Reported Function in HIV Positive Patients in Five European Clinics
Lewis Haddow, United Kingdom

PE15/83  Secondary Hyperparathyroidism in Patients Presenting Low 25-hydroxy-vitamin D: Prevalence and Associated Factors
Ignacio Pérez-Valero, Spain

PE15/84  Effect of Aging in the Neuropsychological Profile of HIV-infected Patients
Alicia González-Baeza, Spain

PE15/85  Prospective Assessment of Bone Mineral Density among a Cohort of Middle-aged HIV-infected and Uninfected Women: Evaluation of a Population at High Risk
Anna Pia Lassandro, Italy

PE15/86  HIV and Subclinical Atherosclerosis
Argyro Lazarini, Greece

PE15/87  Higher HIV Viral Load is Associated with Lower Levels of Vitamin D in Treatment-naive HIV Patients
María Elena Ceballos, Chile

PE15/88  Self-Reported Prevalence of Co-morbidities and Use of Non-HIV Related Medications among People Living with HIV in England and Wales: Results from the Positive Voices Survey
Meaghan Kall, United Kingdom

PE15/89  Relapse of Cerebrospinal Fluid Escape Following Optimization and Subsequent Simplification of Antiretroviral Therapy
Francesca Ferretti, United Kingdom

PE15/90  Study of Comorbidities in HIV Patients over 50 Years Old
Violeta Alastrué del Castaño, Spain

PE15/91  Will the Next Generation of Rehabilitation Professionals Be Ready to Treat People Living with HIV? Results of a Survey of UK Higher Education Institutions
Will Chegwidden, United Kingdom

PE15/92  Changes in Renal Biomarkers Following Tenofovir Discontinuation in HIV-infected Viral-suppressed Patients, Montreal, Canada
Annie Talbot, Canada
Cervical Squamous Intraepithelial Lesion and Risk Factors among HIV-infected Nigerian Women
Chidinma Vivian Gab-Okafor, Nigeria

Diagnostic Value of Anal Cytology, HPV Testing and High Resolution Anoscopy (HRA) in Screening for Anal Intraepithelial Neoplasia (AIN) in HIV Positive Individuals
Deepa Grover, United Kingdom

Low Clearance and High Acquisition Rate of High-risk Human Papillomavirus (HR-HPV) in a Cohort of 260 Spanish HIV-positive Men Who have Sex With Men (MSM)
Carmen Hidalgo-Tenorio, Spain

Low High-density Lipoprotein Cholesterol (HDL) is Associated with the Risk of Non-AIDS Defining Malignancies
Nicola Squillace, Italy

Value of Prostate-specific Antigen (PSA) Screening for Prostate Cancer Detection in aging People Living with HIV (PLWHIV)
David Zucman, France

Incidence and Survival in HIV Infected patients with Malignancies: A 7 Year Romanian Single Center Experience
Cristiana Oprea, Romania

Detection of High Risk HPV in HIV Positive MSM Using Multiple Technologies - Implications for Immunisation and Disease Prevention
Deepa Grover, United Kingdom

Increased risk of Radiation Induced Adverse Effects in Patients on NNRTI Based Antiretroviral Treatment
Markus Hecht, Germany

Maintaining Dose Intensity of R-CHOP Improves Survival in HIV Associated Lymphoma
Alessia Dalla Pria, United Kingdom

Incidence of Cancer in HIV-infected Patients along 30 Years (1983-2013)
Carolina Tudela, Spain

CD4+ and CD8+ T-Cell Kinetics in Aviremic HIV-infected Patients Developing Hodgkin or Non Hodgkin Lymphoma
Christian Hoffmann, Germany

Prevalence and Incidence of Anal Dysplasia and High-risk Human Papillomavirus (HR-HPV) in a Prospective Cohort of Spanish Women Living with HIV (WLHIV)
Carmen Hidalgo-Tenorio, Spain

Is There Evidence for T-cell Activation Prior to HIV-associated Lymphoma in Aviremic Patients?
Christian Hoffmann, Germany

Evaluation of Hematologic and Hepatic Toxicity in HIV-associated Non-Hodgkin Lymphoma: A Cohort Study
Alessandra Bandera, Italy
PE16/15  Prevalence and Persistence of HPV Infection and Citological Abnormalities in a Cohort of HIV Infected Patients  
Nicola Squillace, Italy

PE16/16  Screening for Anal Intraepithelial Neoplasia (AIN) in HIV-positive Patients: The Practical Uptake of a New Guideline  
Robert Jablonka, Germany

PE17/1  Health Seeking Behaviour among Youth with Sexually Transmitted Infection in Nigeria  
Orobosa Enadeghe, Nigeria

PE17/2  "A One Stop Shop" STD Service for MSM in Croatia/South East Europe - A New Approach  
Šime Zekan, Croatia

PE17/3  Factors Associated with Urinary Tract Infections among HIV-1 Infected Patients - Is Active HCV Infection a Risk Factor?  
Agata Skrzat-Wojdacz, Poland

PE17/4  Anal Cytology (AC) and Sexually Transmitted Infection (STI) Screening in Ageing People Living with HIV (PLWH)  
Malika Mohabeer Hart, United Kingdom

PE17/5  HIV-1 Vaginal Shedding is Suppressed among HIV-1 Infected Women on Modern Combined Antiretroviral Therapy  
Sara Grignolo, Italy

PE17/6  Human Papillomavirus 58: An Emerging High-risk Genotype in Italian HIV-infected Men Who Have Sex with Men?  
Claudio Ucciferri, Italy

PE17/7  Men Who Have Sex with Men from Paris. Argument for Universal HPV Vaccination  
Hugues Cordel, France

PE17/8  High Rates of Sexually Transmitted Infections (STIs) and Recreational Drug Use (RDU) amongst HIV-positive Men Who Have Sex with Men (MSM) Attending Outpatients across London (UK)  
Selena Singh, United Kingdom

PE17/9  Long-term Hepatic Safety and Impact of Maraviroc on Fibrosis Progression: A 148 week Randomised, Double-blind Study of Maraviroc versus Placebo in Combination with Other Antiretroviral Agents in HIV-1 Patients Co-infected with Hepatitis C and/or Hepatitis B Virus  
Frank Plonski, United States

PE17/10  HIV and Syphilis: When Do we Need to Perform a Lumbar Puncture?  
Agnès Libois, Belgium

PE17/11  Detection of Anal HPV Infection by Two Techniques in HIV+ MSM Individuals and Correlation with Pathologic Findings in Cytology and Biopsy  
Elena Ferrer, Spain

PE17/12  Should Screening of Asymptomatic Sexually Transmitted Infections Be Performed to All HIV-infected Men Who Have Sex with Men?  
Irene Sanchez, Spain
PE17/13  Prevalence of Anal High-risk Human Papillomavirus Infections among HIV-positive Men Who Have Sex With Men in Istanbul  
Alper Gündüz, Turkey

PE17/14  Acute Kidney Injury in Shigella Infection in an HIV-positive Cohort  
Nadia Ahmed, United Kingdom

PE17/15  The Serum TRUST Titer ≥1:16 is a Predictor for Asymptomatic Neurosyphilis among HIV/Syphilis Co-infected Patients  
Jianjun Sun, China

PE18/1  Sexual Risk and Sexually Transmitted Infections among Chinese HIV-positive MSM after Engagement in Care  
Kenny CW Chan, China

PE18/2  "One Shouldn't Convict People for Hypothetical Risks": Developments in European Criminal Law and Policy following Increased Knowledge and Awareness of the Additional Prevention Benefit of Antiretroviral Therapy  
Edwin Bernard, United Kingdom

PE18/3  A Finger-stick Whole Blood HIV Self-test as an HIV Screening Tool Adapted to the General Public  
Thierry Prazuck, France

PE18/4  Choice of nPEP Regimens and Completion Rates in a MSM Population in Sydney, Australia: Provision of Drugs at what Cost?  
Rohan Bopage, Australia

PE18/5  Acceptability of Pre-exposure Prophylaxis (PrEP) and Reported Adherence to Non HIV Medication Regimens in HIV Negative Portuguese Men who Have Sex with Men (MSM) Eligible to PrEP  
Luis-Miguel Rocha, Portugal

PE18/6  Human Immunodeficiency Virus (HIV): Continuum of Care in Europe and Central Asia  
Teymur Noori, Sweden

PE18/7  Predictors of Knowledge of Non-occupational HIV Post Exposure Prophylaxis among Men Who Have Sex with Men Attending a Suburban Sexual Health Clinic in Sydney, Australia  
Rasanga Liyanage, Australia

PE18/8  Acceptable Rates of Acute HIV Detection Using a Fourth-generation Point of Care HIV Test  
Naomi Fitzgerald, United Kingdom

PE18/9  Evaluation of a Strategy to Improve Linkage to Care in Newly Diagnosed HIV Patients  
Miguel Raffo, Spain

PE18/10  A New Strategy to Avoid HIV Patient's Loss of Follow-up: Intervention at First Visit Failure  
Jose Fajardo, Spain

PE18/11  Randomised Controlled Trial of the Tolerability and Completion of Maraviroc Compared to Kaletra® in Combination with Truvada® for HIV Post Exposure Prophylaxis (MiPEP Trial)  
Ana Milinkovic, United Kingdom

Page 88 / 100
Scientific Programme

PE18/12  Recording of the Professional Exposure to Blood Transmitted Agents at a Tertiary University Hospital in Greece, during 2007-2013
Anestis Ganitis, Greece

PE18/13  Knowledge and Use of Post-exposure Prophylaxis (PEP) among Men Who Have Sex with Men (MSM) in Portugal
Maria-José Campos, Portugal

PE18/14  Cohort for MSM as a Useful Tool to Assure Cost Effectiveness during the Implementation of PrEP
Michael Meulbroek, Spain

PE19/1   Using Quality Improvement to Address High Default from PMTCT Services (Early Infant Diagnosis) at State Hospital Ijebu Ode, Nigeria
Foluwaso Olaoluwa-Moronkeji, Nigeria

PE19/2   Higher Risks of Mother-to-Child HIV Transmission (MTCT) in Countries with Lower Prevalence: UNAIDS 2013 Results for 33 Countries with Generalised Epidemics
Andrew Hill, United Kingdom

PE19/3   Experience of Prevention of Mother to Child Transmission of HIV in Georgia
Ketevan Shermadini, Georgia

PE19/4   Regional Disparity of Maternal-paediatric Antiretroviral Coverage among African Priority Countries
Olutunji Adetokunboh, South Africa

PE19/5   UK National Clinical Audit 2014: Management of Pregnancies in Women with HIV
Sonia Raffe, United Kingdom

PE19/7   Drug Resistance Mutations (DRM) among Pregnant HIV-positive Women in the Duesseldorf University Hospital, Germany, 2009-2015
Ulrike Haars, Germany

PE19/8   Mode of Delivery in Pregnant Women Living with HIV in Denmark: A Risk Assessment of Emergency Caesarean Sections
Mathilde Ørbæk, Denmark

PE19/9   Evaluation of 10 Years of a Mother to Child Transmission Prevention Program in a Community Health Center in Bamako, Mali
Karamoko Tounkara, Mali

PE19/10  HIV Perinatally Exposed Children in Romania - Review
Alina Maria Cibea, Romania

PE20/1   The Effects of Toxic Impact of Tenofovir on the Bone Mineral Density in Children
Natalya Rymarenko, Ukraine

PE20/2   Prevalence and Characteristics of Group B Streptococcus Colonization in HIV-infected Pregnant Women in Belgium
Nicolas Dauby, Belgium
Scientific Programme

PE20/3 Resistance Mutations to Antiretroviral Drugs on HIV Strains of Treated HIV-1 Infectious Pediatric Patients in Venezuela
Diana Lopez, Venezuela

PE20/4 Associations between Paediatric HIV Clients, Their Caregivers and Retention: Evidence from the EMBRACE Cohort, Eastern Cape, South Africa
Hugh Adler, Ireland

PE20/5 The One-stop Clinic of Ifakara: Implementing a Bundle of Measures for Paediatric HIV Services in Rural Africa to Reach the UNAIDS’ Target “90-90-90”
Anna Gamell, Switzerland

PE20/6 Long-term Prognosis of Children Born to HIV-1 Infected Mothers in Japan
Mizue Tanaka, Japan

PE20/7 Abnormal Neurometabolite Levels Reflect Poorer Cognitive Performance in HIV-infected Children
Yvonne Wilma van Dalen, Netherlands

PE20/8 The Eye as a Window to the Brain: Retinal Structure Associated with Cerebral Injury in Perinatally HIV-infected Children
Charlotte Blokhuis, Netherlands

PE20/9 Threatening Levels of Acquired HIV Drug Resistance and Virologic Failure in Children and Adolescents in Rural Tanzania - An Emerging Public Health Concern
Lukas Muri, Switzerland

PE20/11 Educational Intervention Increases Acceptability and Knowledge of Newborn Male Circumcision (NMC) among Parents of Newborn Boys in Port-au-Prince, Haiti
Jessy Dévieux, United States

PE21/1 Evolution of HIV-infected Injecting Drug Users in Spain during 2004-2013: Persistence of Poor Engagement to Care and Worse Clinical Outcomes
Inés Suárez-García, Spain

PE21/2 Are Immigrant Men who Have Sex with Men (MSM) who Visited an HIV Checkpoint (Actuel-sur-Rue) in Montreal, Canada, More Vulnerable to HIV?
David Lessard, Canada

PE21/3 Weight Changes and Prognosis for People Living with HIV Initiating Highly Active Antiretroviral Therapy in the APROCO Cohort Study
Victoire Fokom Defo, Cameroon

PE21/4 Expansion of the CRF19_cpx Variant in Spain
Fernando Gonzalez-Candelas, Spain

PE21/5 A Decade of HIV Care and Treatment in Rural Tanzania: Trends in Treatment, Opportunistic Infections and Laboratory Abnormalities among HIV-positive Adults
Tracy Glass, Switzerland
Scientific Programme

PE21/6  Missed Opportunities for Earlier HIV Diagnosis in Men who Have Sex with Men (MSM) - A Service Evaluation of HIV Testing in UK Sexual Health Clinics
Emily Clarke, United Kingdom

PE21/7  A Universal Testing Programme for Blood Borne Viruses (BBV) in an Urban Emergency Department (ED) - A Call for Widespread Testing in Ireland
Sarah O’Connell, Ireland

PE21/8  Missed Opportunities for HIV Testing and Factors Associated with Delayed Diagnosis
Rosa de Miguel Buckley, Spain

PE21/9  Intervention Packages against HIV and HCV Infections for People who Inject Drug in Georgia: A Modeling and Cost-effectiveness Study
Guillaume Mabileau, France

PE21/10 The Continuum of HIV Care in Catalonia
Colin Campbell, Spain

PE21/11 From Pills to Patients: Determination of the Number of People Living with HIV who Are Receiving Antiretroviral Therapy, Costs and Potential Cost-savings in Germany
Daniel Schmidt, Germany

PE21/12 HIV Infection among Persons Aged 50 Years and over in the EU, 2004-2013: Missed Opportunities for Earlier Diagnosis?
Lara Tavoschi, Sweden

PE21/13 Use of 3 HIV Testing Methods in French Primary Care: Classical ELISA Laboratory Screening versus 2 Rapid Finger-stick HIV Tests with Result under 5 Minutes (INSTI) and up to 30 Minutes (VIKIA)
Angela Daiana Papadima, France

PE21/14 CD4+T-cell Count at cART Initiation among Migrant Men and Women Living in Western Europe
Susana Monge, Spain

PE21/15 Linkage to Care Following HIV Diagnosis in Europe: A Review of the Literature
Sara Croxford, United Kingdom

PE21/16 Comparing a ‘Multi Assay Algorithm’ with the BED Capture Enzyme Immunoassay for the Testing of Recent HIV-1 Infections in Germany
Andrea Hauser, Germany

PE21/17 Coverage and Acceptability of a Targeted Testing Strategy, Resourced by an External Program Intervention, DRIVE Study (Rapid Diagnosis of HIV infection in Spain)
María Jesús Pérez Elías, Spain

PE21/18 Unselected, Emergency Department-based Rapid HIV Screening Detects High Proportion of Early, Asymptomatic HIV Infection
Marilia Rita Pinzone, Italy

PE21/19 Recreational Drug Consumption in People Living with HIV in Europe: A Systematic Review
Cesar Velasco, Spain
### Scientific Programme

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE21/20</td>
<td>HIV Late Presentation in Southern Sardinia, Italy</td>
<td>Goffredo Angioni, Italy</td>
</tr>
<tr>
<td>PE21/21</td>
<td><strong>Travel to the Tropics and its Impact on Viral Control in HIV Patients in the Swiss HIV Cohort Study</strong>&lt;br&gt;Hiwot Gebreselassie, Switzerland</td>
<td>Hiwot Gebreselassie, Switzerland</td>
</tr>
<tr>
<td>PE21/22</td>
<td><strong>Recent HIV-infections in Germany 2008-2014: What Do we Know?</strong></td>
<td>Andrea Hauser, Germany</td>
</tr>
<tr>
<td>PE21/23</td>
<td><strong>High Rate of Transmission Clusters among Men Who Have Sex with Men (MSM) with Acute-recent HIV Infection in Barcelona</strong>&lt;br&gt;Juan Ambrosioni, Spain</td>
<td>Juan Ambrosioni, Spain</td>
</tr>
<tr>
<td>PE21/24</td>
<td><strong>Developments in the Delay of HIV Detection and Treatment Initiation in Recent Years</strong>&lt;br&gt;Borja Carmelo Gracia Tello, Spain</td>
<td>Borja Carmelo Gracia Tello, Spain</td>
</tr>
<tr>
<td>PE21/25</td>
<td><strong>Transmission Clustering among Kiev HIV Sequences</strong></td>
<td>Esther Fearnhill, United Kingdom</td>
</tr>
<tr>
<td>PE21/26</td>
<td><strong>HIV Subtypes: The Same Disease, Different Stories?</strong></td>
<td>Claudia Afonso, Portugal</td>
</tr>
<tr>
<td>PE21/27</td>
<td><strong>HIV Testing in Innovative Environments Mexico</strong></td>
<td>Nalleli Delgadillo, Mexico</td>
</tr>
<tr>
<td>PE21/28</td>
<td><strong>Ongoing Mononucleosis-like Illness – A Clear Indicator Condition for HIV Testing: Results from the HIDES 2 Study - Single Arm Extension</strong>&lt;br&gt;Dorthe Raben, Denmark</td>
<td>Dorthe Raben, Denmark</td>
</tr>
<tr>
<td>PE21/29</td>
<td><strong>The Acute/Recent HIV Infection Cohort from Hospital Clinic, Barcelona: Epidemiological and Virological Trends from 1997 to 2014</strong>&lt;br&gt;David Nicolás, Spain</td>
<td>David Nicolás, Spain</td>
</tr>
<tr>
<td>PE21/30</td>
<td><strong>Healthcare Related Costs of Missed Opportunities for HIV Diagnosis: A Potential Driver to Increase Indicator Condition Guided HIV Testing</strong>&lt;br&gt;Caroline Rae, United Kingdom</td>
<td>Caroline Rae, United Kingdom</td>
</tr>
<tr>
<td>PE21/31</td>
<td><strong>Current Epidemiology and Outcomes of HIV-infected Patients Admitted to an Intensive Care Unit (ICU) in Barcelona, Spain</strong>&lt;br&gt;Veronica Rico, Spain</td>
<td>Veronica Rico, Spain</td>
</tr>
<tr>
<td>PE21/32</td>
<td><strong>Over Half of People in HIV Care in the United Kingdom by 2028 Will Be Aged 50 Years or Above</strong>&lt;br&gt;Zheng Yin, United Kingdom</td>
<td>Zheng Yin, United Kingdom</td>
</tr>
<tr>
<td>PE21/33</td>
<td><strong>Trends and Causes of Hospitalization among HIV-infected People from 1998 to 2015 in a Single Italian Tertiary Care Centre</strong>&lt;br&gt;Alberto Borghetti, Italy</td>
<td>Alberto Borghetti, Italy</td>
</tr>
<tr>
<td>PE21/34</td>
<td><strong>Recent HIV Infection: Epidemiologic, Clinical and Therapeutic Evolution of a Portuguese Cohort</strong>&lt;br&gt;Bernardo Neves, Portugal</td>
<td>Bernardo Neves, Portugal</td>
</tr>
<tr>
<td>PE21/35</td>
<td><strong>Retention in Care of a Population of Migrant HIV-infected IDUs in Greece (Single Center Experience)</strong>&lt;br&gt;Eleni Kakalou, Greece</td>
<td>Eleni Kakalou, Greece</td>
</tr>
</tbody>
</table>
Scientific Programme

PE21/36  Is It Feasible to Reduce the Number of Determinations Performed on Viral Load and CD4 T-lymphocytes in an HIV Specialized Consultation Unit?
Alberto Díaz-De Santiago, Spain

PE21/37  Clinical and Epidemiological Characteristics of HIV Infection Newly Diagnosed in People over 50 Years of the Spanish Cohort VACH
Dolores Merino Muñoz, Spain

PE21/38  Asymptomatic Late Presenters: 12 Years Trend in CD4+ Cell Counts at HIV Diagnosis in a Single Testing Site in Buenos Aires
Mariana Kundro, Argentina

PE21/39  Analysis of New HIV Diagnoses among Young People
Borja Carmelo Gracia Tello, Spain

PE21/40  Dynamics of Transmission Trends in 30 Years of HIV Epidemic in Romania
Mariana Mardarescu, Romania

PE22/2  Late HIV Diagnosis in Georgia: Public Health and Economic Implications
Nikoloz Chkhartishvili, Georgia

PE22/4  Using Mixed-methods to Understand HIV Treatment Cascade among OST Patients and PWIDs in Five Ukrainian Cities
Alyona Mazhnaya, Ukraine

PE22/5  High Proportion of Viral Suppression with Frequent Changes of Antiretroviral Treatment in Newly Diagnosed Patients in Santo Andre Aids Program, Sao Paulo, Brazil
Elaine Matsuda, Brazil

PE22/6  High Proportion of Virological Failure and HIV Drug Resistance among TB/HIV Co-infected Ugandan Adults
Amrei von Braun, Uganda

PE22/7  First -line Antiretroviral Therapy in Resource-limited Settings: the Experience of Serbia
Gordana Dragovic, Serbia

PE22/8  Direct Costs of HIV/AIDS Care in Estonia
Liis Lemsalu, Estonia

PE22/9  Treating HCV with Interferon-free Regimens in Correctional Settings: An Italian Experience
Antonella Foschi, Italy

PE22/11  Deferring CD4 Cell Count Monitoring in HIV+ Treated Patients with More than 350 or 500 CD4 Lymphocyte/µl is a Safe and Cheap Strategy
Benedetto Celesia, Italy

PE23/1  Sexual Risk Behaviours of High School Students in an Urban Town of Cameroon
Tarkang Elvis, Cameroon

PE23/2  Assessing Parental Knowledge and Attitudes towards Disclosure of HIV
Conor Lyons, Ireland
Scientific Programme

PE23/3 HIV Prevalence and Factors Associated with HIV Infection among Injection Drug Users, Uzbekistan
Shukrat Umardzhoev, Uzbekistan

PE23/4 Stigma towards People Living with HIV/AIDS among Healthcare Practitioners and Medical Students
Julia Dabravolskaj, Canada

PE23/5 Lost Opportunities for Early ART
Anastasia Pokrovskaya, Russian Federation

PE23/6 SM@RT-@IDS: The Digital Prevention for the Smart Generations
Carmine Falanga, Italy

PE23/7 HIV Disclosure and Stigma among Women Living with HIV in Denmark - Results from the SHADE Cohort
Maria Wessman, Denmark

PE23/8 Barriers to Accessing HIV Testing, Treatment and Healthcare for Migrants Living with HIV in Europe
Ibidun Fakoya, United Kingdom

PE23/9 Barriers to HIV Routine Screening in Primary Care: What Do Patients Think about it?
Guillaume Conort, France

PE23/10 Disutilities Associated with Central Nervous System (CNS) Side Effects of Antiretroviral Therapy (ART) in HIV: Results from the UK, France and Spain
Rodolphe Perard, United Kingdom

PE23/11 The StigmaIndexUK-2015: A New Methodology for Measuring the Experiences of Stigma among People Living with HIV
Jo Jefferies, United Kingdom

PE23/12 Differences in Patients and Physicians Adherence Evaluation - Results from the German Adherence Cohort Study
Christoph Spinner, Germany

PE23/13 The Impact of Antiretroviral Therapy on Treatment Satisfaction and Quality of Life of PLWH in Europe
Miranda Murray, United Kingdom

PE23/14 HIV/AIDS-related Knowledge and Behaviors of Precarised Migrants in the Geneva Area, Switzerland
Deborah Glejser, Switzerland

PE23/15 Health Workers in B&H and HIV Stigma and Discrimination
Stela Stojsavljevic, Bosnia and Herzegovina

PE23/16 A New International Questionnaire to Assess Health-related Quality of Life (HRQL) Specific to Viral Hepatitis C: Proqol-HCV
Martin Duracinsky, France

PE23/17 Reduced CD4 Count Monitoring: Potential for Large Cost Savings but is it Acceptable to Patients?
Sophie Flavell, United Kingdom
Scientific Programme

PE23/18 Prediction of the Factors Influencing the HIV Test Utilisation among Young People Aged between 17-25 Years in Saudi Arabia
Abdullah Almilaibary, United Kingdom

PE23/19 Clinical and Community Views of the Instant Result HIV Self-testing: Barriers and Facilitators for Effective Implementation amongst MSM (Men who Have Sex with Men)
Jamie Frankis, United Kingdom

PE23/20 Clinical, Psychological and Behavioural Barriers to HIV Testing amongst MSM (Men who Have Sex with Men) who Use Social and Sociosexual Media: Implications for HIV Prevention Programmes
Jamie Frankis, United Kingdom

PE24/1 Integrated HIV and Gynaecological Services for HIV-positive Women in Warsaw - A Luxury or Standard of Care?
Justyna Kowalska, Poland

PE24/2 Gender Differences in Baseline Epidemiological Profile and Clinical Characteristics and its Evolution in the Spanish AIDS Research Network Cohort (CoRIS)
Constanza Muñoz, Spain

PE24/3 Facts on Contraception Use and Unintended Pregnancies in HIV-infected Women on Antiretroviral Therapy in Switzerland
Valentina Mercanti, Switzerland

PE24/4 Epidemiological Trends of HIV Infection in Women Spanish Cohort VACH
Dolores Merino Muñoz, Spain

Special Session
12:45 - 13:55
Room Barcelona

EACS Guidelines Session

Chairs:
Jens D. Lundgren, Denmark
Manuel Battegay, Switzerland

EACS Treatment Guidelines version 8.0: Vision and Mission
Lene Ryom, Denmark 12:45 - 12:50

8.0 Highlights from ART Section
José M. Gatell, Spain 12:50 - 12:58

8.0 Highlights from Co-morbidities Section
Georg Behrens, Germany 12:58 - 13:06

8.0 Highlights from Viral Hepatitis Section
Jürgen Rockstroh, Germany 13:06 - 13:14

8.0 Highlights from Opportunistic Infections Section
Hansjakob Furrer, Switzerland 13:14 - 13:22

EACS and WHO Guidelines: Complementarity
Marco Vitoria, Switzerland 13:22 - 13:32
Panel Discussion
Georg Behrens, Germany
Hansjakob Furrer, Switzerland
José M. Gatell, Spain
Jürgen Rockstroh, Germany
Lene Ryom, Denmark
Stefano Vella, Italy
Marco Vitoria, Switzerland

Parallel Session
14:00 - 16:00
Room Barcelona

PS10, Antiretroviral Therapy II

Chairs:
Paddy Mallon, Ireland
Linos Vandekerckhove, Belgium

ML1 Managing Primary HIV Infection
Jade Ghosn, France

PS10/1 Impact of Baseline Viral Load (VL) and Time to Viral Suppression on Subsequent Virologic Rebound (VR) According to First-line Antiretroviral Therapy (cART)
Clotilde Allavena, France

PS10/2 Retention of People Living with HIV in Antiretroviral Therapy
Marisol Valenzuela-Lara, Mexico

PS10/3 Switching from Ritonavir or Cobicistat Boosted Atazanavir (ATV) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-based Single Tablet Regimen (STR): Week 48 Data in Virologically Suppressed Adults
Bart Rijnders, Netherlands

PS10/4 Durability of Dual Therapy (DT) with Lopinavir/Ritonavir (LPV/ir) and Lamivudine (3TC) in Comparison to Standard Triple Drug Therapy (TT): 96-week Results of the GARDEL Study
Pedro Cahn, Argentina

PS10/5 Second-generation HIV-1 Maturation Inhibitor BMS-955176: Overall Antiviral Activity and Safety Results from the Phase Ila Proof-of-Concept Study (AI468002)
Carey Hwang, United States

PS10/6 No Difference between the Effects of Immediate versus Deferred ART on Neuropsychological Test Performance in HIV-positive Adults with CD4+ Cell Counts above 500 cells/µL: The Strategic Timing of Anti Retroviral Treatment (START) Neurology Substudy
Richard Price, United States

LBPS10/1 Measuring Safety and Satisfaction of ABC/DTG/3TC in a Switch Trial: Secondary Endpoints from the STRIIVING Study
Michael Aboud, United Kingdom
Parallel Session
14:00 - 16:00

**PS11, Co-morbidities II**

**Chairs:**
Nina Friis-Møller, Denmark
Peter Reiss, Netherlands

**ML1**  
*The Inflammation and the Microbiome*  
Roger Paredes, Spain  
14:00 - 14:15

**PS11/1**  
*Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-containing Antiretroviral Treatment*  
Giuseppe Lapadula, Italy  
14:15 - 14:30

**PS11/2**  
*PCR is a Better Predictor of Renal Disease Progression Than RBP or NGAL in HIV-positive Patients*  
Lisa Hamzah, United Kingdom  
14:30 - 14:45

**PS11/3**  
*Is HIV Infection Duration Associated with Myocardial Infarctions?*  
Alexandra Lyons, United Kingdom  
14:45 - 15:00

**PS11/4**  
*Levels of Agreement between Commonly Used Definitions of Cognitive Impairment and the EACS Screening Questions in Older HIV-positive Subjects and Matched Controls*  
Davide De Francesco, United Kingdom  
15:00 - 15:15

**PS11/5**  
*No Difference in Neurocognitive Function between Patients on PI Monotherapy and cART: Evidence from the PIVOT Trial*  
Alejandro Arenas-Pinto, United Kingdom  
15:15 - 15:30

**PS11/6**  
*Changes in Cognitive Function over 96 Weeks after Initiating Darunavir/Ritonavir with Either Raltegravir or Tenofovir-Emtricitabine; NEAT 001 / ANRS 143 Randomised Controlled Study*  
Alan Winston, United Kingdom  
15:30 - 15:45

**ML2**  
*Neurocognitive Disorder - Is It That Frequent in HIV Patients (Pro/Con Debate)*  
Magnus Gisslen, Sweden
Juan Tiraboschi, United Kingdom  
15:45 - 16:00

Parallel Session
14:00 - 16:00

**PS12, Prospects for HIV Cure and Post Treatment Remission**

**Chairs:**
Bonaventura Clotet, Spain
Christine Katlama, France

**ML1**  
*Obstacles to HIV Remission or Eradication*  
Mario Stevenson, United States  
14:00 - 14:15

**ML2**  
*Overview About Current Strategies for HIV Eradication*  
Lars Østergaard, Denmark  
14:15 - 14:30
**Scientific Programme**

**ML3**  
**14:30 - 14:45**  
**Allogenic Stem-Cell Transplantation**  
Javier Martínez-Picado, Spain

**ML4**  
**14:45 - 15:00**  
**Basic Research to Identify Targets to Purge the HIV Reservoir**  
Daria Hazuda, United States

**ML5**  
**15:00 - 15:15**  
**Overview About Current Strategies for HIV Remission**  
Felipe García, Spain

**Panel Discussion**  
Facilitated by Christian Brander (Spain)  
**15:15 - 16:00**

**Industry Sponsored Session**  
**16:30 - 18:00**  
Room Cologne

**Industry Sponsored Session**  
(For more details, please visit the <a href="http://www.eacs-conference2015.com/index.php?article_id=47">EACS Conference website</a>)

**Other**  
**16:30 - 18:00**  
Room Madrid

**Living Well when Living Longer - HIV and Rehabilitation (limited seat availability)**

Session convened by the Rehabilitation in HIV Association (RHIVA) and the Canada-United Kingdom HIV and Rehabilitation Research Collaborative (CUHRRC) in collaboration with the European AIDS Treatment Group (EATG) and the United Kingdom Community Advisory Board (UK-CAB).

**Industry Sponsored Session**  
**18:30 - 20:00**  
Room Cologne

**Industry Sponsored Session**  
(For more details, please visit the <a href="http://www.eacs-conference2015.com/index.php?article_id=47">EACS Conference website</a>)
Scientific Programme

Saturday, 24 October 2015

Plenary Session
08:00 - 08:30  Room Cologne

PL5, Access and Barriers to Treatment in Europe

Chairs:
Daniel Podzamczer, Spain
Anton Pozniak, United Kingdom

Access and Barriers to Treatment in Europe
Deniz Gökengin, Turkey
08:00 - 08:30

Plenary Session
08:30 - 09:00  Room Cologne

PL6, Challenges in Treating HIV

Chairs:
Daniel Podzamczer, Spain
Anton Pozniak, United Kingdom

Challenges in Treating HIV
José Arribas, Spain
08:30 - 09:00

Special Session
09:00 - 10:30  Room Cologne

Clinical Cases

Chairs:
Sanjay Bhagani, United Kingdom
Hansjakob Furrer, Switzerland
Cristiana Oprea, Romania
Lene Ryom, Denmark

End-Stage Liver Disease in HIV
Ellen Dwyer, United Kingdom
09:00 - 09:15

Panel Discussion
09:15 - 09:22

A ‘Difficult’ Opportunistic Infection - TB, MAI and Crypto
Irina Ianache, Romania
09:22 - 09:37

Panel Discussion
09:37 - 09:44

Complicated Renal Impairment - Exploring Issues Around Cause of Renal Impairment and Appropriate ARVs
Alvaro Borges, Denmark
09:44 - 09:59

Panel Discussion
09:59 - 10:06
Scientific Programme

Multi-Resistant HIV, Poor Adherence – Explore ARV Options and Manage DDIs
Anna Eichenberger, Switzerland
10:06 - 10:21

Panel Discussion
10:21 - 10:30

Special Session
10:30 - 12:00
Room Cologne

Standard of Care in Europe

Chairs:
Nathan Clumeck, Belgium
Andrzej Horban, Poland

Access to Antiretroviral Therapy in Eastern Europe
Cristiana Oprea, Romania
10:30 - 10:45

Migrants and Access to Care
Julia Del Amo, Spain
10:45 - 11:00

Linkage to Care
Justyna Kowalska, Poland
11:00 - 11:15

Which Model of Care in Europe
Markus Bickel, Germany
11:15 - 11:30

Panel Discussion
Markus Bickel, Germany
Nikos Dedes, Greece
Julia Del Amo, Spain
Justyna Kowalska, Poland
Cristiana Oprea, Romania
11:30 - 12:00

Ceremony
12:00 - 12:15
Room Cologne

Closing Remarks
Manuel Battegay (Switzerland)
José M. Gatell (Spain)
Antonella d'Arminio Monforte (Italy)
Fiona Mulcahy (Ireland)